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Abstract 
Medulloblastoma (MB) is the most common malignant brain tumour in children.  MBs arise 
in the cerebellum, originating from neural stem cells progenitors.  It has previously been 
shown that the lack of integrity of signalling pathways due to genetic alterations play a key 
role in MB chemosensitivity.  An example is the p53 signalling, with p53 mutations and or 
deletions which are associated with drug resistance.  Here, we explored the role of p53 
induction by chemotherapeutic drugs such as etoposide in MB and the way to bypass the 
need for intact p53 to trigger apoptosis.  We specifically demonstrated that a downstream 
miRNA target transcribed by p53, miR-34a, is able to reduce the number of viable cells in 
cultures of MB cells lacking functional p53, although the effect was limited.  
Beyond the genetic background of a tumour, it is more and more described that the tumour 
microenvironment plays a key role in drug resistance.  MB is a solid tumour and hence will 
contain areas deprived in oxygen (hypoxic).  It has been widely documented that hypoxia is 
associated with poor prognosis and resistance to treatment in other cancer models and we 
here aimed to investigate the specific role of hypoxia in MB response to etoposide.  We 
demonstrated that MB (p53 WT) cell lines became more resistant in chronic but not acute 
hypoxia and this was associated with a decrease in the recruitment of double strand DNA 
damage sensing machinery and subsequent impairment to transactivate p53 and 
transcription of pro-apoptotic genes. 
A transcriptomic microarray profiling study further revealed that chronic hypoxia induced 
broad and significant changes in global gene expression affecting many biological pathways 
including stem cell maintenance, neuronal development and phosphoinositol-3 phosphate 
kinase. 
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 1.1  Human cancer  
Cancer is a disease characterised by abnormal cell growth, caused by multiple changes in 
gene expression leading to deregulation of the cellular program controlling cell fate.  These 
genetic changes result in imbalance of cell proliferation and cell death, promoting the 
growth of malignant tumour cell populations that can invade neighbouring tissues and 
metastasise to other distant parts of the body. 
Cancer can occur in almost any part of the human body and, as the disease progresses, can 
affect the functions of vital organs and is usually life threatening.  In the UK, cancer was 
responsible for 150,000 deaths in 2010, contributing to the major cause of mortality with 
the exclusion of infantile death under one year.  Cancer of the brain and central nervous 
system (CNS) remains the leading killer of childhood cancers in the UK (Stiller, 2007).  This 
project was developed in collaboration with paediatric oncologists and surgeons from the 
Alder Hey Children’s hospital, and therefore this thesis focus on paediatric brain tumours. 
 
 1.2 Cancer cell biology 
Cancer cells have a distinct altered cell biology compared to normal cells.  The functional 
capabilities of cancer cells were first described and classified around 10 years ago by 
Hanahan and Weinberg (Hanahan and Weinberg, 2000).  In their review, they have 
described six hallmarks of cancer cells: self-sufficiency in growth signals, insensitivity to 
anti-growth signals, evading apoptosis, limitless replicative potential, sustained 
angiogenesis and tissue invasion & metastasis.  Over the last decade, advancing studies 
have further lead to the emergence of two additional hallmarks: deregulating cellular 
energetics and avoiding immune destruction (Figure 1.1) (Hanahan and Weinberg, 2011).  It 
is these acquired functions of cancer cells that enable them to survive and proliferate 
during the course of tumour development.  In this thesis, we will consider how some of 
these hallmarks are enabled in brain tumours, hence promoting survival and 
tumourgenesis. 
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Figure 1.1 Hallmarks of Cancer.  A diagram illustrating the ten hallmarks of cancer 
capabilities which contribute to tumourgenesis, as described by Hanahan and Weinberg.  
This figure is from the original paper (Hanahan and Weinberg, 2011). 
 
 1.2.1 Tumour growth 
One of the most eminent capabilities of cancer is deregulated cell proliferation.  Normally, 
cell growth and division are controlled to ensure the maintenance of tissue homeostasis.  
Cells remain non-proliferative until growth is triggered by extracellular mitogenic signals.  
These signals are generally growth factors (GFs), which will bind to GF receptors located on 
the cell membrane, where they will transmit the signals within the cells.  The growth signals 
will then activate a series of signalling cascades to activate cell proliferation.  In the context 
of a developing brain, the brain expresses a large selection of these mitogenic growth 
signals, such as fibroblasts growth factors (FGF), insulin growth factors (IGFs), 
platelet-derived growth factors (PDGFs) and epidermal growth factors (EGF) (Altaba et al., 
2002, Cheng et al., 2001, Xu et al., 2000).  Many of these factors dictate cell proliferation 
and cell differentiation, therefore, the probability of a fault in one of these signalling 
pathways/ response is high.  Indeed, amplification and upregulation of growth factors and 
growth factor receptors is associated with many brain tumours (Tuzi et al., 1991, Diedrich 
et al., 1995, Ekstrand et al., 1991).  Moreover, the loss of functions and or deletions of 
tumour suppressor genes such as p53, PTCH and PTEN are often observed in brain cancer 
(section 1.4.1 and 1.5.1). 
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 1.2.2 Tumour microenvironment  
Tumour microenvironment describes the whole structure of the tumour, including the 
heterogeneity of the cell types within and the surrounding oxygen concentration.  Where 
oxygen tension falls below the cell’s regular demands, cells experience hypoxia.  Hypoxia is 
a common characteristic of solid tumours (such as brain tumours), this is due to the rapidly 
dividing nature of cancer cells outgrowing its vasculature.  In addition to this, although 
angiogenesis (formation of new blood vessels) in the tumour is promoted, these blood 
vessels in tumours tend to be weaker, leaky and have blockages (Dvorak et al., 1991), 
therefore oxygen supply to the cells is often not sufficient.  Depending on the distance 
between tumour cells and the nearest blood vessels, tumour cells experience a varied 
gradient of oxygen concentration across the mass of the tumour, with the centre core being 
the most hypoxic (Figure 1.2).  Additionally, tumour cells can also experience ‘intermittent 
hypoxia’ due to changes in blood flow of microvessels within a tumour, or they can 
experience ‘anoxia’, when there is a complete lack of oxygen (Kimura et al., 1996, Dewhirst 
et al., 2008, Kiani et al., 1994).  Hypoxia is known to contribute to several aspects of cancer 
cell hallmarks including: deregulating cellular energetics; inducing angiogenesis and 
activating invasion & metastasis. 
 
 
Figure 1.2 Tumour hypoxia. A schematic diagram showing oxygenation of tumour cells.  
Blood vessels are in red.  Cells closest to the blood vessels are well oxygenated (dark blue), 
cells away from the blood vessels are hypoxic (light blue).  The tumour core (white) is the 
most hypoxic. 
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 1.2.2.1 Cellular energetics of cancer cells 
More than 50 years ago, it was observed that cancer cells utilise energy differently to 
normal cells (Warburg, 1930, Warburg, 1956a, Warburg, 1956b).  In normal cells, oxidative 
phosphorylation is the major energy metabolism used, where mitochondria consume 
oxygen to produce 36-38 ATP molecules.   It is only under anaerobic conditions that glucose 
is used as fuel, producing relatively little energy by the process of glycolysis.  During 
glycolysis, glucose is metabolized to produce pyruvate, where it is further oxidized in the 
mitochondria to generate only 2 ATP molecules.  Interestingly, cancer cells have a 
preference for utilizing glucose for energy metabolism even in the presence of oxygen.  
Furthermore, the pyruvate produced by glycolysis in cancer cells is directed away from 
mitochondria and used to produce lactate instead.  This favoured aerobic-glycolysis and 
lactate production in cancer cells is termed the “Warburg effect” (Warburg, 1930, Warburg, 
1956a, Warburg, 1956b).  In solid tumours, where the cells are hypoxic, the lack of oxygen 
availability will also drive the cells toward glycolytic activity.  This is partially aided by 
upregulated expression of glucose transporters (GLUT1) and dehydrogenaseA (LDHA) to 
enhance glucose uptake and glycolysis in hypoxia (Jones and Thompson, 2009, Hsu and 
Sabatini, 2008). 
 1.2.2.2 Angiogenesis 
To enhance the delivery of oxygen and nutrient supply, which is required by the rapidly 
dividing cells, tumour cells can promote new vasculature by angiogenesis. In adult human 
cells, angiogenesis is normally only switched on transiently when required, such as during 
would healing.  However, in cancer cells, this process remains constantly turned on 
(Hanahan and Folkman, 1996, Baeriswyl and Christofori, 2009).  At a molecular level, 
angiogenesis is controlled by the vascular endothelial growth factor-A (VEGF-A) and 
fibroblast growth factor-2 (FGF-2), which are both induced by hypoxia (Connolly et al., 
1989, Klagsbrun and Soker, 1993, Shweiki et al., 1992, Veikkola and Alitalo, 1999, Kuwabara 
et al., 1995).  These growth factors bind to tyrosine kinase receptors on endothelial cells, 
stimulating endothelial cell proliferation, migration to hypoxic region and new blood vessel 
formation (Veikkola and Alitalo, 1999, Singh et al., 1995, Volpert et al., 1997, Baeriswyl and 
Christofori, 2009).  Additionally, tumour cells can further promote new vasculature by 
downregulating angiogenesis inhibitors, such as thrombospondin-1 and β-interferon (TSP-1) 
(Laderoute et al., 2000, Lawler, 2002).  The development of new vasculature encourages 
fresh nutrient supply, thus supporting the growth of tumour cells (Hanahan and Folkman, 
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1996).  The induction of angiogenesis is found at the early and mid stage of cancer, during 
the premalignant phase of invasive cancer, therefore this process is often viewed as an 
indication of macroscopic tumour progression (Raica et al., 2009, Hanahan and Folkman, 
1996). 
 1.2.2.3  Tissue invasion and metastasis 
The process of metastasis involves multiple complicated steps and is not completely 
understood.  These steps include Epithelial-mesenchymal transition (EMT), endothelial 
transmigration, survival in the circulatory system, extravasation and proliferation at new 
sites (van Zijl et al., 2011, Semenza, 2012a).  Invasive and metastatic properties of tumour 
cells generally involve the alteration of three classes of proteins: cell to cell adhesion 
molecules (CAM), integrins and proteases (Behrens, 1993, Hood and Cheresh, 2002, Stetler-
Stevenson and Yu, 2001).  Firstly, EMT is a process where epithelial cells lose their cell-to-
cell adhering ability and undergo biochemical changes in order to enhance migratory and 
invasive properties (Klymkowsky and Savagner, 2009, Polyak and Weinberg, 2009, Thiery et 
al., 2009, Barrallo-Gimeno and Nieto, 2005).  EMT is mediated by the reduction of E-
cadherin expression.  The role of E-cadherin is to maintain the structure of epithelial cell 
sheets by forming adherens junctions to adjacent cells (Christofori and Semb, 1999, Berx 
and van Roy, 2009, Cavallaro and Christofori, 2004).  There are a number of factors 
mediating EMT. For example, hypoxia induces EMT regulators such as Snail, Slug and Twist, 
which in turn transcriptionally repress the expression of E-cadherin (van Zijl et al., 2011, 
Tsai and Wu, 2012).  Furthermore, other hypoxia-induced targets such as FGF, VEGF and 
EGF also induce EMT.  FGF induces Snail, leading to repression of E-cadherin (Ciruna and 
Rossant, 2001); both VEFG and EGF induce expression of Snail and Twist (Yang, A. D. et al., 
2006, Wanami et al., 2008); and EGF can also promote E-cadherin endocytosis (Lu et al., 
2003, Lee et al., 2008, Lo et al., 2007). 
Secondly, endothelial transmigration describes the invasion of cancer cells into the blood or 
lymphatic vessel, by which the cells can then be transported to distant parts of the body to 
form secondary tumours.  The overview of this process is that malignant cells attach 
themselves to the endothelial membrane where they can pass through and enter into 
vasculature.  The mechanism of this migration into the blood vessels is thought possible by 
passive movement and/or active process (intravasation) (Bockhorn et al., 2007).  Both 
passive and active movements of cancer cells are shown to be mediated by the 
microenvironment, such as hypoxia.  Hypoxia can mediate passive entry by inducing VEGF, 
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which promotes blood vessel formation, providing a route for cancers cells to enter into 
circulation (Issa et al., 2009, Hicklin and Ellis, 2005).  Many reports support the idea that 
intravasation is associated with increased expression of growth factors and receptors, 
including ones that are induced by hypoxia, such as EGF, EGF-R and TGF-β (Joyce and 
Pollard, 2009, Giampieri et al., 2009).  Other studies in breast cancer have also 
demonstrated that cancer cells can directly enter lymphatic vessels, and suggest this is 
mediated by hypoxia-induced ALOX15 (arachidonate lipogenases) enzyme, which 
subsequently reduces VE cadherin expression, damaging the integrity of the lymphatic 
endothelial cell layer and allowing cell invasion (Hulten et al., 2010, Kerjaschki et al., 2011).  
Once the cancer cells have disseminated into the circulatory system, the metastasis into the 
new sites is termed extravasation.  A process begins by cancer cells adhering to endothelial 
cells (EC), disrupting EC interactions and then migrating through the EC layer.  The adhesion 
can be mediated by hypoxia mediated expression of adhesion molecules such as L1CAM (L1 
cell adhesion molecule) (Zhang et al., 2012) and angiopoietin-like 4 (ANGPTL4) (Padua et al., 
2008).  ANGPTL4 dissociates the cell-cell interaction of EC thus promoting the process of 
extravasation.  Although many of the details and exact mechanisms of metastasis and 
invasion remains open, accumulating evidence supports that these processes can be 
mediated by hypoxia through regulation of growth factors, growth factor receptors and 
cytokines. 
 
 1.3 Cellular oxygen regulation 
The level of oxygen demand within a cellular system is dependent on the cell metabolic 
activity, and determined by the location of the cells in relation to the nearest blood vessels, 
as oxygen has a limited diffusing distance of 150µm (Folkman et al., 2000).  As the oxygen 
requirement varies between cells and tissues, the term ‘hypoxia’ will mean different oxygen 
levels for each cell type.  Some examples of physiological oxygen levels in humans include: 
1% to 5% in the brain (Sharp and Bernaudin, 2004, Panchision, 2009, Jezek et al., 2010); 
19.7% in the airway; 5.6 % in the lungs; 3.8% in muscles; and 1.9% in the heart (Carreau et 
al., 2011, Wiener et al., 1976).  Hypoxia is encountered in many biological processes, 
including developmental biology, stem cell biology and immunity (Iyer et al., 1998, 
Dunwoodie, 2009, Gustafsson et al., 2005, Liu, L. X. et al., 2008, Mohyeldin et al., 2010, 
Zinkernagel et al., 2007).  Hypoxia is also associated with diseases such as myocardial 
infarction (Semenza, 2000), stroke (brain ischemia) (Sun, 1999, Markus et al., 2004) and 
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cancer as mentioned above (Sharp and Bernaudin, 2004, Safran and Kaelin, 2003, Bruick, 
2003). 
 
 1.3.1 The HIF family of protein 
The cellular sensing and response to oxygen level changes is mediated by a transcription 
factor called Hypoxia-Inducible Factor (HIF), first discovered in 1992 by Greg Semenza 
(Semenza and Wang, 1992).  Under normal circumstances, HIF plays a vital role in allowing 
cellular adaptation and survival in low oxygen conditions by promoting the transcription of 
genes involved in processes such as angiogenesis, red blood cell maturation and energy 
metabolism (Shweiki et al., 1992, Forsythe et al., 1996, Semenza et al., 1991, Goldberg et 
al., 1998, Weidemann and Johnson, 2008, Wenger, 2002).  As mentioned earlier, the same 
properties are developed in tumour cells and enhance tumourgenesis. 
HIF is a heterodimeric protein belonging to the basic helix-loop-helix (bHLH) family (Wang 
et al., 1995).  It consists of a constitutively expressed oxygen sensitive alpha subunit and an 
oxygen insensitive beta subunit.  Currently three α-subunit isoforms (HIF-1α, HIF-2α, and 
HIF-3α) and two β-subunits (HIF-1β, HIF-2β) are known (Wang et al., 1995, Jiang et al., 
1996, Gu et al., 1998, Makino et al., 2002).  The HIF-1α is the most characterised isoform, it 
is 826 amino acids long and consists of the bHLH domain, PAS domain (PER-ARNT-SIM), 
oxygen-dependent degradation domain (ODDD), N-TAD (amino-terminal transcriptional 
activation domain) and C-TAD (carboxy-terminal transcriptional activation domain) (Figure 
1.3).  The basic region of the bHLH motif is essential for DNA binding and PAS is the central 
domain which facilitates dimerisation with HIF-1β (Wang et al., 1995).  The ODDD contains 
two hydroxylation sites (proline 402 and 564) and the N-TAD region.  Lastly, there is the 
C-TAD, which contains another hydroxylation site (asparagine 803). 
 
 
Figure 1.3 HIF-1α Domain Structure.  Schematic diagram showing the core domains of 
HIF-1α. (bHLH = basic helix-loop-helix, PAS=PER-ARNT-SIM, ODDD= oxygen dependent 
degradation domain, N-TAD = amino terminal transcriptional activation domain, C-TAD = 
carboxyl terminal transcriptional activation domain).  The key hydroxylation sites are 
indicated (Pro= proline, Asn= asparagine). 
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 1.3.2 The HIF signalling pathway 
Although HIF-1α is constitutively expressed in normoxia, it is also continually degraded.  
HIF-1α protein levels and activity are tightly controlled by a group of prolyl hydroxylases 
(PHD1, PHD2, PHD3) and Factor inhibiting HIF (FIH).  In normoxia, PHDs use oxygen as a 
co-substrate to hydroxylate the two key proline residues located in the ODDD (Figure 1.3) 
of the HIF-1α subunit (Masson and Ratcliffe, 2003).  This hydroxylation acts as a signal, 
allowing interaction with the E3 ubiquitin ligase, Von Hippel-Lindau protein (VHL).  VHL 
promotes lysine-linked polyubiquitination thus mediating HIF-1α for targeted degradation 
by 26S proteasome (Maxwell et al., 1999, Tanimoto et al., 2000) (Figure 1.4).  Additionally, 
in the presence of oxygen, FIH hydroxylates the asparagine residue of HIF-1α, preventing 
HIF-1α from interacting with transcriptional co-activators such as p300 and CREB binding 
protein (CBP) (Arany et al., 1996, Schofield and Ratcliffe, 2004, Lee et al., 2004, Taylor and 
Pouyssegur, 2007).  Taken together, when oxygen is available, HIF-1α is rapidly degraded 
and is transcriptionally inactive. 
Under hypoxic conditions, the lack of oxygen substrate means that PHDs and FIH can no 
longer hydroxylate HIF-1α efficiently, allowing HIF-1α to evade degradation and 
accumulate.  HIF-1α binds to HIF-1β subunit, forming a functionally active heterodimeric 
transcription factor (Wang et al., 1995, Arany et al., 1996).  In the nucleus, it binds to the 
promoter region of target genes, by recognition of the Hypoxia Response Element (HRE) 
sequence (-RCTTG-), interacts with its coactivators p300 and CBP, which together leads to 
transcriptional activation (Pugh et al., 1991, Semenza et al., 1991, Wenger et al., 2005) 
(Figure 1.4).  Over 200 HIF-1α target genes have been described and predicted, among 
which are its own regulators, PHDs, therefore forming a negative feed-back loop with itself 
(Schofield and Ratcliffe, 2004, Ortiz-Barahona et al., 2010, Elvidge et al., 2006, Benita et al., 
2009).  Other well-known target genes include: erythropoietin (EPO) that controls 
erythropoiesis; vascular endothelial growth factor (VEGF) that promotes angiogenesis; and 
glucose transporter1 (GLUT1), which regulates glucose uptake and glycolysis.  Whilst HIF-1α 
plays a crucial role in maintaining and facilitating cell homeostasis when cells are deprived 
of oxygen, HIF-1α can regulate induction of proapoptotic factors such as nineteen kD 
protein-3 (BNIP3), if cells experience near anoxic levels (Sowter et al., 2001, Azad et al., 
2008, Guo et al., 2001, Greijer and van der Wall, 2004). 
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Figure 1.4 A schematic representation of HIF-1α regulation in normoxia (left) and hypoxia 
(right).  In normoxia, HIF-1α is hydroxylated by the PHD proteins and targeted for 
ubiquitination by VHL, which targets the alpha subunit for proteosomal degradation.  In 
hypoxia, the activity of the PHD proteins is reduced and HIF-1α is not hydroxylated causing it 
to accumulate. In the nucleus the HIF-1α / HIF-1β heterodimer binds to the HRE of target 
genes, associates with co-activators p300/ CREB-binding protein (CBP) and activates 
transcription of hypoxia inducible genes.  
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 1.4 Brain tumours 
Brain tumour types are usually named dependent on the tumour cells origin or by their 
location.  They are further classified into benign low grade (grade I and II) and malignant 
high grade (grade III and IV), following the conventional cancer grading system (Louis et al., 
2007).  Although not all brain tumours are malignant, a low grade tumour itself can often 
still cause serious symptoms if located in a crucial part of the brain. 
 
 1.4.1 Gliomas 
Gliomas contribute to half of all primary brain tumours.  The three main types are 
Astrocytoma, Ependymoma and Oligodendroglioma, developed from astrocytes, 
ependymal cells and oligodendrocytes respectively.  Astrocytomas are the most common 
type of glioma in adult and it is graded and classified into different types by histology.  They 
are Pilocytic astrocytomas (grade 1); Low-grade diffuse astrocytomas (grade II); anaplastic 
astrocytomas (grade III); and Gliomastoma multiforme (GBM) (grade IV) (Kleihues and 
Ohgaki, 2000).  GBM is the most malignant form of gliomas and it will be one of the brain 
tumours investigated in this thesis. 
 1.4.1.1 Glioblastoma multiforme (GBM) 
Glioblastoma (GBM) is a highly aggressive hypoxic tumour, found more commonly in adults 
than children.  GBM is characterised by its high invasiveness property and poor response to 
treatment.  Molecularly, GBMs are characterised and classified into one of four subtypes 
based on genetic markers (Verhaak et al., 2010).  Proneural subtypes show p53 mutation, 
loss of PTEN and PDGF-receptors amplifications; classical subtypes show epidermal growth 
factor (EGFR) amplification/ mutations, loss of PTEN, NOTCH and SHH pathway activation; 
neural subtypes are characterised by overexpression of HER2 (human epidermal growth 
factor receptor 2) and mesenchymal subtypes are indicated by loss of TP53/ PTEN and NFκB 
activation (Furnari et al., 2007, Brennan et al., 2009, Agnihotri et al., 2012).  Another 
mutation found in 12% of GBM, is the mutation of the IDH1 (isocitrate dehydrogenase) 
gene (Parsons et al., 2008, Nobusawa et al., 2009), this enzyme is involved in the citrate 
acid cycle and it is also mutated in 70% of gliomas (Yan et al., 2009, Thompson, 2009). 
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 1.4.1.2 Origin of GBM 
The cell of origin for GBM remains elusive, but there is increased support of GBM and the 
cancer stem cells (CSC) hypothesis (Dirks, 2001, Dirks, 2008, Stiles and Rowitch, 2008).  
GBM is a heterogeneous tumour and several groups have found that it contain a CSC 
population.  These cancer stem cells are known as GBM stem cells (GSCs) (Yuan et al., 2004, 
Altaner, 2008, Huang et al., 2010).  GSCs are similar to normal stem cells and neural stem 
cells phenotypically, possessing self-renewal and proliferation properties.  It is hypothesised 
that these stem cells come from mature glial cells dedifferentiating or from mutations in 
neural progenitors or from mutations in adult neural stem cells (Dirks, 2001, Dirks, 2008, 
Stiles and Rowitch, 2008).  The induction of CSC phenotypes is further enhanced by the cell 
micrcoenvironment such as hypoxia (Li, P. et al., 2013, Keith and Simon, 2007).  Regions of 
hypoxia in GBM are often associated with increased expression of stem-cell markers 
(McCord et al., 2009, Bar et al., 2010). 
 1.4.1.3 GBM treatment 
The standard immediate treatment for GBM is surgical resection followed by radiation or 
combined radiotherapy and chemotherapy (Hargrave and Zacharoulis, 2007, Stupp et al., 
2005).  Patients with newly diagnosed GBM treated with radiotherapy followed by 
temozolomide, (an alkylating agent which is the sole drug used to treat GBM), have a 26% 
2-year survival rate (Hargrave and Zacharoulis, 2007, Stupp et al., 2005).  However, 
treatment response is poorer in children, with only a 12% 2-year survival rate (Hargrave and 
Zacharoulis, 2007, Nicholson et al., 2007, Broniscer et al., 2006, Ruggiero et al., 2006). 
Moreover, hypoxia-induced HIF overexpression is correlated to increased angiogenesis, 
tumour dispersal, treatment resistance and a worse prognosis in GBM (Birner et al., 2001, 
Zagzag et al., 2000, Thorns et al., 2003, Kaur et al., 2005, Agnihotri et al., 2012, Hu et al., 
2012). 
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 1.5 Brain tumour in children 
 1.5.1 Medulloblastoma 
Medulloblastoma (MB) is the most common malignant paediatric brain tumour, it accounts 
for 15-20% of cancer of the CNS in children (Figure 1.5) (Pizer and Clifford, 2008).  It has the 
highest prevalence among children between ages 4 to 7 years and it is more common in 
boys than girls.  MB’s arises in the posterior fossa of the brain, which consists of the 
cerebellum and brain stem (Medulla).  They are neuroepithelial tumours originating from 
neural stem cell progenitors in the granule cell layer of the cerebellum (Raffel, 2004).  
Hence MB is often located in the cerebellar vermis, in the roof of the forth ventricle 
presenting as a midline tumour.  In less often cases, it can arise in the cerebellar 
hemisphere in older children.  MB has a tendency to metastasis throughout the CNS via the 
cerebrospinal fluids (CSF), but rarely to other parts of the body outside CNS (Kleinman et 
al., 1981). 
Some of the earliest study of MB molecular genetics revealed the loss of tumour suppressor 
genes such as APC (Adenomatous Polyposis Coli) and NF1 (Neurofibromin 1) are observed 
in primary MB (Huang et al., 2000, Martinez-lage et al., 2002).  Other chromosomal losses 
such as 17q, 10 and 11 were also detected in MB (Gilbertson et al., 2001, Langdon et al., 
2006).  The classification of MB, into subgroup and responses to treatment, was later found 
to be closely related to several important developmental pathways.  Deregulation in 
Hedgehog (Shh), Notch and Wingless (Wnt) developmental signalling pathways has been 
linked to MB growth (Yokota et al., 2002, Rossi et al., 2008, Guessous et al., 2008).  
Additionally, other oncogenic pathways such as MYC (v-myc avian myelocytomatosis viral 
oncogene homolog) and RTK (receptor tyrosine kinase) are also involved in the progression 
of MB (Guessous et al., 2008, Gilbertson, 2004). 
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Figure 1.5 An example of medulloblastoma. A T1-weighted sagittal MRI scan showing a 
medulloblastoma tumour mass situated next to the medulla and cerebellum.  Adapted from 
Pizer et al. 2008. (Pizer and Clifford, 2008) 
 
 1.5.1.1 Histopathology 
Five histopathological variants of MB are currently classified by the World Health 
Organisation (WHO): (i) Classical medulloblastoma (Figure 1.6A) (ii) Medulloblastoma with 
extensive nodularity (iii) Desmoplastic/nodular medulloblastoma (Figure 1.6B) (iv) 
Anaplastic medulloblastoma (Figure 1.6C) and (v) Large cells medulloblastoma (Louis et al., 
2007, Gilbertson, 2004). 
Representing ~80% of MB diagnosed, the type (i) classical MB is the most observed 
phenotype.  These tumours are presented as sheets of small round cells with nuclei as big 
as the cell and little cytoplasm (Figure 1.6A).  Type (iii) desmoplastic MB occurs mostly in 
very young children under the age of 3 (Rutkowski et al., 2005).  Type (iv) anaplasia is 
observed in ~15% of cases and is characterised by nuclei with varied size and shape, this 
MB is associated with poor prognosis.  Finally, the large cells type (v), only occurs in 5% of 
cases but it is associated with the worst outcome (McManamy et al., 2003, Eberhart, 2003). 
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Figure 1.6 Common MB histopathological variants.  Three histological sections of MB 
stained with hematoxylin and eosin.  (A) Classic, small round nuclei arranged sheets. (B) 
Desmoplastic, MB show neurocytic differentiation, surrounded by collagen matrix. (C) 
Anaplastic, large tumour cells with pleiomorphic nuclei.  Adapted from Gilbertson 
(Gilbertson, 2004). 
 
 1.5.1.2 MB subgroup classification and genetic markers 
Currently in clinic, the classification of MB is based on their histopathology.  In the last 
decade, several groups have utilised transcriptomic studies to further classify MB into 
subgroups but final conclusions was varied between studies (Kool et al., 2008, Northcott et 
al., 2011, Thompson et al., 2006).  Recently, a consensus has emerged that there are 4 
principal subgroups of MB, which are: Shh, WNT, Group 3 and Group 4 (Taylor et al., 2012).  
Based on clustergram algorithm, the subgroups appear to further differentiate into 
subtypes, but these are not yet classified and are currently named as α, β and γ (Figure 1.7) 
(Cho et al., 2011, Taylor et al., 2012). 
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Figure 1.7  Classification of Cerebellar embryonal tumours.  MB are spilt into four 
subgroups, Wnt, Shh, Group 3 and Group 4.  Each subgroup is classified to subtype α, β or γ.  
Figure obtained from Taylor et al.  (Taylor et al., 2012) 
 
Wnt subgroup, generally with classical appearance is the best known group with good 
prognosis.  Wnt group express high level of MYC and mutations of the CTNNB1 gene is 
often found in this group (Northcott et al., 2011).  Additionally this group shows positive 
nuclear stain with β-catenin and monosomy six (one copy of chromosome 6 is deleted) 
(Taylor et al., 2012, Ellison, D. et al., 2011, Ellison, D. W. et al., 2011, Clifford et al., 2006).  
Shh subgroups carry mutation involving the Sonic Hedgehog signalling pathway and express 
high level of MYCN (MYC Neuroblastoma derived). Its identification is obtained by 
immunohistology staining for SFRP1 (secreted frizzled-related protein 1) or GAB1 (Growth 
factor receptor-bound protein 2-associated binding protein 1) (Northcott et al., 2011, 
Thompson et al., 2006, Ellison, D. W. et al., 2011).  Group 3 commonly shows classical 
histopathology and high expression of MYC, FOXG1B (Forkhead box G1B) and OTX2 
(orthodenticle homeobox 2) (Cho et al., 2011, Kool et al., 2008, Northcott et al., 2011).  The 
key marker to differentiate Group 3 is with NPR3 (nucleolin related protein 3) staining and 
by transcriptional profiling clustering (Northcott et al., 2011).  Group 4 also expresses high 
level of OTX2 and FOXG1B (Adesina et al., 2007, Northcott et al., 2011). The genetic 
markers for Group 4 are less well classified, the current immunohistochemical marker used 
for this group is KCNA1 (potassium voltage-gated channel).  This group is often associated 
with high incidence loss of chromosome X and 17q.  (Cho et al., 2011, Kool et al., 2008, 
Northcott et al., 2011). 
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 1.5.1.3 MB subgroup characterisation 
The Medulloblastoma Advanced Genomics International Consortium group carried out an 
extensive somatic copy number aberration (SNCA) study involving over 1000 MB samples in 
attempt to identify the molecular genetics of MB (Northcott et al., 2012).  SNCA is the study 
of chromosomal changes including DNA duplications, chromosomal deletions or 
translocation.  They have discovered 62 regions of SCNA which are common in MB.  Some 
of which are specific to certain subgroup (Table 1.1). 
 
Gene SCNA types Subtype 
PTEN Homozygous deletions Shh 
PTCH1 Homozygous deletions Shh 
CDKN2A/B Homozygous deletions Shh 
MYCL1 Amplifications Shh 
PPM1D Amplifications Shh 
MDM4 Amplifications Shh 
MYCN Amplifications Shh, Group 4 
SCNAIP Tandem duplications Group 4 
PVT1 Translocation Group 3 
Table 1.1 Somatic copy number aberrations (SCNAs) in MB.  Example of enriched-SCNAs in 
MB subtype. (Northcott et al., 2012) 
 
In MB, recurrent homozygous deletion is relatively rare but not completely omitted (Table 
1.1).  More strikingly, recurrent high-level amplifications were identified in 28 regions.  This 
include MYCN in the Shh subgroup and Group 4; MYCL1 (MYC lung carcinoma derived) in 
Shh; and MYC in Group 3.  The Shh group remains the most easily identified with other 
enriched SCNAs amplification such as GLI2 (GLI family zinc finger 2), MYCL1 and PPM1D 
(protein phosphotase 1D) (Ruark et al., 2013).  The pathogenesis of Group 4 is poorly 
understood, however, SNCAIP (synuclein, alpha interacting protein) tandem duplication is 
associated with this group (Northcott et al., 2012). 
Besides alteration in copy numbers, translocation assisted by the process of chromothripsis 
is observed in Group 3.  Chromothripsis is a phenomenon where a chromosome ‘shatters’ 
and the fragments rearrange but with a potential deletion (Stephens et al., 2011, Forment 
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et al., 2012).  Chromosome 8 chromothripsis has led to the gene fusion of PVT1 (a non-
protein coding RNA) fusion with NDRG1 (N-myc downstream regulated 1) or PVT1 with MYC 
(Northcott et al., 2012).  Moreover, chromosome 8 chromothripsis is further correlated to 
the deletion of chromosome 17p, hence the loss of TP53.  Finally, the WNT group shows no 
significant frequent deletion and thus there are no specific SCNA’s related to this group. 
In contrast to SCNA, which is common in MB, single nucleotide variants (SNV) are relatively 
less prevalent.  Sanger sequencing study consisting of 22 MB tumours has only detected 8 
SNVs per tumour (Parsons et al., 2011).  Nonetheless, some of these SNVs are enriched in 
certain subgroups.  For example, SNVs in PTCH1 (protein patched homolog 1), CTNNB1 
(catenin (cadherin-associated protein) beta 1) gene are found predominately in Shh group 
(Parsons et al., 2011, Northcott et al., 2012). 
Furthermore, exon sequencing study of MB has shown a list of 12 specific somatic 
mutations.  Some of these genes are mentioned earlier (TP53, PTCH, CTNNB1) but some 
newly identified candidates such as DDX3X (DEAD box polypeptitde 3 X-linked), a RNA 
helicase; GPS2 (G protein pathway suppressor 2) and BCOR (BCL6 corepressor) have been 
identified (Pugh et al., 2012). 
 1.5.1.4 Genetic Predisposition of MB 
The majority of MB arises spontaneously with unknown causes, with only 5% of cases due 
to genetic predisposition (Pizer and Clifford, 2008). Gorlin, Turcot and Li-Fraumeni 
Syndromes are three genetic disorders, which have shown higher incidence of MB 
formation.  These diseases are caused by germline mutations in Patched homolog 1 (PTCH), 
APC and tumour suppressor TP53 genes respectively (Zurawel et al., 2000, Huang et al., 
2000, Barel et al., 1998). 
Gorlin’s syndrome is associated with skeletal abnormalities due to the mutation of PTCH 
gene which encodes a transmembrane protein.  PTCH is a key growth regulator of external 
granular cell layer cells, which binds a family of protein belonging to the Shh pathway.  
Normally, Shh pathway remains in an ‘off state’, this is achieved by the binding of PTCH 
with smoothened protein (SMO).  However, upon SHH binding to PTCH receptor, PTCH is 
relieved allowing a signal transduction to the nucleus promoting granule cell proliferation 
(Kenney et al., 2003).  Therefore, deletion of PTCH and deregulation of the Shh pathway 
leads to constitutive activation and proliferation of granule cells hence MB formation.  
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Turcot’s syndrome is linked to mutations of the APC gene, a component of Wnt pathway.  
The Wnt pathway coordinates a series of developmental processes including the 
proliferation of progenitor cells in the central nervous system (Huang et al., 2000, Yokota et 
al., 2002).  Wnt activation is achieved through a serial cascade of activity, ultimately 
activating expression of genes which are involved in proliferation, inhibition of cell death 
and differentiation of cells. Both mutations in the APC gene and other members of Wnt 
signalling pathway have been shown to be associated with MB (Huang et al., 2000, Yokota 
et al., 2002, Dahmen et al., 2001). 
 1.5.1.5 Symptoms of patients with MB 
Similar to general brain tumours symptoms, MB patients often exhibit intermittent and 
subtle headaches, vomiting and drowsiness, this is due to the increased intracranial 
pressure within the skull.  As the cerebellum is a centre for voluntary motor movement, 
contributing to fine tune motor activity, coordination, timing, equilibrium and balance, 
patients can display a lack of coordinated muscle movement or cranial nerve palsy 
(involuntary muscle spasm). 
 1.5.1.6 Prognosis  
The stage of the disease and the age of the patient upon diagnosis are important 
contributing factors in the prediction of MB outcome.  Thus the prognosis of MB patients 
relies on a combined assessment of patient’s age, histopathology, subgroups, biological 
markers and the stage of the disease.  For a simple overview, MB patients are typically split 
into three groups: (1) Standard/ average risks, if patient is older than 3 years and without 
evidence of metastasis; (2) high risk, patients with evidence of CSF spread; and (3) patients 
under 3 years at the point of diagnosis (with the exception of type III desmoplasia). 
The favourable MB type is the desmoplastic form found in patient under 3 years, they are 
often associated with good outcome (Rutkowski et al., 2005, McManamy et al., 2003). Also, 
the Wnt subgroup with activation of Wnt/Wingless pathway (beta-catenin) markers 
displays a favourable outcome (Clifford et al., 2006, Ellison, D. W. et al., 2011).  
Furthermore, there is evidence that good prognosis upon treatment is associated with 
certain growth factor receptors, such as TrkC (neurotrophin-3 receptor) expression via 
induction of apoptosis (Kim et al., 1999).  Shh and Group 4 MB patients appear to have 
similar intermediate outcome, where their prognosis are worse than Wnt but better than 
Group 3. 
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MB Group 3, which occurs more commonly in boys than girls have the least favoured 
prognosis, with frequent metastatic activity and cancer reoccurrence (Northcott et al., 
2011).  In particular if MYC is amplified in Group 3 patients, this is highly associated with 
death (Taylor et al., 2012). Other factors linking to poor treatment prognosis is the 
expression of the HER2, platelet derived growth factor receptor (PDGF-R) and insulin-like 
growth factor receptor-1 (IGFR-1). 
 
 1.5.2 Current Treatment  
The treatment options for patients are determined by the grade of the tumour and the 
patient’s age.  Where possible, complete or near complete tumour excision by surgical 
resection is the first line of treatment, followed by craniospinal radiotherapy (CSRT).  This 
standard treatment results in a 5-year survival rate of 50-60% (Gilbertson, 2004, Hargrave 
and Zacharoulis, 2007).  Resection is achieved with surgical techniques aided by 
neuronavigation.  Then after surgery, a CSRT dose of 54-55 Gy is applied to the primary 
tumour site and a lower dose of 34-36 Gy is directed at and along the spinal cord, to 
minimise potential spreads through the CSF (Hargrave and Zacharoulis, 2007). 
Another more advanced radiotherapy procedure uses intensity modulated radiotherapy 
IMRT (Pizer and Clifford, 2008).  IMRT is a more precise method that uses a 
computer-controlled linear accelerator to deliver doses of radiation in multiple small 
volumes.  This method can target the three dimensional shape of the tumours precisely 
using a computer generated planning system (Huang et al., 2002).  IMRT is needed for 
tumours which are situated in a location surrounded by normal critical brain structure.  
Lastly, in North America, tight doses of proton beams are also used to target the posterior 
fossa and spinal components (St Clair et al., 2004). 
Chemotherapy treatment is generally applied to younger patients, recurring MB or high risk 
patients (in combination with radiotherapy) (Hargrave and Zacharoulis, 2007).  The majority 
of the drugs used to treat MBs tend to be DNA damaging agents.  MB is a relatively 
sensitive tumour, showing sensitivities to single drug treatment with cisplatin, 
cyclophosphamide and methotrexate (Kortmann et al., 2000, Strother et al., 2001).  The 
cocktail combination of cyclophosphamide, carboplatinum and etoposide shows good 
treatment response of 65% 5-year survival rate for average risk MB (Kortmann et al., 2000, 
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Taylor et al., 2003).  Other drugs such as cisplatin, lomustine and vincristine are also 
commonly used (Rossi et al., 2008, Packer et al., 1994). 
 1.5.2.1 Etoposide 
Etoposide is a topoisomerase II inhibitor, affecting its enzyme regulatory function.  During 
normal DNA replication, highly tensile supercoiled DNA is created.  Topoisomerase II 
induces double stranded breaks (DSB) within the supercoiled DNA, allowing it to unwind 
and relax before re-ligation. In the presence of etoposide, topoisomerase II religation ability 
is inhibited, thus allowing the number of DSB breaks to accumulate within the cell.  Through 
this mechanism, etoposide triggers the activation of the p53 pathway and subsequently 
apoptosis. 
 1.5.2.2 Cisplatin 
Cisplatin (cis-diamminedichloroplatinum(II) or CDDP) is a compound that contain a platinum 
atom with two chloride ions and two amine groups (Siddik, 2003).  Within the cells, cisplatin 
chloride ions are displaced by water, and this allows the binding of platinum atoms to DNA 
bases resulting in DNA cross links.  Cisplatin can form both DNA inter or intra-strand cross 
linking, altering the DNA conformation and preventing DNA synthesis (Eastman, 1987, Pinto 
and Lippard, 1984). 
 1.5.2.3 Methotrexate 
Methotrexate (MTX) is an antimetabolite and antifolate drug, which inhibits purine and 
pyrimidine synthesis (Barnhart et al., 2001, Tian and Cronstein, 2007, Pagnoux and 
Guillevin, 2009).  It is a competitive inhibitor of the dihydrofolate reductase (DHFR), an 
enzyme that reduces dihydrofolic acid to tetrahydrofolate.  The production of 
tetrahydrofolate is required for the de novo synthesis of purines, which are needed for 
DNA/RNA synthesis during S phase (Chen et al., 1984). 
 1.5.2.4 Problems with current MB treatment  
In young patients, the brain is still developing, therefore the current treatments available 
can cause long term side effects (Frange et al., 2009, Gilbertson, 2004).  Surgery leaves 20% 
of patients with limb weakness, cranial nerve palsies, personality changes and involuntary 
movements (Pizer and Clifford, 2008).  Moreover, molecular mechanisms of resistance to 
chemotherapeutic drugs have been reported (Friedman et al., 1992, Dong et al., 1999, 
Bacolod et al., 2009, See, 2012). 
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One of the earliest observations was resistance to cyclophosphamide, a common alkylating 
drug used at that time.  This compound is processed by the body in multisteps to generate 
alkylating metabolites, which are damaging to the DNA thus causing cytotoxity.  However, 
resistance is acquired by overexpression of the aldehyde dehydrogenase enzyme (ALDH).  
ALDH catalyses the oxidation of alkylating metabolites, thus detoxifying the function of this 
drug (Friedman et al., 1992).  In addition to overexpression of ALDH, another alkylating 
agent drug resistance mechanism acquired by MB was observed: the overexpression of O6-
methylguanine-DNA-methyltransferease (MGMT) (Dong et al., 1999).  MGMT transfers the 
alkyl group from DNA into a cysteine residue within the enzyme, thus protecting DNA 
against alkylated guanine.  Finally, another cyclophosphamide resistance mechanism is due 
to overexpression of the metallothionein (Bacolod et al., 2009).   Metallothionein contains 
thiol groups in its cysteine residues, which can covalently bind to cyclophosphamide, 
detoxiyifing it to a non-toxic derivative (Bacolod et al., 2009).  Apart from acquired 
molecular drug resistance mechanisms, inadequate drug administration can itself be 
problematic.  For example, the blood-brain barrier (BBB) can restrict the entry of 
hydrophilic or large lipophilic compounds into the brain (Schinkel, 1999, Gottesman et al., 
2002), hence reducing the concentration of drugs delivered to tumour sites (Gatti and 
Zunino, 2005, Mellor and Callaghan, 2008). 
 1.5.2.5 Tumour hypoxia and chemoresistance  
Tumour hypoxia is often associated with resistance to treatment and poor prognosis 
(Brown, 1999, Sullivan et al., 2008, Rohwer and Cramer, 2011, An et al., 1998, Greijer and 
van der Wall, 2004, Piret et al., 2006, Semenza, 2003).  Although the study of hypoxia and 
chemoresistance in MB is not extensive, we will consider the general role of hypoxia-
induced treatment resistance in tumours.  On a physical level, treatment can be 
compromised due to the poor tumour vasculature of solid tumours, as drug delivery to the 
cells far away from the blood vessels becomes difficult.  Moreover, certain drugs require 
oxygen as a co-substrate for their mechanism of action, these drugs, such as tirapazamine 
will therefore become ineffective in an environment lacking oxygen (Hicks et al., 2004, 
Koch, 1993, Teicher, 1994). 
Molecularly, hypoxia associated chemoresistance has been reported to be mediated by HIF 
expression.  An early study demonstrated HIF-induced multidrug resistance 1 (MDR1) gene 
contributing to drug resistance (Comerford et al., 2002).  MDR1 is a glycoprotein encoded 
by the ABCB1 gene, an efflux pump which has been evolved to remove ‘harmful’ substances 
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such as chemotherapeutic drugs.  Later on, other studies have shown that more genes such 
as multidrug-resistance associated protein 1 (MRP1) (another ABC transporter) and Lung 
resistance protein (LRP) were also upregulated by HIF and contribute to hypoxia-induced 
resistance (Chen, L. et al., 2009, Zhu et al., 2005, Liu, L. L. et al., 2008).  Besides the 
upregulation of drug resistance genes, the strong involvement of hypoxia in cellular 
energetic, cellular response, tissues invasion and metastasis can all potentially play 
contributions to chemoresistance in hypoxic tumour cells (section 1.2.2). 
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 1.6 DNA Damage response 
The DNA damage response (DDR) is a vital mechanism for maintaining genomic integrity in 
mammalian cells.  This is co-ordinated by a complex system, involving a large range of 
proteins categorised into DNA damage sensors, transducers, mediators and effectors.  DDR 
senses damage in DNA and subsequently triggers DNA repair or cell death.  For this reason, 
many chemotherapeutic drugs employ the mechanisms of DDR to trigger cell death in 
tumour cells, highlighting the importance of DDR machinery for successful 
chemotherapeutic treatments. 
Under normal circumstances, DNA is constantly challenged by DNA damage, with several 
thousands of lesions arising in every human cell per day (Lindahl and Barnes, 2000).  
Endogenous DNA damage can be caused by errors which naturally arise during DNA 
replication or physical DNA attacks by free radicals generated from cellular metabolism.  
Exogenously, DNA damage could result from carcinogenic substances, such as nitrosamine 
in tobacco, UV radiation or X-rays.  The type of DNA damage created can be classified into 
single stranded breaks (SSBs) or double stranded breaks (DSBs).  Dependent on the type of 
breaks and when damage occurs, in terms of cell cycle phase, different repair mechanisms 
are employed by the cell.  In the following sections, we will focus on DSBs and their 
mechanisms of repair. 
 
 1.6.1 Double stranded breaks 
DSBs are of greater concern than SSBs, as they can increase the chance of chromosome 
breakage, neurodegeneration, immunodeficiency and cancer predisposition (Jackson and 
Bartek, 2009).  DSBs can arise during normal physiological processes, for example during 
replication, when an unrepaired SSB meets the progression replication fork, it is converted 
into a DSB.  Therefore during this time the DNA is stringently monitored for DSBs (and SSBs) 
by DNA glycosylase, which initiates base excision repair (Almeida and Sobol, 2007, Hitomi et 
al., 2007, Jacobs and Schar, 2012).  Damaged DNA activates processes which halt cell cycle 
progression, allowing time for DNA repair before the cells continue to go through their 
cycle.  Extrinsically, DSBs can also be induced by: radiation or radiometric compounds such 
as bleomycin, alkylating agents (e.g. methyl methane sulphate) and topoisomerase II 
inhibitors (e.g. etoposide), as described in (section 1.5.2) (Vanankeren et al., 1988, Mirabelli 
et al., 1985). 
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The two major pathways involved in sensing and repairing DSBs are homologous 
recombination (HR) and non-homologous end-joining (NHEJ) (Hartlerode and Scully, 2009, 
Pardo et al., 2009). 
 1.6.1.1 Non-homologous End-Joining (NHEJ) repair 
Non-homologous End-Joining (NHEJ) repair is active throughout the cell cycle but with 
increased activity as the cells progress through G0/G1 to S and G2/M phase.  NHEJ directly 
ligates broken ends back together without the use of a homologous template to guide 
repair, therefore this method is error prone and can generate small insertions or deletions 
in the repaired DNA (Riches et al., 2008, Hartlerode and Scully, 2009, Pardo et al., 2009). 
During NHEJ, the first events involve the DNA binding proteins Ku70 and Ku80 associating 
with the DNA break site (Walker et al., 2001).  The Ku70/ Ku80 heterodimer binds each 
exposed end of the DNA terminus of the break site and its function is to aid the alignment 
of DNA strands, protect them from degradation plus to prepare the strands for ligation (van 
Gent and van der Burg, 2007, Weterings and Chen, 2008).  The association of Ku70/ Ku80 
with the DNA also attracts DNA protein kinase (DNA-PK) to the break site, which later plays 
a role in both the processing and ligation of DNA.  The processing of DNA is performed by 
the nuclease Artemis, which trims the DNA followed by the DNA ligase IV/XRCC4 complex, 
which ligates the blunt ends (Yannone et al., 2008).  Once the ligation has occurred, the 
repair process is completed (Figure 1.8A). 
 1.6.1.2 Homologous recombination repair 
This mechanism is more complex than NHEJ, but it is more accurate and less prone to 
errors as it utilises a homologous sister chromatid template.  However, this means that the 
HR repair mechanism is only active during the S and G2/M phase of the cell cycle, when 
sister chromatids are available (these are identical copies of chromatids generated by DNA 
replication) (Filippo et al., 2008). 
Recognition of DSBs, by the MRN complex, happens within minutes after the damage has 
occurred.  The MRN complex consists of meiotic recombination 11 (MRE11), RAD50 and 
Nibrin (NBN) (Lavin, 2007).  The MRN complex plays a key role in sensing, signalling and 
promoting repair of DNA breaks.  In the case where repair mechanisms are triggered, the 
DSBs ends are first processed by resection from 5’ to 3’ ends to produce 3’ single strand 
tails.  This is initiated by MRN complex and CtBP-interacting protein (CtIP).  With the aid of 
Rad51, the 3’ ssDNA then undergo strand invasion, branch migration and DNA synthesis.  
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Following these processes, the crossover DNAs are resolved and the initial broken DNA are 
repaired (Figure 1.8 B). 
 
 
 
Figure 1.8 Mammalian DNA Double Stranded Breaks Repair.  (A) NHEJ repair, DSB 
recognised by KU70/KU80, processed by DNA-PK and ARTEMIS followed by relegation by 
XRCC4/Lig4 complex.  (B) HR repair, DSB recognised by MRN complex followed by resection, 
strand invasion and extension mediated by RPA and RAD51.  After extension, the strands 
are resolved. Adapted from Lans et al. Epigenetics & Chromatin 2012 5:4 
 
Besides triggering repair, once MRN is associated with the exposed ends of DNA, its NBN 
component activates the catalytic function of a kinase called ataxia telangiectasia mutated 
(ATM) (Horejsi et al., 2004, Costanzo et al., 2004).  Additionally, it retains the ATM at the 
site of the DSB, which allows for signal amplification and downstream ATM response 
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(Horejsi et al., 2004, Berkovich et al., 2007).  When ATM is activated, it phosphorylates 
targets such as a histone variant called H2AX, as well as carrying out autophosphorylation 
of itself.  Thus, ATM plays a central role in DSBs response where it can phosphorylate other 
proteins such as Chk2, BRCA1 and p53, involved in repair, cell cycle checkpoint and 
apoptotic responses (Jowsey et al., 2007, Buscemi et al., 2004, Stiff et al., 2004)(Figure 1.9). 
 
 
 
Figure 1.9 Overview of DSB response. A schematic diagram demonstrating the signalling 
cascade of DSB response.  DNA damage is detected by sensor proteins (MRN complex: NBN, 
Rad50 & Mre11), where signals are transduced by ATM which activate Chk2 (left) or ATR 
which activates Chk1 (right).  Activation of Chk2 or Chk1 will then activate p53 signalling 
response.  (http://www.intechopen.com/books/senescence-and-senescence-related-
disorders/molecular-mechanisms-of-cellular-senescence). 
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 1.6.1.3 Pathological relevance of NBN  
Nijmegen Breakage Syndrome (NBS) is a rare autosomal recessive disease where the NBN 
gene is mutated (Weemaes et al., 1981).  Patients with NBS display facial dysmorphism, 
microcephaly and growth retardation.  NBS has been documented to be associated with 
increased cancer incidence, in particular B-cell non-Hodgkin’s lymphoma (Paulli et al., 2000, 
Hama et al., 2000, Kruger et al., 2007).  NBN mutations have been reported in 
gastrointestinal cancer, breast cancer and lymphoblastic leukemia (Ebi et al., 2007, 
Bogdanova et al., 2008, Varon et al., 2001).  Moreover, NBN is also often found to be 
mutated in many GBM cases (Watanabe et al., 2009) and in some cases of MB patients 
(Distel et al., 2003, Bakhshi et al., 2003, Huang et al., 2008).  In the study by Huang et al., 
they screened 42 MB patients and discovered that 7 carried NBN mutations. They then 
hypothesised that NBN mutations might be involved in MB pathogenesis (Huang et al., 
2008). 
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 1.7 The p53 signalling pathway 
The p53 protein was first discovered in 1979, when it was found complex to the Simian 
virus 40 large T-antigen (Lane and Crawford, 1979, Linzer and Levine, 1979).  It was initially 
falsely considered to be an oncogenic protein due to couple of reasons.  Firstly, it was found 
that this ‘p53’ protein was highly expressed in tumour cells.  Secondly, cloning and 
transfection of the p53 gene into cells has enabled them to gain immortality (Eliyahu et al., 
1984, Jenkins et al., 1984).  It wasn’t until the late 1980’s, that it was realised that the p53 
gene used in those studies was a mutant form of p53 and not the WT p53 (Finlay et al., 
1989).  Since then, the studies on p53 have expanded and it became clear that p53 is in fact 
a tumour suppressor protein.  It is now well established that the p53 protein plays a central 
role in maintaining genomic integrity in response to cellular stress (Lane, 1992, Levine, 
1997).  p53 is activated by a variety of stimuli such as DNA damage, heat shock, nutrient 
depletion and oxidative stress.  Activated p53 transactivates many downstream targets 
according to the type of stress signals.  One important role of p53 is its involvement in 
response to DNA damage, senescence and apoptosis in the presence of genotoxic stress.  
The activation of DNA repair proteins can induce cell cycle arrest hence allowing time for 
the cells to repair their DNA damage before cell cycle progression.  Furthermore, when DNA 
damage is beyond repair, p53 can induce cellular senescence or apoptosis (Harris and 
Levine, 2005, Oren, 2003).  For these reasons, mutations or malfunction of the p53 pathway 
are often associated with neoplastic disease and can lead to cancer development. 
 
 1.7.1 Structure of p53 
The p53 protein is encoded by the TP53 gene located on the short arm of chromosome 17; 
17p13.1 (McBride et al., 1986).  The TP53 gene is highly conserved, composed of 11 exons 
and 10 introns (Lamb and Crawford, 1986).  The encoded p53 transcription factor 
comprises of three functional domains: N-terminus, central core and C-terminus (Figure 
1.10). 
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Figure 1.10 p53 domain structure.  A schematic representation of p53 protein with its 
functional domains.  TAD= Transactivation domain, NLS= Nuclear Localisation signal, NES= 
Nuclear export signals. 
 
The N-terminus contains the transactivation domain (TAD) and a proline rich region.  The 
highly conserved and largest domain is the DNA binding domain (residue 102-292) found in 
the central part of the protein.  Lastly, located in the C-terminal, is an oligomerisation 
domain (OD), 3 nuclear localization signals (NLS), nuclear export sequence (NES) and a 
regulatory domain (Figure 1.10).  In summary, the N-terminal is responsible for activation 
of transcription factors, the central region binds and interacts with target DNA and the 
C-terminal allows tetramerisation as well as being involved in negative regulation.  The 
details and functions of each region are described in Table 1.2. 
 
Domains Residues Descriptions 
Transactivation 1-42 An acidic transactivation domain and MDM2 
protein binding sites 
Proline-rich 63-97 Repeated proline rich region and second 
transactivation domain 
DNA binding 
domain 
98-292 Central region, contains DNA binding 
domain 
Tetramerization 324-355 Consists of a beta-stand, alpha helix and a 
nuclear export signal (NES) 
Regulatory 363-393 A strongly basic carboxyl- terminal domain. 
Involved in downregulation of DNA binding    
Table 1.2 Description of p53 domains and their basic functions 
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 1.7.2 Regulation of p53 
 1.7.2.1 p53 regulation by MDM2  
The p53 gene is constitutively transcribed, but its levels are tightly regulated by the 
oncoprotein murine double minute-2 (MDM2).  In the absence of genotoxic stress, MDM2 
protein regulates p53 expression on several levels, targeting p53 for degradation, inhibiting 
translation and inhibiting transcriptional activity.  Firstly, MDM2 binds to the N-terminus of 
p53 protein and targets p53 for ubiquitination and subsequent proteasomal degradation 
(Figure 1.11) (Chen et al., 1995, Haupt et al., 1997, Honda et al., 1997).  Secondly, MDM2 
can inhibit p53 transcriptional activity by physically blocking p53 interaction with its target 
DNA binding domain (Figure 1.11) (Momand et al., 1992). Lastly, MDM2 can bind to the L26 
ribosomal protein (a subunit of the ribosomal 60s translation machinery), inhibiting its 
function of translating p53 mRNA (Figure 1.12) (Takagi et al., 2005, Chen et al., 2012). 
 
 
Figure 1.11 MDM2 regulation of p53 expression.  A simplified diagram depicting how 
MDM2 regulates p53 expression.  MDM2 physically blocks transcriptional activity or by 
binding to p53 N-terminal which targets p53 for ubiquitination and degradation. 
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Figure 1.12 MDM2 inhibits p53 translation via mediating L26 degradation.  A simplified 
diagram demonstrating (A) p53 translation by translation (ribosomal) machinery (B) MDM2 
binds L26 ribosomal subunit, leading to its degradation.  Consequently, p53 translation is 
inhibited. 
 
 1.7.2.2 Activation of p53 
Induction of p53 activity occurs via the dissociation from its negative regulator MDM2.  This 
process is mediated by p53 post translational modifications in the presence of intrinsic or 
extrinsic genotoxic insults.  p53 activity and stability is controlled by a series of 
phosphorylation, acetylation, methylation, glycosylation, sumolyation, neddylation and 
poly-ribosylation events (Appella and Anderson, 2001).  The combination of these various 
types of modifications dictates the functional outcome of p53 but the exact post-
modifications and their corresponding downstream target activation is unclear (Maclaine 
and Hupp, 2009).  Although there are multiple p53 phosphorylation sites, specific sites have 
been identified to play a key role in p53 activation, for example serine 15 (Thompson et al., 
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2004).  Phosphorylation of this residue is mediated by ATM and ataxia telangiectasia Rad3 
related (ATR) kinases and promotes subsequent modifications of other residues such as 
serine 9, 20 and 46 (Sakaguchi et al., 1998, Saito et al., 2002, Saito et al., 2003, Sakaguchi et 
al., 2000).  Furthermore, ATM mediated serine 15 phosphorylation recruits p300 and CBP 
histone acetyl transferase, which are required for p53 transactivation.   
One example of p53 activation through this pathway is upon DNA damage induced by 
UV/gamma radiation or chemical treatment.  DNA damage is detected by the sensor 
proteins, ATM and ATR, which phosphorylate the checkpoint kinase 2 (Chk2) and 
checkpoint kinase 1 (Chk1), respectively (Figure 1.9) (Appella and Anderson, 2001, 
MacLaine and Hupp, 2011).  Consequently, Chk2 and Chk1 kinases phosphorylate p53, 
inhibiting the binding of MDM2 to p53 thus preventing the degradation of p53 (Figure 
1.13).  This allows the protein to stabilise and accumulate, and then to interact with its co-
activators, CBP/p300.  This further transactivates downstream target  genes such as p21, 
BAX and PUMA as well as non coding microRNAs (Harris and Levine, 2005, He et al., 2007).  
Also, p53 induces its own regulator, MDM2, therefore forming a negative feedback loop 
(Figure 1.13) (Wu et al., 1993). 
 
 
 
Figure 1.13 Activation of p53.  A diagram demonstrating activation of p53 by etoposide via 
ATM and Chk2 phosphorylation. The p53 and MDM2 regulatory negative feedback loop is 
shown. 
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 1.7.2.3 Oscillations of p53  
Oscillations in the cellular localisation of transcription factors including p53 have been 
observed (Hoffmann et al., 2002, Bar-Or et al., 2000, Lahav et al., 2004, Geva-Zatorsky et 
al., 2006, Hamstra et al., 2006).  The negative feedback loop between p53 and MDM2 is 
central for the oscillations to take place.  Oscillations in p53 was first reported by Lev Bar-Or 
et al., where dampened p53 oscillations were observed post DNA damage induction by γ-
irradiation on a cell population level (Bar-Or et al., 2000).  Later work based on single cell 
image analysis clarified that dampened p53 oscillations are due to varied frequencies of 
oscillation and the loss of synchronicity of oscillation over time within a cell population 
(Lahav et al., 2004, Geva-Zatorsky et al., 2006).  Lahav et al. proposed that the p53:MDM2 
feedback loop resulted in ‘digital’ oscillations, with the number of oscillations increasing 
when DNA damage increased (Lahav et al., 2004).  p53 oscillation signalling allow a 
repeated but short duration of p53 transactivation.  Purvis et al. demonstrated that 
oscillatory function in p53 can alter the pattern of downstream gene expression and cellular 
fate decisions (Purvis et al., 2012).  Cells that experience repeated p53 pulses express cell 
cycle arrest related genes and recover from DNA damage, whilst cells with sustained p53 
signalling undergo senescence through activation of apoptotic genes (Purvis et al., 2012).  
However, the question of whether p53 indeed oscillates or whether it is due to repeated 
individually repetitive triggers still remains to be elucidated.  
 
 1.7.3 p53 mutations in cancer 
Defects in the p53 pathway are a common feature in tumours, TP53 gene mutations are 
found in over 50% of all human cancers including brain tumours (Tabori et al., 2010, Baker 
et al., 1989, Bennett et al., 1999, Nigro et al., 1989, Toledo and Bardot, 2009, Oren and 
Rotter, 1999, Vogelstein et al., 2000).  Commonly, p53 mutations found in cancer are 
missense mutations or single base-pair substitutions.  In some cases, loss of the 
chromosome 17 have been observed, such as in ovarian cancer and breast cancer (Russell 
et al., 1990, Tavassoli et al., 1993, Negri et al., 2010).  Additionally, impairment of p53 
function can be also due to an elevated MDM2 expression (Oliner et al., 1992, Momand et 
al., 1992, Haupt et al., 1997). 
For most other tumour suppressor genes, mutations observed tend to be the result of gene 
‘truncation’ or ‘deletion’ (Weinberg, 1991), therefore leading to an inactivated protein or 
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little/ no gene expression.  However, because the majority of TP53 mutations are often due 
to missense resided to residues belonging to the ‘functional domain’, TP53 mutations 
regularly result in a full length protein, which lacks specific DNA binding function (Freed-
Pastor and Prives, 2012).  Many of these p53 mutants have been further shown to cause 
two functional outcomes: a dominant negative (DN) or a gain of function (GOF) effect. 
Mutant p53 often have an increased half life and thus prolonged protein stability, which is 
unlike its WT counterpart (Strano et al., 2007).  Due to the increased stability, these excess 
mutant proteins can exert DN effects on the remaining WT protein and mask its function 
(Brosh and Rotter, 2009).  A DN effect can result when mutant p53 forms a tetramer with 
the WT p53 (of varied combination), thus resulting in an altered functional p53 protein 
(Chan and Lung, 2004, Xu et al., 2011).  Moreover, missense mutations in TP53 are 
commonly followed by ‘loss of heterozygosity’ (Baker et al., 1989, Brosh and Rotter, 2009).  
This leads to the mutant p53 ‘Gain of function’ hypothesis, where mutant p53 not only 
reduces WT functions but are selected for expressions.  Mutant p53 GOF is well 
documented, and is generally referred to as functions gained by these proteins in the 
absence of WT p53.  GOF mutants have been demonstrated to interact with a selection of 
proteins, forming complexes with their partners and altering their functions.  For example, 
mutant p53 is found to interact with p63 and p73, inhibiting their usual function of 
mediating transcription of p53 target genes (Gaiddon et al., 2001, Strano et al., 2002, Di 
Como and Prives, 1998, Marin et al., 2000).  Moreover, as mutant p53 is transcriptionally 
active, the different mutant forms are found to be associated with activation of a wide 
variety of downstream targets, including genes involved in proliferation, metabolism, cell-
cell/ cell-ECM signalling and anti-apoptotic functions (Table 1.3) (Bossi et al., 2008, 
Sampath et al., 2001, Sun et al., 2000).  Altogether, p53 mutations and its mutant protein 
demonstrate roles in tumourgenesis and thus enhance cancer progression through DN and 
GOF effects.  
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Gene Description Biological process Mutant Reference 
MAP2K3 
Mitogen-activated 
protein kinase 3 
Cell proliferation 
R175H, 
R273H, 
R280K 
(Bossi et al., 
2008, Gurtner et 
al., 2010) 
PCNA Proliferating cell 
nuclear antigen 
Cell proliferation 
D281G, 
R248W 
(Deb et al., 
1992) 
BCL2L1 
Bcl-xl Anti-apoptotic 
R175H, 
R273H 
(Bossi et al., 
2008) 
MDR1 
Multidrug resistance 
protein 1 
Chemoresistance 
R273H, 
R273H 
(Chin et al., 
1992, Strauss et 
al., 1995) 
IDI1 Isopentenyl-
pyrophosphate 
isomerase 
Metabolism 
R273H (Freed-Pastor 
and Prives, 
2012) 
MMP3 Matrix 
metalloproteinase 3 
Cell-ECM signalling 
R175H (Sun et al., 2000) 
ITGA6 
Intergin α 6 Cell-cell signalling 
D281G (Scian et al., 
2005) 
Table 1.3 Example of p53 mutant transcriptional targets.  A table demonstrating different 
p53 mutant target genes involved in a wide range biological of processes.  The Mutant 
column shows the site of missense mutation (R= arginine; H= histidine; D=aspartic acid; G= 
glycine; W=tryptophan). 
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 1.8 MicroRNA 
MicroRNA (miRNA) is a class of small non-coding RNA first discovered 20 years ago in 
C.elegans (Lee et al., 1993).  Their mature form is between 18-21 nucleotides long and their 
main function is to control gene expression at the post transcriptional level (Lee et al., 
1993, Hammond et al., 2000, Bartel, 2004, Lewis et al., 2005).  A key feature of miRNAs is 
their ability to control the expression of multiple gene targets (Bartel, 2004, Xie et al., 2005, 
Lewis et al., 2003).  These post transcriptional regulators are found to have roles in cell fate 
and are associated with cancer (Cho, 2007, Tsuchiya et al., 2006). 
 
 1.8.1 Biogenesis of miRNA 
The regulation of miRNA transcription is similar to coding mRNA, whereby miRNA coding 
sequences are regulated by promoter regions and their expression is controlled by 
transcription factors.  A hairpin structured pri-miRNA is transcribed by RNA polymerase II 
and processed by Drosha/DGCR8 protein complex into a pre-miRNA within the nucleus (Lee 
et al., 2002, Lee et al., 2003) (Figure 1.14).  The export of pre-miRNA into the cytoplasm is 
assisted by exportin-5-RAN-GTP (Yi et al., 2003, Bohnsack et al., 2004, Lund et al., 2004).  
After nuclear export, the pre-miRNA hairpin loop is cleaved by DICER, releasing a miRNA 
duplex (Hutvagner et al., 2001, Knight and Bass, 2001, Ketting et al., 2001).  The duplex 
miRNA is loaded onto Argonaute (Ago) protein, while the antisense strand of the miRNA 
duplex is degraded, the mature miRNA (sense strand) remain on the Ago protein.  The Ago 
protein with miRNA, combined with the TRBP and Dicer, is known as the RNA-induced 
Silencing (RISC) complex (Figure 1.14) (Lingel et al., 2004, Bartel, 2004, Kim et al., 2009, 
Chendrimada et al., 2005).  RISC-miRNA can guide and bind to the 5’UTR region of target 
mRNA, by perfect or incomplete base complementation, subsequently inducing mRNA 
degradation or translational repression of target genes (Hammond et al., 2000, Bartel, 
2004). 
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Figure 1.14 Schematic diagram of miRNA processing.  pri-miRNA is transcribed by RNA pol 
II and cleaved by DROSHA/DGCR8 into pre-mRNA.  Pre-miRNA is exported by 
RAN-GTP/Exportin5 into the cytoplasm and processed by Dicer.  Mature miRNA incorporates 
onto RISC complex and targets mRNA for degradation or translation repression. 
 
 1.8.2 MicroRNA expression in cancer 
Recent expression profiling of miRNAs has revealed their association with tumour 
progression and prognosis (Calin and Croce, 2006, Yanaihara et al., 2006, Volinia et al., 
2006). Many studies have reported varied expression of miRNAs in human cancers, for 
example increased levels of miR-155 have been observed in B cell lymphoma (Kluiver et al., 
2005), whilst reduced levels of miR-335 & miR-126 are found in metastatic breast cancer 
(Tavazoie et al., 2008).  Alteration of miRNA expression can be due to genetic mutations, 
for instance, frequent chromosome deletions such as 13q14 in chronic lymphocytic 
leukaemia patients results in no detectable expression of miR-15a and miR-16 cluster (Calin 
et al., 2005, Cimmino et al., 2005). 
Specific miRNAs (Oncomirs) involved in targeting tumour suppressor genes, genes 
controlling cellular differentiation or apoptosis are often up-regulated in cancer.  Reversely, 
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miRNAs targeting oncogenes might be down-regulated.  In addition to their roles in 
controlling cell fate, miRNAs have also been demonstrated to be involved in angiogenesis, 
invasion and metastasis, genomic instability and evasion of the immune system, which are 
all hallmarks of cancer mentioned in section 1.2 (Figure 1.1). 
 1.8.2.1 Hypoxia regulated miRNAs 
Several microRNAs have been found to be regulated under hypoxia.  These miRNA are 
termed as hypoxia-responsive miRNA (HRM) (Kulshreshtha et al., 2007, Chen et al., 2013, 
Ghosh et al., 2010, Camps et al., 2008, Huang et al., 2009).  Kulshreshtha et al. used a 
microarray-based screen method and examined miRNA expression of selected cancer cell 
lines incubated in hypoxia (0.2%).  They have identified 27 HRM which were upregulated in 
at least two of the four cell lines investigated (Kulshreshtha et al., 2007).  These include 
miR-21, miR-107, miR-155 and miR-210, which are commonly found to be associated with 
cancer (Si et al., 2007, Volinia et al., 2006, Huang et al., 2009, Gee et al., 2010, Bruning et 
al., 2011).  Although there are reports of hypoxia/ HIF-induced miRNA, there is no extensive 
evidence of a general miRNA signature of hypoxic cells. 
 1.8.2.2 MicroRNA expression in brain tumours 
In brain tumours, many miRNAs are found to be dysregulated (Table 1.4).  The miRNA 
expression profiling study on primary MB performed by Ferretti et al. has demonstrated 
typical miRNA expression patterns classifying MB histotypes (Ferretti et al., 2009).  The 
majority of miRNAs in MB are found to be downregulated, two of which are miR-9 and 
miR-125 (Ferretti et al., 2009), which are also downregulated in neuroblastoma (Laneve et 
al., 2007).  Table 1.4 demonstrates some of the miRNAs commonly found to be 
differentially expressed in brain tumours (Table 1.4). 
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MicroRNAs Cancer Expression Reference 
miR-9 Medulloblastoma/ 
Neuroblastoma 
Reduced expression (Ferretti et al., 2009) 
miR-17/92 Medulloblastoma Overexpressed (Ferretti et al., 2009, 
Uziel et al., 2009, 
Northcott et al., 2009)  
miR-30b/ d Medulloblastoma Overexpressed (Lu et al., 2009) 
miR-34a Glioma, 
Neuroblastoma 
Reduced expression (Welch et al., 2007, Li 
et al., 2009) 
miR-124a Medulloblastoma Reduced expression (Pierson et al., 2008) 
miR-125a/b Medulloblastoma, 
Neuroblastoma 
Reduced expression in MB (Ferretti et al., 2009) 
miR-199b Medulloblastoma Reduced expression (Garzia et al., 2009) 
Table 1.4  miRNA involved in brain tumours. Examples of miRNA expression in brain 
tumours. 
 
 1.8.2.3 miR-34 microRNA family  
MiR-34a is a miRNA that has caught the interest of many researchers, as it is commonly 
expressed at reduced levels in glioma and neuroblastoma.  MiR-34a has been 
demonstrated to down-regulate many oncogenes and pro-survival genes (Table 1.5), 
illustrating its role as a tumour suppressor.  Moreover, miR-34a expression is regulated by 
p53.  It has been shown that p53 binds directly to a p53 responsive element, located 
upstream of the miR-34a transcription start site (Bommer et al., 2007, Raver-Shapira et al., 
2007).  Independent studies have confirmed that miR-34a expression is correlated with p53 
status and that induction is dependent on p53 activation both in vivo and in vitro (He et al., 
2007, Bommer et al., 2007, Wei et al., 2006). 
MiR-34a is a family of three transcripts consisting of miR-34a, miR-34b and miR-34c, with 
the latter two located on the same chromosome while miR-34a is located in chromosome 
1p36.  The tumour suppressor role of miR-34a was first described by Welch et al 2007, 
where the deletion of chromosome 1p results in a reduced level of miR-34a in 
neuroblastoma patients.  Later, low levels of miR-34a were also reported in other cancer 
types such as pancreatic, colon and lung cancer (Bommer et al., 2007, Chang et al., 2007, 
Tazawa et al., 2007).  Additionally, miR-34a expression is found to be silenced in melanoma 
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and prostate cancer (Lodygin et al., 2008).  Although miR-34b and miR-34c are less well 
documented, there is evidence of reduced expression in 40% of non-small cell lung 
carcinoma patients (Bommer et al., 2007).  Many independent studies have since confirmed 
the link between cancer and miR-34a, demonstrating an important role in cell cycle arrest, 
senescence and apoptosis (Bommer et al., 2007, Chang et al., 2007, Raver-Shapira et al., 
2007). 
 
miR-34a target genes Description of target genes Reference 
SIRT1 Pro-survival  (Raver-Shapira et al., 
2007, Yamakuchi et 
al., 2008) 
MYCN Oncogene (Wei et al., 2008) 
BCL2 Anti-apoptotic  (Raver-Shapira et al., 
2007, Li, L. et al., 
2013) 
MAGE-A Oncogene (Weeraratne et al., 
2011)  
E2F3 A transcription factor 
involved in cell cycle 
progression 
(Tazawa et al., 2007, 
Welch et al., 2007) 
CDK6 A cyclin dependent kinase, 
involved in cell cycle 
progression 
(Sun, F. et al., 2008) 
c-Met A tyrosine-kinase growth 
factor receptor involved in 
cell proliferation 
(Li et al., 2009) 
Table 1.5 miR-34a target mRNA.  Examples of miR-34a target gene and a description of 
their role. 
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 1.9 Project aims and hypothesis 
The major theme of this thesis is to understand the causes of MB resistance to 
chemotherapeutic agents and how this could be overcome.  In young MB patients, 
treatment is dependent solely on chemotherapy due to the high risks involved with the 
other therapeutic methods highlighting the importance of chemotherapy.  Moreover, 
chemoresistance has been observed in MB patients and derived cell lines, emphasising the 
need for a better understanding of this phenomenon to improve treatment strategy. 
As mentioned in section 1.4.1, although MB of different subgroups shares identical 
histopathology, studies have revealed that these subgroups are highly variable in terms of 
their biology.  The treatment response and prognosis of these subgroups can be very 
different, and this is governed by the differences in their genetic background.  For example, 
chemoresistance in MB and MB cell lines have been shown to be associated with mutations 
in the p53 pathway (Tabori et al., 2010, Meley et al., 2010). 
Here, we aim to further understand the molecular mechanisms, which contribute to MB 
chemoresistance.  One aim being to overcome the resistance arising from p53 mutations.  
The second line of approach is to consider the role of the tumour environment such as 
hypoxia in mediating drug insensitivity.  Most in vitro pharmacological studies are 
performed under atmospheric conditions, thus neglecting the classical pathological 
environment within solid tumours where hypoxic regions exist.  Importantly, the role of 
hypoxia and its associated effect on chemoresistance and cancer malignancy have been 
well documented in GBM, yet little is known in MB.  We hypothesised that hypoxia might 
also play a role in MB chemotherapy response and that it might be due to a potential 
crosstalk between the hypoxic and the p53-dependent signalling networks. 
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The specific project aims were to: 
 
1.  Investigate the importance of p53 in MB cell death induction, and to find new 
molecular targets that could bypass p53 activation to induce cell death in p53 
mutated cells. 
 
2.  Assess the importance of hypoxia in MB chemosensitivity and to define the link 
between hypoxia and p53 activity in MB and GBM. 
 
3.  Explore the effects of hypoxia on global gene expression and to identify potential 
targets involved in chemoresistance in hypoxia that could be used to re-sensitise 
resistant cells. 
 
  
 
 
 
 
 
 
 
 
Chapter 2: Materials and Methods 
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 2.1 Chemical and Reagents 
All tissue culture media was purchased from Gibco (Invitrogen, UK) and foetal calf serum 
from Harlan Seralab (UK) or PAA cell culture company (Austria).  Restriction enzymes, real 
time PCR reagents were purchased from Roche (UK).  DNA oligonucleotides, shRNA 
plasmids and all other reagents were purchased from Sigma-Aldrich (UK) unless otherwise 
stated. 
 
 2.2 Drug and Chemical Treatments 
A variety of chemotherapeutic drugs and chemical were used for cell treatments.  Typical 
and optimised concentrations of drug and chemicals used are listed in Table 2.1. 
Drugs/ Chemicals Molecular Action Concentration used Source 
Etoposide 
Topoisomerase 
inhibitor 
20µM Sigma E1383 
Nicotinamide SIRT1 inhibitor 10-100mM Sigma 479865-U 
EX527 SIRT1 inhibitor 50-100µM Tocris 2780 
Sirtinol SIRT1 inhibitor 50-100µM Sigma S7942 
Table 2.1 A List of drugs used in this project.  The purpose of the drugs and the general 
dosages used are shown. 
 
 2.3 Cell Lines and growth requirements 
Medulloblastoma, Glioblastoma, breast cancer, 293TN-HEK and HeLa cultured cell lines are 
used in this project.  A summary of the cell lines and culturing medium and supplements 
required are listed in Table 2.2 and Table 2.3. 
MB Cell line Culture Medium Source 
D283-MED 
EMEM, 10%FCS, 1% 
NEAA, 1% NaPyr 
ATCC-HTB-185 
MEB-Med8A DMEM, 10%FCS 
Provided by Prof T. Pietsch 
(University of Bonn, Germany) 
MHH-Med1 DMEM, 10%FCS 
Provided by Prof T. Pietsch 
(University of Bonn, Germany) 
Table 2.2 Summary and sources of MB cell lines. 
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GM Cell line Culture Medium Source 
U87MG 
EMEM, 10%FCS, 1% 
NaPyr 
ATCC-HTB-14 
T98G 
EMEM, 10%FCS, 1% 
NaPyr 
ATCC-CRL-1690 
Table 2.3 Summary and sources of GB cell lines. 
 
 2.3.1 Routine sub-culturing protocol 
Cell lines are typically cultured in 75cm2 tissue culture flasks (Corning, UK) and maintained 
in a growth condition of 37oC, 5% CO2 in a humidified incubator (SAYO, Japan).  The 
following table contains a brief summary of the sub-culturing schedule for each of the cell 
lines in a typical week (Table 2.4). 
Cell Lines Monday Wednesday Friday  
D283-MED Sub-culture Add media Sub-culture 
MEB-Med8A Sub-culture Add media Sub-culture 
MHH-Med1 Sub-culture Add media Sub-culture 
U87MG Sub-culture Sub-culture Sub-culture 
T98G Sub-culture Replace media Sub-culture 
Table 2.4 Summary of sub-culturing procedure in a typical week. 
 
 2.3.1.1 Sub-culturing protocol for non-adherent cells 
Non-adherent cells are collected in a tube and pelleted by centrifugation for 5 minutes at 
100g and the supernatant was removed.  The pellet was resuspended with 10ml of fresh 
media and cell counts were determined using a particle cell counter (Beckman Coulter).  
Cells are transferred to new flask to maintain the cell culture or distributed to other culture 
dishes for experiments (Table 2.5) 
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Cells Plates 
Number of Cells 
Plated 
Volume (ml) 
D283 / Med 1 
96-well 1-2 x104 0.1 
24-well 0.5 x106 1 
6-well 1-2 x106 2 
35mm dish 1-2 x106 2 
75cm2 Flask 10-15 x106 20 
Table 2.5 Commonly used culture vessels.  Typical plating density is shown. 
 
 2.3.1.2 Sub-culturing protocol for adherent cells 
The media of adherent cells was removed from the flask and washed with Ca2+ free 
phosphate buffered saline (PBS).  All adherent cell lines were incubated for 2- 5 min at 37oC 
with 1ml of 1x trypsin/ EDTA (Sigma, UK) to allow cells  to detach from the flask.  A further 
9ml of media was added to inhibit trypsin activity and the cells were counted using a cell 
counter (Beckman Cell Coulter counter).  Cells were transferred to new flasks to maintain 
the cell culture or distributed to other culture dishes for experiments (Table 2.6). 
Cells Plates 
Number of Cells 
plated 
Volume (ml) 
Med8A 96-well 2 x104 0.1 
U87MG / T98G 96-well 5 x103 0.1 
U87MG / T98G 
/Med8A 
6-well 0.5-0.8 x106 2 
35mm dish 0.5-0.8 x106 2 
75cm2 Flask 2.5 x106 15 
Table 2.6 Commonly used culture vessels.  Typical plating density is shown. 
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 2.4 Molecular Biology techniques 
 2.4.1 DNA propagation 
 2.4.1.1 Transformation of Competent Cells 
Plasmid DNA propagation was performed by transforming Escherichia coli (E.coli) DH5α 
competent cells (Invitrogen).  DH5α competent cells were thawed on ice and incubated for 
30min with the addition of 10ng of DNA plasmid in a 1.5ml microfuge tube.  The cells were 
submitted to a heat-shock at 42°C  for 60 seconds and chilled on ice immediately for 
another 2 minutes prior to addition of 900µl LB broth (1% (w/v) bactotryptone; 0.5% (w/v) 
yeast extract; 1% (w/v) NaCl, pH 7.0).  The cells were incubated at 37oC in a shaking 
incubator for 30 minutes then pelleted at 1000g for 1 minute and 900µl of supernatant was 
then removed.  The pellet was resuspended with the remaining supernanant and plated 
onto LB-agar plates containing the appropriate antibiotic (100µg/ml ampicillin or 50µg/ml 
kanamycin).  The plate was then incubated at 37oC overnight. 
 2.4.1.2 Purification of Plasmid DNA (Plasmid Maxi Preparation) 
One colony of transformed E.coli cells were inoculated in 5ml of LB broth with appropriate 
antibiotic selection for 6-8 hours prior to transfer to a 2L conical flask containing 250 LB 
broth containing the appropriate antibiotic.  The flasks were cultured overnight at 37oC in a 
shaking incubator at 225rpm.  The cells were harvested by centrifugation at 6000g for 15 
minutes at 4oC.  Plasmid purification was carried out following the manufacture’s 
instruction with either Plasmid Maxi Kit (Qiagen) or PureLine Maxi Kit (Invitrogen).  
Plasmids were typically dissolved in 100µl of TE.  The plasmid concentration was quantified 
using a Nanodrop spectrometer (ThermoScientific) and adjusted to a final concentration of 
1µg/µl. 
Materials and Methods 
-49- 
 2.4.2 Plasmid Transfection 
Cells were transfected using FuGene®6 (Roche, UK) or Lipofectamine 2000 (Invitrogen, UK) 
following the manufacturer’s instruction.  The ratio of transfection reagent (µl) to DNA (µg) 
used was dependent on cell types (Table 2.7).  Total transfection reaction volume was 
determined empirically based on surface area of culture vessels (adherent cells) or cell 
culture volume (suspension cells).  The table demonstrates a typical transfection of a 35mm 
dish with 2 ml cell culture medium. 
 
Cells FuGene6/Lipofectamine (µl): DNA (µg) 
Volume of 
serum free 
medium (µl) 
D283 4:2 100 
Med8 4:2 100 
Table 2.7 Reagents and DNA ratio used for plasmid transfection. 
 
The required volume of transfection reagents are added to serum free medium and 
incubated at room temperature for 5 min.  DNA was added to the pre-incubated mixture 
and further incubated at room temperature for 30 minutes (Figure 2.1).  The complete 
transfection mix was then added onto the cells in a dropwise manner.  Fresh media was 
added to the plate hours after transfection. 
 
 
Figure 2.1.Expression plasmid (A) pMT-p53-dsREDXP (B) mdm2-MDM2-YFP 
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 2.4.3 Oligonucleotides (miRNA, siRNA) Transfection 
Small nucleotides RNA mimics and inhibitors (Table 2.8} were transfected into cells using 
HiPerfect  (Qiagen) transfection reagents. 
siRNA Source Cat no 
miR-34a mimic Dharmacon C-300551-07 
mimic control Dharmacon CP001000-02-05 
mimic transfection control 
with Dy547 
Dharmacon CP-004500-01 
miR-34a inhibitor Dharmacon IH-300551-08-0005 
miR-34a Hairpin negatives Dharmacon IN-0010050105 
Sip53  Invitrogen  1299001 
 
scrambled siRNA Dharmacon D001810-10-05 
Table 2.8 siRNA and miRNA used. Sources are shown. 
 
The required volume of transfection reagents and oligonucleotides (final conc [100nM]) are 
added to opti-MEM, mixed and incubated at room temperature for 15 min then added on 
to the cells gently (Table 2.9).  Transfection medium was replaced (adherent cells) or 
topped up (suspension cells) 6 hours after transfection.  Expression time is typically 
between 48-72 hours. 
Reagents Volume (µl) 
Opti-MEM 100 
HiPerFect 15 
siRNA/ miRNA mimics or inhibitors [100nM] 5 
Table 2.9 Reagents and DNA ratio used for siRNA or miRNA transfection. 
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 2.5 Real time PCR (qPCR) 
 2.5.1 Total RNA extraction 
The RNeasy Mini kit (Qiagen, Germany) was used to extract mRNA from D283 cells.  The 
cells were typically treated with drugs or hypoxic exposure one day after plating on a 35mm 
dish.  Prior to lysis, the cells were pelleted for 5 minutes at 300g, washed with 1ml of PBS 
and further centrifuged as previously described.  After removal of PBS, the cells were lysed 
with 350µl of buffer RLT containing 1% β-Mercaptoethanol (v/v).  The lysates were typically 
frozen at -80oC at this point until the rest of the samples were collected for mRNA 
extraction.  Sample homogenisation was achieved by using a QIAshredder (Qiagen) and the 
‘Spin Protocol’ extraction procedure was carried out as detailed in the manufacturer 
protocol.  RNA was eluted with 30µl of RNase free water and the sample purity was 
quantified using spectrophotometry. 
 2.5.1.1 Reverse Transcription 
The reverse transcription of mRNA to cDNA was carried out using SuperScript® VILO cDNA 
synthesis Kit (Invitrogen).  Each conversion reaction consisted of 1µg of RNA, 
1xSuperScript® enzyme, 1x VILO™ reaction mix (containing random primers, RNase 
inhibitor and recombinant ribonuclease inhibitor) made up to 20µl total volume with DEPC-
treated water.  PCR reactions were performed using a Px2 Thermal Cycler (Thermo) for 10 
minutes at 25oC, 60 minutes at 42oC and 5 minutes at 80oC.  The cDNA was then diluted 20-
fold with DEPC-treated water and stored at -20oC prior usage in qPCR. 
 
 2.5.2 MicroRNA extraction 
The miRNeasy Mini kit (Qiagen, Germany) was used to extract mRNA from D283 cells.  The 
cells were typically treated one day after plating on 35mm dish.  Prior to lysis, the cells 
were pelleted for 5 minutes at 300g, washed with 1ml of PBS and further centrifuged as 
previously described.  After removal of PBS, the cells were lysed with 700µl of Qiazol.  
Sample homogenisation was achieved by passing the samples through a 10 gauge needle 
using a syringe for ten times.  The lysates were frozen at -80oC at this point until all samples 
were collected.  MiRNA extraction was carried out following the manufacturer’s protocol.  
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RNA was eluted with 30µl of RNase free water and the sample purity was quantified using 
spectrophotometry. 
 2.5.2.1 Reverse Transcription-First Strand cDNA synthesis 
The reverse transcription of miRNA to cDNA was carried out using Ncode™ miRNA 
First-Strand cDNA synthesis Kit (Invitrogen).  Poly (A) tailing reaction consist of 1µg of RNA, 
5x miRNA reaction buffer,  2.5mM MnCl2, 80µM ATP, 0.5µl Poly A polymerase made up to 
25µl total volume with DEPC-treated water and incubated at 37oC for 15 minutes using a 
Px2 Thermal Cycler (Thermo).  Immediately after, 4µl of the polyadenylated RNA was added 
to 1µl of Annealing buffer, 9µM of Universal RT Primer made up in a total volume of 8µl and 
incubated at 65oC for 5 minutes and then placed on ice for 1 minute.  2x First-Strand 
Reaction mix and 2µl SuperScript™ III RT/ RNaseOUT™ Enzyme Mix was added to the 
reaction tubes, RT reactions were performed using a Px2 Thermal Cycler (Thermo) for 50 
minutes at 50oC and 5 minutes at 85oC.  The cDNA was then diluted 10-fold with 
DEPC-treated water and stored at -20oC prior usage in qPCR. 
 2.5.2.2 Quality Quantification of Nucleic Acid 
The concentration and purity of RNA and DNA samples were quantified using a Nanodrop 
spectrometer (Thermo Scientific).  High yields DNA from maxiprep were diluted to suitable 
concentration with a reading range between 2ng/µl to 1000ng/µl.  Purity of nucleic acids 
was determined by absorbance value at different wavelengths, the ratio at 260/280 nm 
indicates presence of protein and at 260/230 nm of organic solvents. 
 
 2.5.3  qPCR 
PCR primers were designed using primer 3 software, to search for primer size of 18-25 
nucleotide long with a product melting temperature between 56-60oC 
(http://bioinfo.ut.ee/primer3-0.4.0/) (Koressaar and Remm, 2007, Rozen and Skaletsky, 
2000) and quality of primers was determined by Primer stat 
(http://www.bioinformatics.org/sms2/pcr_primer_stats.html) (Stothard, 2000).  Primers 
used are listed on Table 2.10. 
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Target genes Forward Primers Reverse Primers 
Cyclophilin A GCTTTGGGTCCAGGAATGG GTTGTCCACAGTCAGCAATGGT 
miR-34a TGGCAGTGTCTTAGCTGGTTGT Universal primer (Invitrogen) 
MDM2 GCAAATGTGCAATACCAACA CTTTGGTCTAACCAGGGTCTC 
MDR1 GTGGGGCAAGTCAGTTCATT TTCCAATGTGTTCGGCATTA 
NBN AGAATTGGCTTTTCCCGAACT CAAGAAGAGCATGCAACCA 
p21 GACTCTCAGGGTCGAAAACG TAGGGCTTCCTCTTCCAGAA 
PHD2 GGAAGATGGAGAACCTGCTG GCTTGTGCTTCTTCCAGTCC 
PUMA CCTGGAGGGTCCTGTACAAT CACCTAATTGGGCTCATCT 
SIRT1 TTTGGAAATGTTTCAGTTGCTTTA CACTCTCCCCAGTAGAAGTACCAT 
VEGF GGGCAGAATCATCACGAAGT CACACAGGATGGCTTGAAGA 
Table 2.10 A list of primers and their sequences is shown. 
 
All q-PCR reactions were carried out in triplicate.  Each reaction consists of 1xSYBR®Green 
PCR master mix (Roche), 200nM forward and reverse primers, 2µl of DNA made up in a 
total volume of 20µl with RNase free water.  Real time PCR was performed using a 
LightCycler 480 (Roche) using the following temperature cycling parameters in Table 2.11. 
Step Temperature 
(oC) 
Duration 
(s) 
Ramp Rate 
(oC/s) 
No. of Cycles 
Pre-incubation 95 600 4.4 1 
Amplification 
95 
60 
5 
30 
4.4 
2.2 
45 
Melt Curve 
95 
65 
97 
5 
60 
continuous 
4.4 
2.2 
0.11 
1 
Cooling 40 10 1.5 1 
Table 2.11 Typical qPCR cycling parameters used with SYBR®Green. 
 
Results were analysed using the LightCycler480 software (version 1.5.0.39), Advanced 
Relative Quantification function.  Fold change was calculated based on the threshold of 
amplification cycle for each reaction using the 2-CT method (Pfaffl et al., 2002).  The fold 
changes of target genes were normalised to cyclophilin A (a house keeping gene) and over 
untreated or time zero control. 
Materials and Methods 
-54- 
 2.6 Microarray study 
Microarray is a high-throughput screening technique which allows the study of 
transcriptome, proteome or microRNAome.  In a DNA microarray, cDNA samples are first 
labelled with a one-colour fluorescent dye prior to being placed on the microarray slide, 
typically made out of glass, silicon or plastic.  The fluorescently labelled cDNA samples are 
hybridized with the microscopic spots (probes) pre-attached on the surface of array slide.  
The slide is then washed and the fluorescent intensity of each spot on the microarray slide 
is scanned and measured using a computer.  The intensity signals of each spot therefore 
serves as an indication of the relative abundant of target gene present in the sample. 
 
 2.6.1 Design of the microarray study  
D283 cells were incubated for a varied hypoxic duration (0, 6, 64 and 96 hours in triplicate), 
cDNA samples were prepared and sent directly to NimbleGen. 
The NimbleGen 12 plex format microarray glass slide, which supports 12 arrays was chosen 
for the purpose of our experiment (Figure 2.2).  Each array contains 135000 oligonucleotide 
probes which are of 60mer long.  These relatively long oligonucleotides provide an 
increased sensitivity, specificity and can help reduced signal to noise ratio. 
 
 
Figure 2.2 NimbleGen 12x135K Format array slide.  A schematic diagram of a 12 sample 
array slide containing 135,000 probes spotted on each chip.  Glass slide sized 25 x 75mm. 
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 2.6.2 Microarray sample preparations 
 2.6.2.1 Messenger RNA extraction with Rneasy Plus 
RNA extraction using Rneasy Plus (Qiagen, Germany) kit was identical to extraction using 
Rneasy kit as described earlier with the exception of one extra step.  After homogenisation 
with QIAshredder (Qiagen), the homogenized lysate was transferred to a DNA Eliminator 
spin column, centrifuged for 3 seconds at 10,000rpm.  The flow through was collected and 
used for RNA extraction following the ‘Spin Protocol’ as described in the manufacturer 
handbook.  RNA was eluted with 30µl of RNase free water and the sample purity is 
quantified using spectrophotometry. 
 2.6.2.2 Transcriptome amplification 
The reverse transcription and amplification of the cDNA library was carried out using a 
Transplex® Whole Transcriptome Amplification kit (Sigma).  Following the manufacturer’s 
protocol, each conversion reaction consisted of 300ng of RNA, 2.5µl WTA Library Synthesis 
Buffer, 2.5µl WTA Library Stabilisation Solution and 1µl WTA Synthesis Enzyme.  Cycling 
conditions were 24oC for 5 minutes; 42oC for 120 minutes and 95oC for 5 minutes.  The 
amplification step was carried out using all cDNA library products from the reverse 
transcription step.  Each reaction consists of cDNA library, 300µl water, 37.5µl WTA 
amplification Master Mix, 7.5µl dNTP Mix and 12.5 units of Jumpstart Taq DNA polymerase 
(Sigma).  The reaction was incubated in a thermal cycler with the conditions listed in Table 
2.12. 
Step Temperature 
(oC) 
Duration 
(s) 
No. of 
Cycles 
Pre-incubation 95 180 1 
Amplification 
94 
65 
20 
5 
17 
Hold 4 - 1 
Table 2.12 PCR cycling parameters for transcriptomic amplification 
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 2.6.2.3 PCR purification 
PCR purification was carried out using QIAquick PCR purification kit (Qiagen) to remove 
residual primers and nucleotides.  The manufacturer’s protocol was followed and the 
amplification product was purified and quantified using spectrophotometry. 
 2.6.2.4 Agarose Gel electrophoresis 
Gel electrophoresis (1% w/v) is used to separate DNA fragments.  Agarose is dissolved in 
1xTAE buffer by heating it for 3-5 minutes using a microwave, 1x SYBR safe (Invitrogen) was 
added to the agarose solution before setting to gel.  Hyperladder I DNA Ladder (Bioline) and 
DNA samples combined with 5x Loading Buffer (Bioline) are separated by electrophoresis at 
100V for 90minutes.  Gels were imaged using Syngene G:box imaging system (Syngene, UK). 
 
 2.6.3 Microarray analyses 
 2.6.3.1 Microarray Raw data 
In our microarray, the expression of ~45k transcripts representing ~25k genes (of which, 
23,611 are unique genes) were measured.  Within the 135k probes, each transcript binds to 
3 unique probes that are scattered randomly on the array.  Among the 135k probes, there 
were also random probes (2500) which are spread across the array, for the purpose of 
experimental control and normalisation between and within cards.  The expression values 
measured by each probe are generated using the Robust Multichip Average algorithm and 
quantile normalisation (Irizarry et al., 2003a, Irizarry et al., 2003b, Bolstad et al., 2003).  The 
raw results are sent back as an excel format where the expression data of each probe are 
listed, arranged according to transcripts ID.  One can appreciate the scale of this data set 
(135k by 12) which therefore requires organisation before interpretation. 
Dr Boris Noyvert (University of Warwick) provided a customized visualization code to 
enable generation of a more easily accessible html file by collecting the data together by 
gene names.  Transcripts belonging to the same gene were grouped together and organised 
alphabetically into their own html page (Figure 2.3A & B).  In each page, gene names, gene 
IDs and annotation are displayed among with their transcript expression plots (Figure 2.3C). 
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Figure 2.3 Screenshots and Examples of Microarray data on html page.  (A) Screenshot of 
search tools classified by gene names (B) Screenshots of part of gene lists organised 
alphabetically (C) Screenshots of EGLN3 transcripts html page displaying gene information 
and expression plots. 
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 2.6.3.2 Transcript expression plots 
As there were 3 replicates for each hypoxic time point and that transcript was measured by 
3 probes, 9 measurements are generated for each time point.  However, the absolute 
expression value measured for each probe can be quite different, for example, values can 
be in the range of tens in one probe while it is in the thousands for another. This problem is 
overcame by rescaling the data of each probe for every transcript by multiplying it to a 
factor ‘X probe’, making it possible to plot a meaningful ‘average probe expression’ on the 
same graph (Figure 2.4). 
 
Figure 2.4 Calculating average expression plot.  ‘A’ is the average mean of all three probes. 
‘ X probe’ is the multiplication factor which is to be used for scaling up the raw expression data 
for that probe. 
 
The expression plot on the graph is thus showing the mean of the three median expression 
levels for all 3 probes (after rescaling) (Figure 2.5).  The purpose of the html pages allows 
quick searches and visual interpretation on expression pattern of the gene of interest, 
however the plots do not bear statistical significance. 
 
Figure 2.5 Expression plots on html page.  An example of a transcript expression plot with a 
description of the meaning of the different parts. 
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 2.6.3.3 Statistical analysis of Microarray Data 
As mentioned earlier, a large data set was generated from the microarray study with 
sample repetition for each time point, multiple probes for each transcript and potentially 
more than one transcript per gene (Figure 2.6).  The purpose of having separate probes 
binding to the same transcript allows a more reliable signal detection and confidence of the 
results. For example, we would expect the three individual probes targeted for the same 
transcript will all give rise to three similar expression profiles. 
 
 
Figure 2.6 An example of data values for one single transcript.  Transcript ID is listed 
vertically (red box), each horizontal row shows values measured by one single probe (blue 
box).  Every 3 columns are data obtained from one time point. 
 
An important aspect of handling microarray data is choosing an appropriate statistical 
method to allow the selection of genes with a significant differential expression.  There are 
many software or mathematic programs such as GeneSpring, Spotfire, R and Bioconductor, 
which can be used to analyse/ interpret an array.  Here, we have employed the use of 
MATLAB, combining the use of its built-in features of the statistical and bioinfomatics tool 
box with manually created programming codes to analyse our microarray data (Damon 
Daniels, University of Manchester).  See Appendix 1.1 to 1.3 for MATLAB codes. 
A workflow of microarray data handling is illustrated in (Figure 2.7), the details of each step 
will be described throughout the next sections.  Initially, an ANOVA (analysis of variance) 
test was performed on the log2 transformed data of each probe.  ANOVA test makes 
comparison of the means of several groups of data and provide a statistical test to 
determine whether the variations between the groups are significantly different.  The data 
values obtained at each time point for every probe were combined and used for analysis.  
An ANOVA test between every time point is carried out for each of the probes and a list of p 
values is produced for every probe in the microarray. 
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Figure 2.7 A workflow of microarray analysis. 
 
As each gene transcript in the microarray is tested using three separate probes, three p 
values are therefore obtained for every transcript.  In our analysis, a gene transcript is 
considered to be significantly differentially expressed (at any given time points) under two 
conditions: (1) if the p value for all 3 probes is <0.01 or if the p value of 2 out of 3 probes is 
<0.001. The latter criteria minimise false negatives in the cases where one ‘faulty’ probe 
might be present for a particular transcript.  (2), a minimum of two fold change in gene 
expression must be met (Table 2.13). 
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Criteria Value Description 
p value ≤0.01 p-value for all 3 probes for one single transcript 
Or 
p value ≤0.0001 p- value for all 2/3 probes for one single transcript 
And 
Fold change 2 Minimum fold change at any given time point 
Table 2.13 Criteria for calculating significantly expressed genes 
 
 2.6.3.4 Biological analysis with Ingenuity Pathway Analysis  
Data were analyzed through the use of IPA (Ingenuity Systems®, www.ingenuity.com).  The 
significantly expressed data of T6 and combined T64+T96 hours time point resulted from 
MatLab were selected for analysis.  The transcript IDs were converted to Entrez gene ID 
using Clone/Gene ID converter (Alibes et al., 2007), and their fold change is listed along side 
in excel.  The excel files were submitted to IPA and the results generated were analysed by 
manual interpretation.   
In IPA, Fisher’s Extact test statistical methods were chosen to calculate the significance of 
data observation (Fisher, 1922).  The null hypothesis of this method state: “is the 
proportion of genes (with significant expression) mapped to a particular pathway in the 
data similar to the proportion that map in the entire population?”  The p-value threshold 
was set to 0.05 in all analysis. 
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 2.7 Single cell Imaging  
 2.7.1 Immunocytofluorescence 
Coverslips were placed in 12 well plates and coated with 1ml polyornithine [100µg/ml] for 2 
hours.  After removal of polyornithine, cover slips were washed with PBS then MEM.  
Coverslips were then incubated with fresh MEM for 30 minutes prior to seeding cells onto 
it.  Cells were plated on pre-coated coverslips 16 hours prior to experimental treatments.  
Cells were rinsed with PBS prior to a 15 minute fixation with paraformaldehyde (4%), then 
washed with PBS three times.  Cells were blocked and permeabilised with PBS containing 
1%BSA and 0.1% Triton-X for 20minutes.  Cells were incubated with primary antibody (as 
indicated in (Table 2.14) for one hour, washed in PBS for 5 minutes three times then 
incubated with secondary antibody (as indicated in Table 2.14) for 30minutes protected 
from light. After secondary incubation, the cells were washed with PBS for 5 minutes and 
stained with DAPI (Hoechst, 1µl/ml in PBS) for 5 minutes, washed with PBS for 5minutes 
twice more.  The coverslips were rinsed with RO water prior to mounting on glass slides 
with mounting medium (Dako).  Image analysis was carried out with LSM 710 (Zeiss) or 
Leica DM2500 (Leica) microscope and quantified using AQM Advance 6 software (Kinetic 
Imaging Ltd, UK). 
 
Antibody Dilution Host Species Source Cat No. 
Cy3-anti mouse 1:500 Sheep Sigma C2181 
Alexa Fluor 488-anti 
rabbit 
1:500 Goat Invitrogen A11008 
SIRT1 1:200 Rabbit Abcam ab13749 
γH2AX 1:1000 Mouse Millipore 05-636 
Table 2.14 Summary of antibodies and sources. 
 
 2.7.2 Comet Assay 
Comet assays were performed using OxiSelectTM comet assay kit (Cell Biolabs).  The cells 
(300k/ml) were plated in 12 well plates directly prior to treatment.  After incubation, the 
cells were collected and centrifuged at 700g for 3 minutes, supernatant removed and 
sample resuspended in 1ml ice-cold PBS. The samples were diluted with pre-warmed 
agarose and loaded on the slide provided.  The subsequent procedure was carried out as 
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per manufacturer’s protocol followed by alkaline electrophoresis.  Vista dye was added 
immediately before the slides were observed by Leica DM2500 microscope.  Images were 
analysed and quantified using the ImageJ 1.45s open source software (National Institutes of 
Health, USA). 
 
 2.7.3 Confocal Imaging  
Time-lapse confocal microscopy was carried using a LSM510 system (Zeiss, Germany).  
Transfected cells in glass bottom dishes (Iwaki, Japan) were kept in a microscope mounted 
incubator at 37°C, 5% CO2 and 21% O2 and imaged using a 63x Plan Apochromatic oil 
immersion objective (NA 1.4).  YFP-tagged protein was excited using an Argon ion laser 
(488nm) and dsRedXP-tagged protein was excited using a green-neon laser (543nm).  
Emitted light was detected through a 505-550nm band-pass filter or 560nm long pass filter 
through a dichroic mirror for YFP and dsRedXP fluorescence respectively.  Imaging data 
were quantified using CellTracker v.6 software (http://dbkgroup.org/celltracker), (Hailin 
Shen, Douglas Kell). 
 2.7.3.1 Tracking analysis-calculating threshold 
A threshold for fluorescent intensity is used for determining whether a plasmid is expressed 
above background level.  The threshold was calculated using the raw data exported by 
CellTracker software.  For each cell, the average fluorescent intensity and the standard 
deviation prior to stimulation were calculated.  In our experiment, the threshold is set to be 
the average intensity prior to treatment plus 2 times standard deviation. 
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 2.8 Western blotting 
 2.8.1 Sample preparation 
Cells were seeded in 35mm dishes in 3ml medium in normoxia or hypoxia with or without 
etoposide treatment as indicated for each experiment.  Cells were pelleted by 
centrifugation for 5 minutes at 300g, washed with 1ml PBS and a repeat centrifugation was 
performed.  The cells were lysed with 100µl of lysis buffer (Tris-HCl 50mM pH7.5, EDTA 
1mM, EGTA 1mM, Sodium Orthovanadate 0.5mM, Triton X-100 1%, sodium fluoride 50mM, 
Sodium Pyrophosphate 5mM, Sodium β-glycerophosphate 10mM, PMSF 0.1mM and 
protease inhibitor cocktail 1/100).  The samples were rotated for one hour at 4oC on a 
rotation wheel and centrifuged at 14000g for 20 minutes at 4oC , the supernatant was then 
collected. 
 2.8.1.1 Protein concentration assay 
Protein concentration was quantified using BCA assays (Thermo Scientific).  The BCA assay 
was performed in a 96 well plate, in which 5µl of protein sample was diluted in 20µl of 
water.  A triplicate standard curve was performed, using BSA protein at a total volume of 
20µl and concentrations (µg/µl) of: 0.00, 0.25, 0.50, 1.00 and 1.50.  BCA and copper 
sulphate solution reagent mix was added to samples prior to incubation at 37oC for 30 
minutes.  The absorbance measurement at 570nm was measured using Multiskan plate 
reader (Thermo Scientific). 
 
 2.8.2 Protein separation by SDS-PAGE 
Protein samples were boiled for 5 minutes in the presence of 2x Laemmli buffer (Tris-HCL 
0.125M, SDS 4%, glycerol 20%, β-Mercaptoethanol 0.02% and bromophenol blue 0.001%).  
Using the Mini-PROTEAN 3 system (BioRad), the gels were cast using glass plates with 
1.5mm spacers.  A 10% SDS resolving gel (0.38M Tris base, 0.1% SDS, 10% acrylamide, 
0.25mg/ml APS and 0.125% Temed) and 4% stacking gel (0.14M Tris base, 4% acrylamide, 
0.75mg/ml APS and 4% Temed) were prepared in water.  30-50µg of proteins were loaded 
into each well.  The gel was submerged in running buffer (Tris 25mM, Glycine 192mM, 1% 
SDS) and the sample was resolved for 90 minutes at 120 volts. 
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 2.8.3 Protein transfer onto nitrocellulose membrane 
The transfer was performed at 4oC using a Bio-Rad transfer tank filled with pre-chilled 
transfer buffer (20% (v/v) methanol, Tris 25mM and glycine 200mM). The proteins resolved 
on the acrylamide gel were transferred by electrophoresis onto nitrocellulose membrane 
(Bio-Rad 162-0112) at 300mA for 90 minutes at 4oC. 
 
 2.8.4 Antibody incubations and protein detection 
Nitrocellulose membranes were washed in TBS-T (Tris 20mM, NaCl 140mM, adjusted to 
pH7.6 and 0.1% Tween) and blocked with 5% (w/v) dry skimmed milk for 60 minutes.  After 
removal of blocking buffer, membranes were rinsed with TBS-T and incubated with primary 
antibody at 4oC overnight (as indicated in Table 2.15).  Membranes were washed 3x in 
TBS-T then incubated with either anti-mouse or anti-rabbit secondary antibody (Table 2.15) 
for 1 hour.  Membranes were further washed 3 times in TBS-T. Membranes were developed 
with ECL (Thermo Scientific) and imaged with Syngene gel imaging G:box. 
 
Antibody Dilution Host Species Source Cat No. 
Anti-mouse HRP 1:5000 Sheep Abcam ab6808 
Anti-rabbit HRP 1:3000 Goat Cell Signalling CS7074 
Anti-goat HRP 1:1000 Donkey Santa Cruz SC2020 
HIF-1α 1:1000 Mouse BD Biosciences 610959 
p53 1:1000 Mouse Santa Cruz SC126 
p53 serine 15 1:1000 Rabbit CalBiochem PC386 
SIRT1 1:1000 Rabbit Abcam ab13749 
β-Actin 1:10000 Mouse Abcam Ab8226 
β-Actin 1:1000 Goat Abcam Ab8229 
Cyclophilin A 1:1000 Rabbit Abcam Ab3563 
Table 2.15 Summary of western blot antibodies and sources.  Typical concentrations used 
are also shown. 
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 2.9 Cell Viability assays 
 2.9.1 MTS Assay 
Viable cells were determined by measuring the cell’s metabolic activity using the CellTiter 
96®Aqueous One Solution Cell Proliferation Assay Kit (Promega).  The assay contains a 
tetrazolium compound, [3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS), which is reduced to a coloured formazan product by 
mitochondrial reductase activity.  Absorbance values of formazan indicate the level of 
mitochondrial activity and hence viable cells.  Cells were plated in 96 well plates followed 
by the appropriate treatment in a total volume of 100µl.  For the MTS assay, 20µl of 
substrate was added to each well and the plates were incubated for 120 minutes at 37oC 
before measurement of the absorbance value at 492nm using a Multiskan plate reader 
(Thermo scientific). 
 
 2.9.2  ViaCount viability assay 
Appropriate culture conditions and treatments were applied to cells in a 6 well plate.  For 
the viability assay, 500µl of sample was taken from the plate, centrifuged at 300g for 3 
minutes and resuspended in 500µl-1000µl of HBSS.  Subsequently, 25µl of the cell 
suspension was placed in a 96 well plate in duplicate prior to 5min incubation with 225µl of 
Guava ViaCount Reagent (Millipore).  Samples were run using a ViaCount analysis on a 
GUAVA instrument (Guava EasyCyte Plus).  Percentages of viable cells were measured using 
the Guava ViaCount software. 
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 2.10 Cell cycle Analysis 
Desired culture conditions and treatments were applied to cells plated in a 6 well plate.  
Cells were collected, centrifuged at 3000rpm for 3min and resuspended in an appropriate 
volume of HBSS to obtain a cell concentration between 100-500 cells per µl, 200 µl of each 
sample was stained with 25 µl of a solution containing propidium iodide [10µg/ml], 
ribonuclease A [0.1mg/ml] and 0.1% (v/v) Triton-X 100 in PBS in a 96 well plate.  FACS 
analysis was performed immediately using a GUAVA instrument (Guava EasyCyte Plus) and 
a population of 5000 cells was used for analysis.  Percentages of cells in each cell cycle 
phase were calculated using the Guava Express Pro software. 
 
 2.11 Statistical analysis 
Statistical significance test was performed using one-way ANOVA followed by Bonferroni 
test using built-in statistical analysis in OriginPro 8.6.0 (OriginLab Corporation, USA).  With 
the exception of qPCR data, non parametric Krustal-Wallis ANOVA was used (OriginLab 
Corporation, USA), as data are not normally distributed. 
 
  
 
 
 
 
 
 
 
 
Chapter 3: Chemoresistance in MB 
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 3.1 Introduction 
Currently, a combination of surgery and radiotherapy provides a relatively good outcome 
for MB patients, but often leaves long term neurological side effects (Frange et al., 2009, 
Rutkowski, 2006, Gilbertson, 2004).  Moreover, for younger children and complicated 
tumour location, surgery is not possible and treatment relies on chemotherapy only. 
Unfortunately, resistance to chemotherapeutic intervention has been observed in MB 
(Meley et al., 2010, Dong et al., 1999, Bobola et al., 2005).  One factor of MB 
chemoresistance is directly linked to the p53 genotype and this is also associated with poor 
survival (Friedman et al., 1992, Tabori et al., 2010, Pfaff et al., 2010). 
Generally, p53 signalling pathway is upregulated by drugs such as etoposide, and it plays a 
key role in activating genes involved in cell cycle arrest and apoptotic response.  As a 
transcription factor, p53 not only induces transcription of downstream target’s mRNA but 
also of non-coding RNA such as miRNAs.  One such direct p53 target is miR-34a, which 
represses many genes involved in tumourgenesis (Yamakuchi and Lowenstein, 2009, 
Tazawa et al., 2007, Raver-Shapira et al., 2007). 
The aim of this chapter is to investigate potential novel drug targeting downstream of p53 
activation, to overcome the chemoresistance due to p53 malfunction.  We hypothesised 
that direct activation of a miRNA downstream of p53, might have sufficient broad effects 
due to the nature of miRNA function compared to a single mRNA.  More specifically, it 
might be possible to escape the need for p53 activation for triggering cell death by using a 
miR-34a mimic.  The advantage of manipulating miRNA is that it represses hundreds of 
targets, potentially exerting a global effect compared to targeting one gene only. 
 
Objectives: 
1.  To test MB cell lines for their sensitivity to chemotherapeutic drugs and to assess the 
consequences of p53 mutation for cell death induction in MB cells. 
2.  To understand the role of p53-induced miR-34a for triggering cell death in MB. 
3.  Attempt to re-sensitise resistant MB cells through miR-34a induction. 
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 3.2 Results 
Previously, Meley et al. have shown that some MB cell lines displayed resistance to 
etoposide (Meley et al., 2010), cisplatin and methotrexate (unpublished data, Meley).  
Meley et al. have shown that D283 cell line (p53 WT) was the most sensitive to treatment, 
showing only ~20% of viable cells with etoposide after 24 hours of treatment.  However, 
another p53 WT cell line, Med1, showed ~60% of cell viability upon 24 hours of etoposide 
treatment.  The difference in etoposide response in these two p53 WT cell lines was 
explained by the additional signalling pathways, which are likely to be required for inducing 
cell death (Meley et al., 2010).  Med1 cells were shown to carry a NF-kappa β/p65 mutation 
and hence to be more resistant to etoposide (Meley et al., 2010).  Med8 is a cell line with a 
carrying a truncated p53 protein and showed the highest resistance, ~70% of viable cells 
were observed after 48 hours of etoposide treatment.  These results demonstrated that 
different MB cell lines display a varied sensitivity to etoposide, with D283 cells being the 
most sensitive to treatment. 
 
 3.2.1 D283 response to etoposide treatment 
Etoposide is one of the drugs within the chemotherapeutic cocktail combination used for 
treating MB in the clinic.  It is also the most cytotoxic drug out of the three drugs Meley et 
al. have tested.  Since D283 was the most sensitive to etoposide, we used D283 cell line to 
further investigate the mechanisms for cell death induction. 
The cells were treated with a varied concentration of etoposide [1 to 20µM] for a 48 hours 
time course and the resulting cell viability was measured by MTS assay (Figure 3.1).  
Following 6 hours of treatment, there was no significant difference in the levels of cell 
numbers in the 3 drug concentrations.  After 24 hours treatment, 20µM etoposide exerted 
a strong cytotoxic effect with a reduction in viable cell number to ~30%, whilst at the lower 
concentration of 5µM and 1µM etoposide, ~50% and ~85% of cells remained viable.  
However, after 48 hours of treatment, the levels of viable cells observed with 5µM 
etoposide and 20µM treatment were similar (~20%), with no significant difference.  Taken 
together, the chemosensitivity response of D283 cells to etoposide treatment is both dose- 
and time-dependent. 
Chemoresistance in MB 
-71- 
 
Figure 3.1 Sensitivity of D283 cells to etoposide treatment.  D283 cells were treated with 
[20µM], [5µM] or [1µM] Etoposide for a 48 hours time course.  The percentage of cell 
viability was measured by MTS assay over the untreated control.  Data shown are the mean 
of three independent experiments ± S.E.M. 
 
 3.2.2 Effect of etoposide on the p53 signalling pathway in MB cells 
The established etoposide mechanism of action is to inhibit the topoisomerase II, allowing 
double strand breaks to accumulate and, as a result, leading to the activation of the 
pro-apoptotic p53 protein. We first sought to measure p53 activation in the different cell 
lines upon etoposide treatment. 
 
 3.2.2.1 Etoposide-induced p53 protein levels 
We measured the total p53 protein levels upon etoposide treatment by western blot.  D283 
and Med8 MB cell lines were treated with etoposide [20µM] for 4, 7 or 24 hours before 
assessment of total p53 protein levels normalised to a housekeeping protein and untreated 
control.  For D283 cells, we saw a strong and transient increase of p53 protein by 4 and 7 
hours, which further decreased towards basal levels by 24 hours (Figure 3.2A).  In Med8 
cells, the p53 induction was delayed with no increase detected until 24 hours and the 
molecular weight of the immunoreactive p53 band was lower than that observed for D283 
cells (Figure 3.2B).  It has to be noted that Meley et al. also previously observed that the 
p53 band in Med8 cells was running at a lower molecular weight than in other cell types, 
suggesting a truncated p53 isoform in Med8 cells. 
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Figure 3.2 Etoposide-induced total p53 protein levels.  (A) D283 cells (B) Med8 cells were 
treated with etoposide [20µM] for indicated time points. Total p53 protein, cyclophilin A and 
actin are probed by western blot.  Quantification are normalised to T0 and untreated 
control.  The plots are representative of repeated experiments (N=2 for each cell line). 
 
 3.2.2.2 Etoposide-induced p53 transcriptional activity 
We then investigated if the increase of p53 levels were associated with an induction of its 
activity.  The p53 protein is regulated by post-translational modifications such as 
phosphorylation, methylation and acetylation (Yang, 2003, Dai and Gu, 2010, MacLaine and 
Hupp, 2011), which direct the ability of p53 to activate downstream targets (Thompson et 
al., 2004, Ashcroft et al., 1999, Maclaine and Hupp, 2009).  MDM2 is known to be one of 
the main targets of p53 and part of its feedback loop regulation, therefore MDM2 was used 
here as a readout of p53 activity.  The relative MDM2 mRNA levels normalised to untreated 
control were measured by real time PCR (Figure 3.3). 
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Figure 3.3 Levels of MDM2 upon etoposide-induced p53 activation.  MB cells were treated 
with etoposide [20µM] for 7 and 24 hours. The transcription of MDM2 was assessed by 
qPCR.  Fold changes were normalised to cyclophilin A and over the untreated control.  (A) 
D283 cells (B) Med1 cells (C) Med8 cells.  Data shown are the mean ± S.E.M of three 
independent experiments for each cell line.  Kruskal-Wallis ANOVA test was performed 
(*indicates p<0.05). 
 
In D283 cells, MDM2 mRNA levels increased ~17 fold by 7 hours, reaching up to 25 fold at 
24 hours (Figure 3.3A).  This increase was also present in Med1 cells but with a lower 
amplitude of ~2-3 fold induction (Figure 3.3B).  In Med8 cells, no MDM2 induction was 
detected at 7 hours but a delayed and small yet significant increase of MDM2 was observed 
after 24 hours of etoposide treatment (Figure 3.3C).  These results support the conclusion 
that both D283 and Med1 cells have a functional p53 pathway and that etoposide can 
indeed induce p53 transcriptional activity promptly in these cell lines.  In Med8 cells, 
etoposide-induced p53 activation is not completely abolished but it appears to be delayed 
compared to D283 and Med1 cells, consistent with the western blot data in Figure 3.2.  This 
delay of MDM2 mRNA level induction suggests that the truncated p53 isoform in Med8 
Chemoresistance in MB 
-74- 
could be functionally less active or that the cells might carry mutations elsewhere within 
the p53 pathway, thus resulting in a delayed p53 transactivation.  Another alternative 
explanation is that the induction of MDM2 is contributed by other p53 protein family 
members such as p63 or p73.  Further investigations and confirmation is required to 
elucidate the delayed p53 transactivation in Med8 cells. 
 3.2.2.3 Restoration of p53 pathway 
We hypothesised that the Med8 cells might be re-sensitised to etoposide by expressing an 
exogenous full WT p53 protein.  Med8 and D283 cells were transiently transfected with 
pMT-p53-dsRedXP and pmdm2-MDM2-YFP plasmids to express fluorescently tagged p53 
and MDM2 proteins.  The fluorescent fusions allow visualisation of increased levels of p53 
due to the stabilising effect of etoposide treatment in D283 cells, previously observed by 
western blot (Figure 3.2).  Using time-lapse confocal microscopy, the cells were imaged 
every 5 min, with etoposide [5µM] stimulation during the experiment. The fluorescence 
levels of both p53-dsRedXP and MDM2-YFP were measured over time, and quantified by 
cell tracker analysis (chapter 2.7.3).  A strong p53 induction of 10-fold or more above 
background levels was observed in 30 of 33 D283 cells analysed and MDM2 was also 
induced with a slight delay compared to p53.  Two examples of single cell traces are shown 
on Figure 3.4A.  On average, increase in p53 and MDM2 above background was measured 
at 1.2 hours and 2.3 hours after etoposide treatment respectively (N=2; n=33; p53, SE=0.34; 
MDM2, SE=0.51).  The delay of MDM2 induction is likely to be due to the time needed for 
p53 to activate the MDM2-YFP promoter.  In 10% of the cells, no detectable MDM2 
induction was measured even if p53 levels increased.  A typical example is shown Figure 
3.4B.  In D283 cells, an increase in p53 and MDM2 was observed in ~90% of the transfected 
cells after etoposide stimulation (Figure 3.6).  Many cells underwent apoptosis or showed 
apoptotic morphology within 24 hours, due to their sensitivity to etoposide. 
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Figure 3.4 Etoposide-induced p53 activity at a single cell level in D283 cells.  D283 cells 
were co-transfected with p53-dsRedXP and MDM2-YFP and imaged by time lapse 
microscopy.  Etoposide [5µM] stimulation is indicated.  (A) A cell (indicated by arrow) 
showing p53 and MDM2 response (B) A cell showing p53 response but no MDM2 response.  
The level of p53 was assessed by the intensity of fluorescent protein expression measured by 
Cell Tracker normalised to untreated control, threshold was calculated as average intensity 
of untreated control + 2SD (N=2, n=33). 
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We observed an induction of p53 in 78% of transfected Med8 cells (Figure 3.6), with only 
35% MDM2 induction detected (Figure 3.5A and Figure 3.6) (N=2, n=22).  The p53 increase 
in this cell line was lower compared to D283 cells, with 76% of cells showing increased p53 
levels (Figure 3.5B and Figure 3.6).  The timing of p53 and MDM2 induction in Med8 cells 
was also much slower, with an average of 2.6 hours after stimulation for p53 increase and 
4.8 hours for MDM2 (N=2; p53, n=17; SE=0.57; MDM2, n=6, SE=1.61) to be compared with 
1.6 hours (for MDM2) and 1.1 hours (for p53) in the D283 cells.  These results further 
support the theory that the p53 protein in Med8 is functionally less active and that the lack 
of negative feedback mechanism observed suggests that Med8 bares a mutated p53 
pathway.  Furthermore exogenous expression of WT p53 in Med8 did not restore normal 
p53 activation, nor re-sensitise these cells to etoposide treatment as little apoptosis was 
observed up to 24 hours. 
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Figure 3.5 Etoposide-induced p53 activity at a single cell level in Med8 cells.  Med8 cells 
were co-transfected with p53-dsRedXP and MDM2-YFP and imaged by time lapse 
microscopy  (A) A cell showing p53 response (B) A cell showing a weak p53 response just 
above threshold.  The level of p53 was assessed by the intensity of fluorescent protein 
expression measured by Cell Tracker normalised to untreated control, threshold was 
calculated as average intensity of untreated control + 2SD (N=2, n=22). 
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Figure 3.6 Live measurement of p53 and MDM2 activation.  A stack column showing the 
percentage of MB cells with or without p53 or MDM2 expression above threshold level upon 
etoposide treatment.  Threshold was calculated as average intensity of untreated control + 
2SD (see material and methods 2.7.3.1).  D283 cells (N=2, n=33); Med8 cells (N=2, n=22) 
 
 3.2.3 Bypassing p53 activation 
In section 3.2.2.3, our results support that etoposide-induced cell death is correlated with 
the cell ability to induce p53 activation.  To overcome chemoresistance due to impaired p53 
activation, we hypothesised that downstream p53 target genes could constitute potential 
drug targets, which would then bypass the need for p53 activation. 
As described in chapter one, p53 has a broad genetic program of target genes involved in 
DNA repair, cell cycle arrest and apoptosis (chapter 1.7).  Therefore, we anticipated that 
targeting individual downstream candidates might not be enough to induce a significant cell 
death response. For this reason, we focused on a p53-dependent miRNA, a non coding 
RNA, which can itself regulate hundreds of downstream targets (Bartel, 2004, Cai et al., 
2009).  Single miRNA can alter the expression of hundreds of proteins, and have been 
suggested as potential powerful targets for cancer treatment. One well described p53 
miRNA targets is miR-34a (Raver-Shapira et al., 2007). 
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 3.2.3.1 Induction of miR-34a by etoposide 
We investigated the expression of miR-34a upon etoposide treatment in MB cell lines.  MB 
cells were treated with etoposide [20µM] for up to 24 hours and miR-34a levels were 
assessed by qPCR.  miR-34a mRNA levels were increased by ~2.5 fold after 7 hours and ~12 
fold by 24 hours of etoposide in D283 cells (Figure 3.7A).  The kinetics of miR-34a 
transcription induced by etoposide was correlated with the up-regulation of p53 
transcriptional activity measured by MDM2 as observed in Figure 3.3.  In Med1 cells, 
miR-34a induction was also increased by ~2 fold up to 24 hours of etoposide treatment 
(Figure 3.7B).  We did not observe any induction of miR-34a transcription upon etoposide 
treatment in Med8 cells (Figure 3.7C). 
 
 
 
Figure 3.7 miR-34 induction upon etoposide treatment.  MB cells were treated with 
etoposide [20µM] for indicated time points. The transcription of miR-34a and MDM2 was 
assessed by qPCR.  (A) D283 cells (B) Med1 cells (C) Med8 cells.  Fold changes were 
normalised to cyclophilin A and the untreated control.  Data shown are the mean ± S.E.M of 
three independent experiments.  Kruskal-Wallis ANOVA test was performed (*indicates 
p<0.05). 
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 3.2.3.2 Etoposide-induced miR-34a is p53 dependent 
We then sought to confirm the role of p53 in etoposide-induced miR-34a levels in D283 
cells.  Cells were transfected either with siRNA directed to silence p53 expression or with a 
non-specific scrambled siRNA control for 48 hours.  The levels of miR-34a were assessed by 
qPCR post transfection and etoposide [20µM] treatment or no treatment for comparison 
(Figure 3.8). 
 
 
Figure 3.8 Etoposide-induced miR-34a transcription is p53 dependent.  D283 cells were 
transfected for 48 hours with siRNA directed to p53 or non-specific siRNA as a negative 
control before a 7 hour treatment with etoposide [20µM].  The transcription of miR-34a was 
assessed by qPCR, data were normalised to cycA and untreated control.  Data shown are the 
mean ± S.E.M of three independent experiments.  Kruskal-Wallis ANOVA test was performed 
(*indicates p<0.05). 
 
The transfection itself (scrambled siRNA or sip53) without etoposide treatment, did not 
alter the level of miR-34a transcript.  In non-transfected D283 cells or cells transfected with 
a scrambled siRNA, a two fold increase in miR-34a level was observed upon etoposide 
treatment as previously shown in Figure 3.7.  However, no induction of miR-34a was 
measured in the presence of sip53.  These data show that etoposide-induced miR-34a 
transcription is inhibited by p53 knockdown, confirming that in D283 cells, etoposide-
dependent induction of miR-34a is p53 dependent.  These data confirm the essential role of 
p53 in miR-34a regulation and further explains the lack of miR-34a transcription in Med8 
cells where p53 function is impaired. 
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 3.2.3.3 Functional role of miR-34a 
Independent studies have shown that miR-34a exhibits tumour suppression functions, 
targeting the expression of pro-survival and oncogenes genes such as SIRT1, E2F3, MYCN, 
Notch1, c-Met, Bcl2 (Li et al., 2009, Yamakuchi et al., 2008, Bommer et al., 2007).  In 
particular, SIRT1 is one of the most validated targets of miR-34a.  It is a pro-survival protein 
and plays a protective role towards cellular oxidative stress and DNA damage by 
deacetylating transcription factors including p53 (Yamakuchi and Lowenstein, 2009, Deng et 
al., 2007, Kwon and Ott, 2008).  SIRT1 therefore downregulates p53 transcriptional 
activation, thus mediating cell survival during cellular stress through inhibition of apoptosis 
(Luo et al., 2001, Vaziri et al., 2001).  In this respect, in cells with intact p53, etoposide 
induction of p53 may up-regulate miR-34a and repress SIRT1 as part of its signalling 
cascade, hence forming a positive feedback loop for p53 activity (Figure 3.9).  Moreover, 
SIRT1 can deacetylate other proteins (e.g. Forkhead Box protein (FOXO), Retinoblastoma 
protein (Rb), BAX and E2F1), involved in cell cycle arrest and apoptosis, therefore SIRT1 
inhibition have a potential to reduce cell growth independently of p53 (Figure 3.9) (Ford et 
al., 2005, Wong and Weber, 2007). 
 
 
 
Figure 3.9 Schematic diagram of p53-miR-34a positive feedback loop.  p53 induces 
miR-34a which represses SIRT1 expression. Reduction of SIRT1 increases p53 acetylation and 
downstream activation.  SIRT1 also deacetylates E2F1; Rb; BAX and FOXO, altering their cell 
cycle arrest and apoptotic functions. 
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We first investigated the ability of etoposide-induced miR-34a to regulate SIRT1 expression.  
SIRT1 levels were measured by both western blot and qPCR.  Figure 3.10 shows that SIRT1 
mRNA levels decreased concomitantly with miR-34a increase following etoposide 
treatment.  After 24 hours of etoposide stimulation, miR-34a levels have increased ~5 fold 
whilst SIRT1 mRNA levels have decreased by ~4 fold (Figure 3.10A).  SIRT1 protein levels 
clearly decreased after 7 hours of etoposide treatment (Figure 3.10B).  By 24 hours, SIRT1 
band intensity on western blot decreased by 80% compared to untreated control.  This was 
also confirmed by immunocytofluorescence detection of SIRT1 (Figure 3.10C).  These 
results suggest that etoposide-induced miR-34a is functional and is associated with down 
regulation of SIRT1 expression at both mRNA and protein levels. 
 
 
Figure 3.10 Decrease in SIRT1 levels upon etoposide treatment.  D283 cells were treated 
with etoposide [20µM] for indicated time points.  (A) SIRT1 mRNA levels were measured by 
qPCR (N=2, error bars here are SD of the 2 experiments). (B) Western Blot with SIRT1 
antibody normalised to the house keeping protein actin, this blot is a representative of four 
independent experiments. (C) Immunocytofluorescene with SIRT1 antibody after etoposide 
treatment at indicated time point, this image is a representative of three independent 
experiments. 
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 3.2.3.4 The effect of SIRT1 inhibitors on cell number 
In order to better assess the importance of SIRT1 decrease for triggering MB apoptosis, we 
sought to inhibit SIRT1 directly.  There are several inhibitors known to inhibit the family of 
SIRT1 proteins such as nicotinamide, EX527 and sirtinol (Ota et al., 2006, Peck et al.).  D283 
and Med8 cells were treated with nicotinamide [25mM to 100mM] for a 48 hours time 
course and cell viability was measured by MTS (Audrito et al., 2011, Bitterman et al., 2002, 
Aoyagi and Archer, 2008).  In D283 cells, nicotinamide was very potent at 50mM and 
100mM, with respectively only ~25% and ~5% of viable cell at 48 hours (Figure 3.11A).  
These results were comparable to etoposide toxicity (10% of viable cells at 48 hours; Figure 
3.1).  More importantly and interestingly, nicotinamide was able to induce cell death in 
Med8, which was resistant to etoposide.  We observed almost no viable cells by 48 hours 
with 50 or 100mM nicotinamide (Figure 3.11B) compared to the ~70% cell viability with 48 
hours etoposide treatment observed by Meley et al. (Meley et al., 2010).  Nicotinamide 
[50mM] can effectively induce cell death in both p53 WT and p53 mutated cell lines (Figure 
3.11C).  This finding was also reported by Audrito et al., where 50mM of nicotinamide 
induce apoptosis in chronic lymphocytic leukemia cells in vitro (Audrito et al., 2011).  
However, it has to be noted that the concentration of 50mM nicotinamide required to 
induce cell death is higher than what would be possible to obtain in a physiological setting.  
The dosage of nicotinamide used in neck and head cancer patients without severe side 
effect is 60mg/kg, measuring at ~0.8mM peak plasma concentration (Bussink et al., 2002), 
which is 60 times lower than the in vitro dose needed to observe an effect. 
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Figure 3.11 Cell viability assay of MB cell lines treated with nicotinamide.  (A) D283 cells 
(B) Med8 cells were treated with nicotinamide (Nic) for 6, 24 or 48 hours, concentration as 
indicated (n=1, error bars shown are SD of 6 replicates). (C) MB cell lines treated with 
nicotinamide [100mM] at indicated time points.  The percentage of cell viability was 
measured by MTS assay over the untreated control.  Data shown are the mean ± S.E.M of 
three independent experiments.  One-way ANOVA followed by Bonferroni test was 
performed (* indicates p<0.05). 
 
We subsequently investigated the effects of other SIRT1 inhibitors, EX527 and sirtinol.  A 
dose dependent response was observed for EX527 in both D283 and Med8 cells.  In D283 
cells, cell viability of ~70% and ~45% was observed with 48 hours of EX527 [50µM] or 
[100µM] treatment respectively (Figure 3.12A).  Whilst for Med8 cells, viability remained 
~100% and ~70% at these concentrations (Figure 3.12B).  In D283 cells treated with sirtinol, 
cell viability remained relatively high at ~55% and ~58% with [50µM] or [100µM] sirtinol for 
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48 hours.  These results demonstrated that the use of EX527 and sirtinol was not 
comparable to etoposide in terms of their cell death induction property. 
 
 
 
Figure 3.12 Cell Viability assay of MB cell lines treated with SIRT1 inhibitors.  (A) D283 
cells. (B) Med8 cells were treated with EX527 for 6, 24 or 48 hours, at indicated 
concentrations.  (C) D283 cell line treated with sirtinol [50µM] and [100µM] for 6, 24 or 48 
hours (n=1, error bars shown are SD of 6 replicates). 
 
Taken together for all SIRT1 inhibitors tested, only with the use of nicotinamide at high 
concentrations induced a strong cytotoxic effect in both D283 and Med8 cells.  The use of 
sirtinol and EX525 did not induce apoptosis and would not make a suitable MB drug.  
Therefore, instead of targeting this one single target, we next investigated the potential of 
using miR-34a itself as a cell death inducer. 
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 3.2.3.5 The effect of miR-34a on cell number 
A synthetic miR-34a mimic (Dharmacon, UK) was used to potentially induce cell death in 
MB cells.  Control experiments were first performed to test the delivery and expression 
efficiency of miR-34a mimic.  The delivery of miR-34a mimic oligonucleotides was tested by 
transfection alongside a fluorescently labelled (Dy547) mimic transfection control.  Images 
show that all cells were stained positive with Dy547, suggesting a ~100% delivery (Figure 
3.13).  The level of transfected miR-34a was also measured by qPCR, ~250 fold increase of 
miR-34a was detected compared to non transfected or negative transfection control 
(Figure 3.14). 
 
 
Figure 3.13 Validation of synthetic miR-34a transfection delivery.  D283 cells were (A) Not 
transfected (B) Transfected with miR-34a mimic [50nM] and negative control Dy527 [50nM] 
for 72 hours.  Samples were fixed by immunocytofluorescence protocol and Imaged on 
LSM710, (n=2). 
 
 
 
Figure 3.14 Validation of synthetic miR-34a transfection levels.  MB cells were transfected 
with miR-34a mimic [100nM] or non specific negative control [100nM] for 72 hours. The 
level of miR-34a was measured by qPCR normalised to cycA housekeeping gene, (n=1, errors 
shown here are SD of 3 replicates). 
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The effect of miR-34a on cell viability was assessed 72 hours post transfection.  The effects 
of miR-34a mimic transfection on cell viability were measured by MTS in both p53 WT 
(D283) and p53 mutated cells (Med8).  We observed that 80% of D283 cells and 67% of 
Med8 cells were viable upon miR-34a transfection (Figure 3.15).  The number of viable cells 
in D283 cells is higher than what was obtained with the SIRT1 inhibitors, EX527 [100µM] 
and sirtinol [100µM], where ~70 % of cells were viable after 24 hours treatment (Figure 
3.10).  The cytotoxicity effect of miR-34a mimic is minimal compared to etoposide 
treatment in D283 cell line (Figure 3.1). 
 
 
Figure 3.15 miR-34a mimic reduce cell numbers in p53 WT and p53 mutated MB cell line.  
D283 (p53 WT) and Med8 (p53-mut) cells were transfected with miR-34a mimics [100nM] 
and expressed for 72 hours before MTS assay.  Percentage (%) of cell viability were 
normalised over transfection control.  Data shown are the mean ± S.E.M of four 
independent experiments.  One-way ANOVA followed by Bonferroni test was performed 
(*indicates p<0.05). 
 
Interestingly, miR-34a mimics also reduce cell proliferation in the resistant Med8 cells.  The 
effect of miR-34a mimics on viable cell number in this cell line is more pronounced than 
etoposide [20µM] or EX527 [100µM] which had no effect and a reduction of ~20% of viable 
cell number respectively after 24 hours of treatment ((Meley et al., 2010), (Figure 3.12), 
compared to the a reduction of 33% in viable cell number when treated with miR-34a 
mimic (Figure 3.16).  The ability of miR-34a mimics to reduce cell proliferation in Med8, a 
p53 mutated cell line, indicates that miR-34a introduction can indeed bypass p53 upstream 
activation and be used as a target for MB treatment. 
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Figure 3.16 The effect of miR-34a mimic and etoposide in p53 mutated Med8 cells.  Med8 
cells were transfected with miR-34a mimics [100nM] and expressed for 72 hours or treated 
with etoposide [20µM] for 24 hours before MTS assay.  Percentage (%) of cell viability were 
normalised over transfection control.  Data shown are the mean ± S.E.M of four 
independent experiments.  One-way ANOVA followed by Bonferroni test was performed 
(*indicates p<0.05). 
 
 3.2.4 Role of miR-34a in other brain tumours 
We next investigated the potential of miR-34a in inducing cell death in other brain tumours, 
such as Glioblastoma (GBM).  The use of a miR-34a mimic to induce cell death in p53 WT 
cell line (U87) and in a p53-mutated cell line (T98G) was tested.  We observed a 10% 
reduction in U87 cell number and 18% in T98G cell number upon miR-34a transfection 
(Figure 3.17).  These results demonstrated that the effect of miR-34a induction is not 
restricted to MB and it is also observed in GBM.  However, the potential use of miR-34a to 
induce cell death in GBM is limited. 
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Figure 3.17 Effect of miR-34a mimics induce in p53 WT and p53 mutated GBM cell line.  
U87 (p53 WT) and T98G (p53-mut) cells were transfected with miR-34a mimics [100nM] and 
expressed for 72 hours prior to MTS assay.  Percentage (%) of cell viability was normalised 
over transfection control.  Data shown are the mean ± S.E.M of three (T98G) and four (U87) 
independent experiments.  One-way ANOVA followed by Bonferroni test was performed 
(*indicates p<0.05). 
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 3.3 Chapter 3 Discussion 
 3.3.1 p53 status and chemoresistance 
It is well established that the loss of WT p53 is associated with many human cancers, 
including those in the brain (Levine et al., 1991, Hollstein et al., 1991, Frankel et al., 1992).  
Generally, in most cancers, p53 itself is not a critical marker for chemoresistance, but 
nevertheless many studies have supported evidence that successive chemotherapeutic 
treatments require a functional p53 response (Lowe et al., 1993, Lowe et al., 1994, Wattel 
et al., 1994, Gasco and Crook, 2003).  This is true for many cancer models including breast 
cancer, gliomas and GBM (Gjerset et al., 1995, Trepel et al., 1998, Hermisson et al., 2006, 
Jin et al., 2010).  In breast cancer, TP53 mutation is associated with resistance to 
anthracyclines and mitoycin (Knappskog and Lonning, 2012).  In glioma cells, mutant p53 
are resistant to temozolomide (Roos et al., 2007) and in GBM, knockout of WT p53 with 
siRNA prevented chloroquine-induced cell death (Kim, E. L. et al., 2010). 
In brain tumours such as gliomas and GBMs, WT p53 is not always associated with better 
chemotherapeutic response and treatment outcome can be dependent on the choice of 
drug used (Batista et al., 2007, Roos et al., 2007).  Roos et al. have demonstrated that p53 
mutated GBM cells confer resistance to methylating drugs such as temozolomide (Roos et 
al., 2007), but the reverse effect was observed using carmustine (BCNU), where p53 
mutated cells are more sensitive to treatment (Batista et al., 2007).  Similarly, the negative 
association of p53 WT expression and poor chemotherapy response has been observed in 
other models too, such as breast, colon and head & neck cancer (Fan et al., 1995, Parsels et 
al., 1997, Brachman et al., 1993).  Thus it is rather important to understand the relationship 
between p53 status in a particular tumour type and its response to treatment to enable the 
best chemotherapeutic choice. 
Currently, the association of p53 mutation, chemosensitivity and treatment outcome in MB 
is understudied (Tabori et al., 2010, Woodburn et al., 2001, Meley et al., 2010).  A 
sequencing study performed by Tabori et al. has shown that TP53 mutation was found in 
8/49 (15%) of MB patients samples (Tabori et al., 2010).  Furthermore, patients with p53 
mutated tumours had a shorter average recurrence time of 10 months compared to 14 
months in non mutated tumour and the 5-year survival rate was 0% compared to 74% in 
p53 WT tumours (Tabori et al., 2010).  The author concluded that the overall poor survival 
of patients with TP53-mutated tumours is contributed by the resistance to treatment 
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(Tabori et al., 2010).  Here, we have also confirmed that MB cell lines do exhibit altered 
sensitivities to chemotherapeutic drugs and that drug resistance observed was correlated 
with the cells p53 status.  This is in agreement with previous studies by Meley et al. (Meley 
et al., 2010).  Therefore, it is necessary to be able to activate apoptosis via an alternative 
route or bypass p53 upstream activation in resistant MB cell lines. 
 
 3.3.2 Inhibition of a pro survival gene, SIRT1  
SIRT1 is a deacetylase that removes the acetyl group from p53, thus reducing its target 
activation.  We have demonstrated in the presence of etoposide, activated p53 induce 
miR-34a expression, and subsequently down regulates SIRT1.  This agrees with the current 
literature where p53, miR-34a and SIRT1 forms a positive feedback loop (Yamakuchi et al., 
2008, Yamakuchi and Lowenstein, 2009).  The effect of this signalling is evident in several 
other cancers such as colon cancer, as it is shown that an increase of miR-34a leads to a 
reduction of SIRT1, resulting in an increased level of acetylated p53.  Consequently, an 
increase of p53 proapoptotic target genes such as PUMA was detected (Yamakuchi and 
Lowenstein, 2009). 
We have used nicotinamide, EX527 and sirtinol SIRT1 inhibitors to confirm the role of SIRT1 
inhibition in cell death induction in our model.  The use of EX527 has asserted minimal 
effect on cell viability at relatively high concentrations and that sirtinol failed to induce cell 
death in D283 p53 WT cell line.  This finding is similar to that of Solomon et al. where they 
found that EX527 has no effect on cell viability even though they measured a decreased 
SIRT1 deacetylate activity in epithelial cells (Solomon et al., 2006).  These compounds have 
been demonstrated to be active at these concentrations because they increased p53 
acetylation, but it seems that p53 acetylation at lysine 382 might not be sufficient to 
activate a pro-apoptotic p53 response. 
The effect of nicotinamide at high concentration [50mM] in inducing cell death is in line 
with other findings, where SIRT1 inhibition can trigger apoptosis (Peck et al., 2010, Audrito 
et al., 2011).  Interestingly, apoptosis was observed in both p53 WT and p53 mutated cells, 
suggesting that the p53 activated-apoptosis can be bypassed.  It is speculated that 
nicotinamide-induced cell death is caused by mechanisms independent of p53.  For 
example, treatment of [50mM] nicotinamide for 24 hours has been demonstrated to inhibit 
poly (ADP-ribose) polymerase which can lead to cell cycle arrest and apoptosis (Saldeen et 
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al., 2003).  However, with the high concentrations needed in vitro to induce sufficient cell 
death, this limits the potential of using this SIRT1 inhibitor in clinic. 
 
 3.3.3 Introduction of miR-34a  
MiR-34a expression has been reported to be associated with drug sensitivity in several 
models including MB (Fujita et al., 2008, Zenz et al., 2009, Weeraratne et al., 2011).  
Weeraratne et al. have observed that primary MB baring functional p53 expressed 
significant higher levels of miR-34a and that it was positively correlated with sensitivity of 
these cell lines to chemotherapeutic drugs.  Several studies have highlighted the 
importance of loss of miR-34a in tumourgenesis and the potential use of miR-34a in altering 
tumour cells fate, but via different mechanisms.  For example, Li et al. and Guessous et al. 
have found that pre-miR-34a levels are lower in GBM compared to normal tissues or in 
mutated p53 than p53 WT tumours.  They further demonstrated that miR-34a levels 
negatively correlated to c-Met (Met proto-oncogene) expression, and that transfection with 
miR-34a in both GBM or MB cell lines downregulated c-Met expression and inhibited cell 
proliferation and survival (Li et al., 2009, Guessous et al., 2010); Welch et al. have 
demonstrated that miR-34a directly targets E2F3, reducing its protein level and preventing 
cell cycle progression (Welch et al., 2007).  In a gastric cancer model, Ji et al. have shown 
that restoration of miR-34a with mimic molecules impaired cell growth, increased 
caspase-3 activation and sensitised cells to treatment (Ji et al., 2008).  These results 
demonstrate how the use of one miRNA can alter cell fate.  In our hands, we have also 
observed that direct introduction of a miR-34a mimic was able to reduce viable cell 
numbers in both MB and GBM.  Although these results confirm that we can directly alter 
MB cell viability, the effect of miR-34a-induced cell death is limited and may not translate 
well into pre-clinical or clinical models. 
 
  
 
 
 
 
 
 
 
 
Chapter 4: Hypoxia-induced Chemoresistance 
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 4.1 Introduction 
Brain tumours such as MB are typically present as solid tumours.  Tumour cells can 
experience varied levels of oxygen and nutrient supply dependent on the cells’ proximity to 
the nearest blood vessels.  Cells located at the centre of the mass, away from the vessels, 
are often deprived of appropriate oxygen supply causing hypoxic regions within the tumour 
mass (chapter 1.2.2).  
Hypoxia is commonly associated with resistance to chemotherapy and radiotherapy either 
through a direct effect on a drug’s efficiency or through alterations of intracellular signals 
(Sullivan et al., 2008, Brown, 1999).  Firstly, the efficiency of drug delivery relies on the 
presence of a well vascularised structure.  Secondly, a hypoxic environment might affect 
the drug’s mechanism of action if oxygen is required for the drug function, thus hindering 
drug’s cytotoxicity (chapter 1.5.2.5) (Hicks et al., 2004, Koch, 1993, Teicher, 1994).  Lastly, 
hypoxia can activate signalling pathways, which can consequently lead to activation of 
genes involved in drug resistance (Cosse et al., 2007, Flamant et al., 2010, Sermeus et al., 
2008). 
However, there are discrepancies on the length and severity of hypoxia required to induce 
drug resistance and this appears to be dependent on cell type.  We hence sought to 
investigate the effects of altered duration of hypoxia and how it affects MB drug sensitivity. 
Moreover, the crosstalk between hypoxia, HIF and p53, and their involvement in apoptosis 
in hypoxia is unclear.  Since we have previously demonstrated the importance of a fully 
functional p53 pathway for etoposide-induced cell death (chapter 3), here we aim to 
investigate if hypoxia affects the DNA damage induced by etoposide and if the subsequent 
p53 activation is altered.  We have selected the D283 cell line to test our hypothesis as this 
cell line is sensitive to etoposide and we have demonstrated in this cell line, 
etoposide-induced p53 activation. 
 
Objectives: 
1.  To investigate etoposide-induced death of D283 cells in hypoxia 
2.  To measure DNA damage induced by etoposide in normoxic and hypoxic conditions  
3.  To measure etoposide-induced p53 activation in hypoxia in comparison to normoxic 
conditions. 
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 4.2 Results 
 4.2.1 Effects of Hypoxia on Cell Fate 
Oxygen plays an important role in many cellular processes such as cell fate, cell migration 
and cellular energy expenditure. Under hypoxic conditions, a cell may switch the focus of its 
energy expenditure to maintain homeostasis, altering the rate of cell cycle progression.  As 
chemotherapeutic drugs commonly target rapidly dividing cells, treatment may become 
ineffective during a slowed cell cycle.  Therefore, it was necessary to initially determine cell 
viability and proliferation rate in hypoxic conditions.  To investigate the effects of hypoxia 
on cell growth and cell cycle, D283 cells were cultured and monitored under hypoxic 
conditions for a prolonged period of 5 days.  Given that physio-pathological O2 
concentrations in brain tumours are around 1% or below (chapter 1.3).  We have used 1% 
O2 for our ‘hypoxic condition’, with ‘normoxic’ referring to the atmospheric 21% O2 for 
studies in this chapter. 
 4.2.1.1 Growth Analysis of D283 cells in hypoxia 
D283 cells cultured under normoxia or hypoxia were visualised by light microscopy to 
provide an indication of cell morphology and a rough assessment of cell growth and 
viability (Figure 4.1).  We saw no observable differences of cell density in hypoxia compared 
to normoxia up to 72 hours.  However, at 96 and 120 hours incubation, cell density of the 
hypoxic cells appeared to be more sparse than those in normoxia, suggesting a potential 
slower cell proliferation rate or an increase in cell death due to hypoxia. 
 Hypoxia-Induced Chemoresistance 
-96- 
 
Figure 4.1 Brightfield pictures of D283 cells in normoxia and hypoxia.  0.25x106 cells/ml of 
D283 cells were plated in 3 ml medium and incubated in normoxia or hypoxia (1% O2) for 
indicated periods.  Bright field images were captured on a Zeiss Axiovert 25 light microscope 
attached to a GXCAM-3 with a 20x objective. 
 
To accurately determine the rate of cell growth in normoxia and hypoxia, we performed a 
cell count using a Beckman Coulter cell counter.  In agreement with the microscopy images, 
the population of cells counted was higher in normoxia than cells in hypoxia (Figure 4.2A), 
with 2.6x106 cells/ml at 96 hours in normoxia and only 1.6x106cells/ml in hypoxia.  We 
further determined cell viability in these two conditions using the ViaCount cell viability 
assay (chapter 2.9.2).  After 5 days of incubation in normoxia, 75% of cells were viable; this 
value was reduced to ~40% for cells incubated in hypoxia.  This result demonstrates that 
chronic hypoxia incubation induces some cell death in D283 cells (Figure 4.2B). 
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Figure 4.2 Cell counts of D283 cells in hypoxia.  Cells cultured under normoxic or hypoxic 
(1% O2) condition were counted at indicated time points.  (A) The graph shows the number 
of cells in normoxia and hypoxia over a 96 hours time course.  (B) Viable cell count of D283 
cells measured by ViaCount assay.  Data shown are the mean ± S.E.M of three independent 
experiments. 
 
 4.2.1.2 Cell Cycle profile of D283 cells in hypoxia 
Cell cycle distribution profiles for D283 cells were obtained from measuring the intensity of 
Propidium Iodide (P.I) incorporation using flow cytometry.  The plot shown in Figure 4.3 is a 
typical plot, showing the size (forward scatter) and granularity, which are granular materials 
inside the cells (side scatter) of the analysed cell.  The use of PI is ideal for cell cycle 
profiling as PI can intercalate into double stranded DNA and hence the quantity of PI 
staining is directly proportional to the amount of DNA material present within the cells.  
Cells in G0/G1 phase contain one copy of DNA and will therefore have 1xintensity of PI 
staining.  Cells in G2/M phase will have two copies of DNA and therefore will have 2x 
intensity of PI staining, twice that of the cells in G0/G1 (Figure 4.3B).  The amount of DNA 
material for cells undergoing DNA synthesis (cells in S phase) is between the one of G1 and 
G2, depending on the stage of DNA replication process.  The markers for each of the cell 
cycle phase were manually placed on the cell cycle profile graph and this gating remained 
the same for each sample (Figure 4.3). 
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Figure 4.3 GUAVA Express Pro analysis.  (A) A Scatter graph showing the size and 
granularity of cells. (B) A cell cycle profile graph demonstrating the different phases of cell 
cycle stage, the first peak (red) in the graph represents cells in G0/G1 phase and the second 
peak (purple) represents cells in G2/M phase.  The blue portion in between the two peaks 
represents cells in S phase.  The green portion is likely to be cells that are clumped together 
or cells which have polyploidy, therefore this section of the graph was disregarded in the 
analysis. 
 
The cell cycle profile of D283 cells cultured in normoxia or hypoxia were obtained every 24 
hours up to 96 hours (Figure 4.4A).  We found that the cell cycle distribution of both 
hypoxic and normoxic cells remained similar throughout the time course.  At any given time 
points (24-96 hours), we measured ~45% of cells in G0/G1 phase, ~10% of cells in S phase 
and ~20% in G2/M phase in both conditions (Figure 4.4A).  Altogether our results suggest 
that chronic hypoxia does not arrest the cell cycle and that the decreased proliferation is 
more likely attributable to the increased cell death. This also suggests that the cells, which 
survive in hypoxia continue cycling and it is this remaining population of cell, which is likely 
to be the most resistant to cell death and the hardest to kill in the context of a tumour.  
Therefore we have focused on how this remaining population of surviving cells in chronic 
hypoxia responded to the chemotherapeutic agent etoposide. 
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Figure 4.4 Cell cycle profile of D283 cells in hypoxia.  (A) Cell cycle profiles obtained from 
flow cytometry. D283 cells were cultured in normoxia or hypoxia (1% O2) for indicated times. 
(B) Cell cycle profile quantification showing percentage of cells in each cell cycle phase.  This 
is a representative of three independent experiments, error bars shown are experimental 
errors of 2 replicates. 
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 4.2.2 Effect of hypoxia on response to chemotherapy 
The exact mechanism of hypoxia-induced chemoresistance remains unclear, it seems to be 
cell type dependent (Cosse et al., 2007) and varies depending on the length and degree of 
hypoxic exposure (Hussein et al., 2006, Cosse et al., 2007, Sullivan et al., 2008). It has been 
reported that hypoxia is able to prevent etoposide-induced cell death in several tumours 
such as neuroblastoma, breast cancer and prostatic cancer (Hussein et al., 2006, Sullivan 
and Graham, 2009).  Cosse et al. and Sermeus et al. have observed drug resistance in 
various cell lines after 16 hours of 1% hypoxic incubation.  However, Hussein et al. found 
that exposure to hypoxia of up to 16 hours had little effect on drug induced apoptosis in 
neuroblastoma cell lines, whereas long exposure up to 1 week decreased drug-induced 
apoptosis.  Whilst Sullivan et al. have demonstrated that breast cancer cell lines incubated 
at 0.2% hypoxia for 24 hours were sufficient enough to cause etoposide resistance (Sullivan 
et al., 2008).  Given the variation in these findings, the effects of hypoxia induced 
chemoresistance needed to be clarified in our cellular model. 
In this chapter, where cells have been incubated in hypoxia, any subsequent treatment was 
also performed in hypoxic conditions, in order to avoid any effect of re-oxygenation during 
the drug treatment. 
 4.2.2.1 Sensitivity of Etoposide treatment in hypoxia 
We investigated the effect of hypoxia on etoposide-induced cell death in D283 cells. The 
effect of short term hypoxia (24 hours pre-exposure) and chronic hypoxia (5 days 
pre-exposure) on etoposide-induced cell death was tested using MTS assay.  We observed 
~90% of cell death after 48 hours of etoposide treatment in cells cultured in normoxia or 
short term hypoxia.  Strikingly, the same etoposide treatment in chronic hypoxic cells 
resulted in only 43% of cell death (Figure 4.5). 
It has to be noted that the MTS assay does not directly measure cell survival but rather the 
cellular mitochondrial activity.  The MTS reagent is a tetrazolium compound which can be 
chemically reduced by cells into formazan.  The reduction of MTS is carried out by a 
dehydrogenase enzyme, which is only found in metabolically active cells.  Usually, the 
production of formazan (measured by its absorbance at 492nm) indicates the proportional 
number of viable cells.  However, under low oxygen levels, it is possible that the 
mitochondrial activity is altered, without affecting cell survival and therefore the MTS 
reaction might be wrongly interpreted. 
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To ensure that the MTS experiment is a reliable viability assay in hypoxia, we repeated this 
experiment with a different viability assay (ViaCount) based on using two differential 
permeable DNA binding dyes, one staining nucleated cells and one staining only dying cells.  
The results obtained from the ViaCount assay showed a similar trend compared to the one 
obtained from the MTS assay (Figure 4.5A).  However, the actual percentage of viable cells 
obtained from ViaCount was higher than the values obtained from MTS assay in both 
normoxic and hypoxic conditions.  This can be explained by the fact that one method is 
based on measuring metabolic activity (MTS) and one is dependent on the integrity of 
plasma membrane (ViaCount), thus can resulted in a varied kinetic of measurements.  
Considered together, these results clearly show that D283 cells incubated in chronic 
hypoxic conditions are more resistant to etoposide treatment compared to cells cultured in 
normoxia or in short term hypoxia, where no significant changes were observed. 
 
 
 
Figure 4.5 Chronic hypoxia increases etoposide resistance in D283 Cells.  D283 cells were 
pre-incubated in 1% O2 for 5 days (blue line), 24 hours (red line) or left in normoxia 21% O2 
(black line). Cells were treated with etoposide [20 µM] for the indicated time.  Cell survival 
was assessed using (A) MTS assay (B) ViaCount assay.  Results are expressed as % of cell 
survival relative to the untreated control.  Data shown are the mean ± S.E.M of three 
independent experiments (N>3).  One-Way ANOVA followed by a Bonferroni test was 
performed (* indicates p < 0.05). 
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 4.2.2.2 Etoposide-induced G2/M accumulation  
Etoposide primarily acts on proliferating cells during S phase, by inducing double strand 
breaks (DSBs), hence inducing p53-mediated cell cycle arrest and, accumulation in G2/M 
phase.  We investigated whether chronic hypoxia would affect etoposide-induced cell cycle 
arrest using flow cytometry.  Given that the regular etoposide dosage of [20µM] induces a 
high level of cell death, the cells were treated with a lower dose of etoposide [1µM] to 
allow the monitoring of the cell cycle distribution after 30 hours of treatment. 
When normoxic cells were treated with etoposide [1µM] for 30 hours, we observed an 
increase of cells from 30% to 60% in the G2/M phase. (Figure 4.6A).  In contrast, the 
proportion of cells accumulating at the G2/M phase in chronic hypoxia was only ~40%, 
implying that hypoxia reduces the ability of etoposide to induce a G2/M arrest (Figure 
4.6B). 
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Figure 4.6 Reduction of etoposide-induced G2/M arrest in chronic hypoxia.  Cells were 
incubated in normoxia or 5 days hypoxia and treated with etoposide [1µM] for 30 hours.  
(A) Cell cycle profile obtained from the Guava software, this is a representative of 3 
independent experiments. (B) Quantitative data showing the percentage of cells in each 
phase, value is calculated by dividing the number of cells in each phase by the total number 
of cells for that sample.  Data shown are the mean ± S.E.M of three independent 
experiments. 
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 4.2.3 Validating etoposide drug action in hypoxia 
We next tested if the reduction of etoposide effects on cell death and cell cycle arrest in 
chronic hypoxia was due to a loss of its activity at low oxygen level, such as previously 
reported for the drug tirapazamine (Hicks et al., 2004, Koch, 1993, Teicher, 1994).  For this, 
the first physical effect of etoposide on triggering DNA breaks was measured using the 
comet assay.  Comet assay is a single cell gel electrophoresis method, whereby DNA 
damage can be visualised as a ‘comet tail’.  When DNA nicks and breaks occur, the DNA 
integrity is compromised and the chromosomes become less compacted.  Such DNA will 
therefore migrate slower when an electrophoretic field is applied, hence creating a ‘tail’.  
Whereas undamaged DNA migrates as an intact unit within the gel matrix appearing as a 
circular shape (Figure 4.7). 
 
 
 
Figure 4.7 An example of Comet assay.  Untreated D283 cell shows an intact circular DNA 
stain.  Etoposide treated cells present as a ‘comet’.  The whole cells including the head and 
tail are marked in red, the tail moment length are marked in blue. 
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Typically, the amount of DNA damage measured using a Comet assay is expressed as the 
‘Olive Tail Moment’ (Cell Biolabs, Inc, comet assay manual).  This takes into account the 
intensity of the DNA within the head/ tail region and the length of the comet tail. The 
method of calculation is described in Figure 4.8.  Apart from the degree of DNA damage, 
the length of the comet tail is also governed by the duration of electrophoresis. 
 
 
 
Figure 4.8 Calculation methods for ‘Olive Tail moment’.  Cells Biolabs, Inc.  
(http://www.cellbiolabs.com/sites/default/files/STA-350-comet-assay-kit.) 
 
 4.2.3.1 Visualising DNA breaks induced by etoposide in normoxia and hypoxia 
A comet assay was performed on normoxic and chronic hypoxic cells in the presence or 
absence (control) of etoposide.  The physical properties of the comet were measured 
(Figure 4.9) and later used for Olive tail moment calculations.  These properties includes (A) 
Head size (B) Head intensity (C) Tail size (D) Tail intensity and (E) Tail moment. The 
measurement of comet head size and head intensity indicates intact DNA, while the latter 3 
measurements indicate the degree of fragmented DNA.  In the absence of etoposide 
treatment, we have observed no change in any of these properties between normoxic and 
hypoxic samples, indicating hypoxia itself do not induce DNA damage.  Upon etoposide 
treatment, we also detected no significant difference of any comet measurements between 
normoxic and chronic hypoxic cells, at any time points (Figure 4.9A to F). 
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Figure 4.9 Summary of Comet assay measurements.  D283 cells were pre-incubated in 1% 
O2 for 5 days or left in 21% O2 prior to etoposide [20µM] treatment for indicated durations.  
Graphs shown are (A) Head size (B) Head intensity, which indicated intact DNA (C) Tail size 
(D) Tail intensity (E) Tail moment (F) Tail DNA % which indicates fragmented DNA.  Data 
shown are the mean ± S.E.M of three independent experiments (n >100cells). 
 
Using the raw measurements of the comet’s properties (Figure 4.9), we were able to 
further quantify the data and calculate the Olive tail moments (Figure 4.8), as used 
conventionally for comet assay analysis (chapter 4.2.3).  In the untreated control sample, 
Olive tail moments were similar in both conditions.  After 15 minutes of etoposide 
treatment, Olive Tail moment of ~3000(A.U) was measured in both normoxia and chronic 
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hypoxia.  After 30 minutes, the Olive tail moment remain similar at ~3400 and ~3000 
respectively (Figure 4.10).  Furthermore, the size of the comet tails reached maximum 
length of ~45μm and ~52μm for normoxic and chronic hypoxic conditions respectively 
(P>0.05) after 30 minutes of etoposide treatment.  These results indicate that hypoxia on its 
own, does not induce any DNA damage and that etoposide can effectively create physical 
DNA damage even in chronic hypoxia. 
 
 
 
 
 
Figure 4.10 Etoposide induces DNA damage in both normoxia and hypoxia.  D283 cells 
were pre-incubated in 1% O2 for 5 days (green bar) or left in 21%O2 normoxia (pink bar) prior 
to etoposide [20µM] treatment for indicated durations.  Comet assays were performed 
following manufacturer’s protocol.  Percentages of Olive tail moment were calculated.  Data 
shown are the mean ± S.E.M of three independent experiments (n >100cells).  One-way 
ANOVA followed by Bonferroni test was performed (* indicates p<0.05). 
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 4.2.4 Effect of chronic hypoxia on p53 signalling pathway 
We have established from comet assay experiments that etoposide can efficiently induce 
DSBs in normoxic or chronic hypoxic cells.  Therefore the differences of chemosensitivity 
observed in Figure 4.5 cannot be due to a lack of efficacy of etoposide. In the previous 
chapter, we saw the importance of functional p53 pathway for etoposide-induced 
apoptosis.  Moreover, many studies have reported effects of hypoxia on cell death/ cell 
survival through regulation of the p53 pathway where several studies have demonstrated 
the stabilisation and accumulation of p53 protein (An et al., 1998, Greijer and van der Wall, 
2004, Koumenis et al., 2001) but with no direct evidence of downstream p53 activity.  We 
therefore investigated the degree of p53 basal levels and activity as well as activation upon 
etoposide in chronic hypoxia. 
 4.2.4.1 Etoposide-induced p53 transcriptional activity in hypoxia 
As a readout of p53 activity, the mRNA levels of three well known p53 target genes, MDM2, 
PUMA and p21 were measured by qPCR.  We first examined the effect of hypoxia only on 
the basal levels of these target genes in normoxia and upon hypoxic incubation.  There 
were no changes on the basal levels of all three target genes after either 1 day or 5 day 
hypoxia, suggesting that hypoxia itself do not alter the basal p53 activity (Figure 4.11). 
 
 
 
Figure 4.11  Basal levels of p53 targets genes in hypoxia.  p53 target genes of untreated 
samples were assessed by qPCR.  D283 cells were incubated in 1% O2 for 24 hours or 5 days, 
or left in normoxia (21% O2).  The level of MDM2, PUMA and p21 were normalised to the 
normoxic samples.  Data shown are the mean ± S.E.M of three independent experiments. 
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Upon etoposide treatment, we observed a strong induction of MDM2, PUMA and p21 
mRNA levels in normoxic conditions, with a ~32, ~5 and ~26 fold increase respectively 
(Figure 4.12).  The same induction of target genes was observed in cells pre-exposed to 
24hr hypoxia before etoposide treatment.  The fold changes observed in PUMA were 
similar to that of normoxic cells, but MDM2 and p21 expression were respectively ~60% 
and ~50% less than in normoxia.  These data suggest that after 1 day of hypoxic incubation, 
the cells already show reduced p53 activation by etoposide.  Moreover, in cells pre-exposed 
to 5 days hypoxia, the mRNA level induction of all three target genes was significantly 
reduced.  MDM2 and PUMA level were only increased 3 times upon stimulation (compared 
to 32 and 5 times in normoxia), and no increase could be detected for p21. This strong 
reduction in etoposide-induced p53 transcriptional activity is likely to contribute to the 
resistance to cell death as well as to the absence of cell cycle arrest upon etoposide 
treatment, which were observed in chronic hypoxia (Figure 4.4). 
 
Figure 4.12 Etoposide-induced p53 transcriptional activity is reduced by chronic hypoxia.  
Three p53 target genes (A) MDM2 (B) PUMA (C) p21were assessed by qPCR in D283 cells 
treated with etoposide [20µM] for 7 hours.  Cells were incubated in 1% O2 5 days or left in 
normoxia (21% O2), prior to and during etoposide treatment. The levels of MDM2, p21 and 
PUMA were normalised with the house-keeping gene cyclophilin A and over untreated 
control.  These data are representative of three independent experiments, error bars here 
are SD of a single experiment. 
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 4.2.4.2 Etoposide-induced p53 phosphorylation in chronic hypoxia 
To understand why there is a reduction of p53 activity in chronic hypoxia, we focused on 
the p53 protein.  We measured p53 total protein levels and its phosphorylated form 
(p53-serine15), a marker of active p53 (Craig et al., 1999, Sakaguchi et al., 1998, Schon et 
al., 2002) in both normoxia and chronic hypoxia following etoposide treatment.  Firstly, in 
untreated control, both p53 and p53-serine15 levels were similar in normoxia and chronic 
hypoxia.  Upon etoposide treatment, in normoxic conditions, p53 total protein levels 
increased transiently with a peak after 4 hours of treatment, (Figure 4.13).  In chronic 
hypoxia, however, the p53 total protein accumulation was slower with a maximum protein 
stabilisation only reached by 7 hours. Furthermore, the p53 protein levels were lower than 
in normoxic conditions (Figure 4.13).  To assess the ability of etoposide to induce serine15 
phosphorylation, the level of phosphorylated form were measured and normalised to the 
total p53 levels (Figure 4.13).  In normoxia, the level of serine15 induced by etoposide was 
~4 fold higher compared to chronic hypoxia at 4 hours treatment.  These data suggest that 
both etoposide-induced total p53 expression and the level of phosphorylated p53 were 
reduced in cells exposed to chronic low oxygen environment, explaining the reduction of 
p53 transactivation observed in Figure 4.12. 
 
Figure 4.13 Etoposide-induced p53 protein levels are reduced in chronic hypoxia.  D283 
cells were incubated in normoxia (21% O2) or pre-incubated in hypoxia (1% O2) for 5 days 
and treated with etoposide [20µM] for the indicated time points.  Total p53 and 
phosphorylated p53 serine15 levels were assessed by western blot.  Quantification of the 
band intensity is measured by AQM software and p53 serine 15 is normalised over the p53 
total.  This blot is a representative of three repeated experiments. 
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 4.2.5 Bridging DNA damage to p53 activation  
We have so far demonstrated that etoposide can cause physical DNA damage and that p53 
activity, although not completely abolished, is strongly reduced in chronic hypoxia.  The 
observed reduction of p53 accumulation, phosphorylation and transcriptional activity is 
likely to be due to an impaired signalling upstream of p53 activation (Figure 4.14). 
 
 
 
Figure 4.14 From DNA damage to p53 activation.  DSBs are sensed by the MRN complex 
(Mre11/Rad50/NBS1 or nibrin) which activates ATM, in turn phosphorylating Chk2 and 
H2AX.  ATM and γH2AX form a positive feedback loop which amplify DSB signals and 
mediates p53 response.  Activated p53 transactivate apoptotic targets or induce cell cycle 
arrest through, for example, p21 induction.  Diagram adapted from 
www.hindawi.com/journals/ijcb/2010/214074/fig3. 
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Upon etoposide treatment, DNA damage sensors, namely the MRN complex, are recruited 
to the breakage site, rapidly activating effector proteins such as ATM (Horejsi et al., 2004, 
Costanzo et al., 2004).  ATM kinases phosphorylate targets including Chk2 (a p53 activating 
kinase) and a histone variant called H2AX (Stiff et al., 2004).  In turn, γH2AX 
(H2AX-serine139) can itself phosphorylate ATM, hence forming a positive regulatory loop.  
The interplay of these DNA damage proteins acts as an important signal amplifier to 
provoke responses such as p53 activation (chapter 1.6.1.2 and 1.7.2.2). 
 4.2.5.1 ATM activities in chronic hypoxia 
Due to the interaction between ATM and H2AX, with H2AX phosphorylated within minutes 
of DSB damage, γH2AX makes a suitable candidate as a DSB marker and a reporter for ATM 
activity and DNA repair signal amplification.  Moreover, the detection of γH2AX has been 
extensively reported in the literature as a measurement of DSBs.  Immunocytofluorescence 
was used to measure the intensity of γH2AX staining after etoposide treatment of normoxic 
and chronic hypoxic cells.  In untreated conditions, little γH2AX staining was visible in both 
normoxic and hypoxic conditions. This was used as the background threshold for measuring 
γH2AX intensity in treated samples.  
In normoxia, a steady increase of γH2AX level was observed as quickly as 15 minutes after 
etoposide treatment with a steady increase up to 120 minutes, then reaching a plateau up 
to 360 minutes.  The intensity has increased to ~4 fold by 30 minutes and ~10 fold by 360 
minutes.  In hypoxic cells, γH2AX level increased up to ~3 fold in 30 minutes but the 
maximum fold change was only ~6 fold at 360 minutes post treatment (Figure 4.15).  These 
results indicate that in chronic hypoxia, initial ATM activation remains functionally similar to 
that of normoxia.  However, by 120 and 360 minutes, the reduction of γH2AX staining 
suggests a lower amplification signal, which can explain the previously observed reduction 
of p53 activation by etoposide (Figure 4.12 & Figure 4.13). 
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Figure 4.15 DNA damaging sensing is reduced in hypoxia.  D283 cells were pre-incubated in 
1% O2 for 5 days or left in 21% O2 normoxia prior to etoposide treatment for indicated 
durations.  D283 cells were stained with γH2AX and Cy3 antibodies and fluorescence 
intensity was quantified for individual cells.  Data shown are the mean ± S.E.M of three 
independent experiments (n >350 cells).  One-way ANOVA followed by Bonferroni test was 
performed (* indicates p<0.05). 
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 4.2.6 Role of hypoxia on p53 activation in other brain tumours 
To test if the reduction of p53 activation in hypoxia was also true in other brain tumours, 
we examined p53 protein levels and activity in a p53 WT GBM cell line, U87, in normoxia 
and chronic hypoxia (4 days hypoxic exposure). 
 4.2.6.1  Etoposide-induced p53 expression in Glioblastoma 
The basal total p53 and p53 serine15 levels in U87 were similar in both oxygen conditions 
(Figure 4.16).  As observed in D283 cells, the levels of p53 serine15 phosphorylation over 
p53 total level after etoposide treatment were lower compared to normoxia at 4 hours 
etoposide treatment (Figure 4.16).  These data demonstrate that etoposide-induced p53 
expression and p53 phosphorylation is also reduced and slowed in a GBM cell line in 
chronic hypoxia (Figure 4.16), validating our previous observation with MB cells. 
 
 
 
Figure 4.16 Etoposide-induced p53 protein levels are also reduced in chronic hypoxic U87 
cells.  U87 cells were incubated in normoxia (21% O2) or pre-incubated in hypoxia (1% O2) 
for 4 days and treated with etoposide [20 µM] for the indicated time points.  Total p53 and 
phosphorylated p53 serine15 levels were assessed by western blot.  Quantification of the 
band intensity is measured by AQM software and p53 serine 15 is normalised over the p53 
total.  This blot is a representative of three repeated experiments. 
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 4.2.6.2 Etoposide-induced p53 activity in Glioblastoma 
We next looked at the p53 transcriptional activity in hypoxic GBM cells following etoposide 
treatment.  As previously in MB cells, the mRNA levels of MDM2, p21 and PUMA were 
measured by qPCR following 24 hours of etoposide activation in normoxic or chronic 
hypoxic conditions (Figure 4.17).  The level of induction of all three target genes was higher 
in normoxic cells than chronic hypoxic cells after etoposide stimulation.  The fold induction 
for MDM2, PUMA and p21 was 12, 14 and 10 respectively in normoxia compared to 6, 2 
and 4 in hypoxia.  These results are similar to the ones obtained for D283 cells (Figure 4.12), 
and further support the conclusion that chronic hypoxia reduces p53 transactivation. 
 
 
 
Figure 4.17 Etoposide-induced p53 transcriptional activity is reduced in chronic hypoxia in 
U87 GB cells.  Three p53 target genes (A) MDM (B) PUMA (C) p21were assessed by qPCR in 
U87 cells treated with etoposide [20µM] for 7 hours. Prior to etoposide treatment, cells 
were incubated in 1% O2 for 4 days or left in normoxia (21% O2). The levels of MDM2, p21 
and PUMA were normalised with the house-keeping gene cyclophilin A and over untreated 
control.  These data are representative of three experiments. 
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 4.2.6.3 Chemosensitivity of U87 cells in hypoxia 
We further aimed to confirm in U87 cells, that the reduced p53 activation by etoposide in 
hypoxia was also correlated with a decreased sensitivity to treatment. U87 cells were 
treated with different concentrations of etoposide ranging from [20µM] to [100µM] for 24 
hours, and cell viability was measured using the MTS assay (Figure 4.18).  U87 cells were 
relatively resistant to etoposide compared to D283 cells, showing 60% cell viability after 24 
hours of treatment at high concentrations of etoposide [100µM].  This resistance to 
treatment was even higher for cells incubated in chronic hypoxia with a cell viability of 90% 
(Figure 4.18).  These results demonstrate that the previous observation made in D283 MB 
cells is also valid in GBM cells.  
 
 
 
Figure 4.18 Chronic hypoxia-induced etoposide resistance in U87 cells.  U87 cells were 
treated with [20µM], [50µM] or [100µM] Etoposide for a 24 hours.  (A) Normoxia (B) 5 Day 
hypoxia.  The percentage of cell viability was measured by MTS assay over the untreated 
control.  Data shown are the mean ± S.E.M of three independent experiments.  One-way 
ANOVA followed by Bonferroni test was performed (* indicates p<0.05). 
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 4.3 Chapter 4 Discussion 
 4.3.1 Hypoxia duration and acquired chemoresistance 
Hypoxia is strongly associated with tumour progression, invasiveness and metastasis 
(chapter 1.2.2).  Although the role of hypoxia contributing to chemoresistance has been 
documented in some cancers, the length of hypoxia required and the mechanism of 
resistance acquisition were not consistent in the literature, partly due to differences in 
experimental settings. 
Hypoxia-induced chemotherapy resistance has been demonstrated by several groups, such 
as the studies of Flamant et al., Sermeus et al. and Cosse et al. (Flamant et al., 2010, Cosse 
et al., 2007, Sermeus et al., 2008).  Flamant et al. have shown that hypoxia protects breast 
cancer cells (MDA-MB231) against paclitaxel-induced apoptosis (Flamant et al., 2010); in 
both Sermeus et al. and Cosse et al. reports, a Hepatocellular carcinoma (HCC) HepG2 cell 
line became more resistant to etoposide, after 1% hypoxic incubation during 16 hours 
(Cosse et al., 2007, Sermeus et al., 2008).  In our hands, we have observed the dampening 
of etoposide-induced cell death in hypoxia, with it requiring a much longer time frame.  We 
observed that etoposide-induced cell death is only reduced after 5 days of hypoxia in D283 
MB and U87 GBM cells but not acute hypoxia (24 hours).  These findings are similar to 
those of Hussein et al. where they have demonstrated that in neuroblastoma cell lines, 16 
hours of 1% hypoxic incubation did not have any effect on etoposide- or viscristine-induced 
cell death while a longer exposure of up to 7 days promoted hypoxia-induced resistance 
(Hussein et al., 2006).  
Despite several reports supporting a cell death resistance role of hypoxia, this is not true for 
all cellular models.  In an extensive study performed by Sermeus et al., 7 cell lines and their 
response to 5 different drug treatments in hypoxia were investigated.  Agreeing with their 
previous studies, some cell lines gained resistance but some other cell lines such as lung 
carcinoma (A549) showed increased sensitivity with certain drugs (e.g. etoposide) whilst 
other drugs (e.g. cisplatin) had no effect on cell death when exposed to hypoxia (Cosse et 
al., 2007, Sermeus et al., 2012).  Similarly, MCF-7 cells became more sensitive to treatment 
under the same treatment condition of 1% O2 for 16 hours (Cosse et al., 2007).  These 
results reaffirm that hypoxia-induced resistance is cell line dependent.  This difference has 
been experienced in our own laboratory, where neuroblastoma cell lines (SK-N-AS, SHEP, 
IMR32) did not exhibit any acquired resistance to etoposide nor doxorubicin upon chronic 
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hypoxia incubation (Heyward, unpublished observations). We have proposed a theory in 
the next chapter which might predict the effects of hypoxia on drug resistance based on the 
expression of a DNA break sensing protein, nibrin (chapter 5.2.7 and 5.2.8). 
 
 4.3.2 The relationship of hypoxia and p53 
The effect of hypoxia on p53 expression levels and activity remain unclear, and this is once 
again dependent on the severity and length of hypoxic exposure as well as the cell type 
studied.  It is generally agreed that ‘mild hypoxia’ does not influence p53 protein levels, as 
we have observed, (Pan et al., 2004, Wenger et al., 1998), while severe hypoxia, anoxia, and 
hypoxic mimics up-regulate p53 expression.  For example, cobalt chloride (CoCl2), a PHD 
inhibitor, which mimics a similar effect to severe hypoxia was able to stabilise p53 protein 
expression in breast cancer cells (An et al., 1998).  This was similar to the Archison et al. 
report, where they observed that colorectal carcinoma (HCT116) cells incubated in anoxia 
(0.1%) showed stabilisation of p53 (Achison and Hupp, 2003). 
In addition to p53 stabilisation in hypoxia, several reports have suggested that 
hypoxia-induced p53 leads to p53 dependent apoptosis, but again these studies are 
performed in relatively low oxygen concentration between 0.001% to 0.02% or with CoCl2 
(Graeber et al., 1994, Blagosklonny et al., 1998).  However, our data are in direct contrast 
to this.  We saw that under 1% chronic hypoxia, a relatively mild hypoxic condition, p53 
protein levels were not significantly changed and, if any effect, it was rather a reduction 
than an induction of p53.  Moreover, p53 activation by etoposide was also dampened in 
these conditions.  Our results therefore suggest that chronic hypoxia-induced 
chemoresistance might be partly due to the impairment of p53 activation.  The finding that 
hypoxia reduces p53 activity, is supported by similar work of Cosse et al., where they have 
observed that HepG2 cells expressed a lower level of p53 in hypoxia, a reduction of p53 
binding activity and a decrease in etoposide-induced apoptosis (Cosse et al., 2007).  From 
another study, Archsion et al. have further demonstrated that hypoxia-induced 
p53-dependent apoptosis is indeed dependent on the hypoxic level.  In their study, anoxia 
increased p53 induced apoptosis, whilst 1% hypoxia inhibited p53 serine15 and 392 
phosphorylation upon 5-FU (florouracil) treatment, leading to attenuation of cell death 
(Achison and Hupp, 2003). 
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It must also be noted that hypoxia or other stress-induced p53 expression can often occur 
without DNA damage and therefore might result in a different classical p53 downstream 
outcome even upon protein stabilisation (Nitta et al., 1997, Giaccia and Kastan, 1998, 
Williams et al., 1999, Liu and Chen, 2006).  Whilst in most cases p53 induction is followed 
by transcriptional activation and apoptotic response, in some cases, stabilisation of p53 
does not lead to p53 transactivation or apoptosis (Koumenis et al., 2001). This effect is 
illustrated in a study by Ashcroft et al, who used a hypoxic mimic drug (deferoxamine 
mesylate) to induce p53, and were only able to detect phosphorylation at serine15 but not 
serine20.  In addition, all three tumour cell lines (breast, colon and osteosarcoma) that they 
have tested failed to induce classical p53 targets such as p21 and MDM2 (Ashcroft et al., 
1999). 
Furthermore, there are indications that hypoxia-induced p53 can actually lead to 
transcriptional repression by formation of a repression complex with the corepressor 
molecule mSin31 (Murphy et al., 1999, Hassig et al., 1998, Koumenis et al., 2001, Hammond 
and Giaccia, 2005).  However, the role of p53 repression in hypoxic condition remains 
relatively unexplored. 
 
 4.3.3 ATM activation and p53 induced apoptosis 
ATM is one of the key components, which is activated in response to DNA damage.  It 
phosphorylates proteins involved in cell cycle, DNA repair and apoptosis (chapter 1.6).  
There is evidence that shows the loss of ATM is correlated to sensitivity to chemotherapy 
treatment (Shiloh et al., 1983, Barlow et al., 1996), but contrasting results have been 
reported (Haidar et al., 2000, Ripolles et al., 2006, Austen et al., 2007).  Its functional 
importance in achieving good treatment response has been demonstrated in primary cell 
lines obtained from ataxia telangiectasia (A-T) patients or from ATM knockout mice.  In 
these cases, the absence of ATM render the cells hypersensitive to both ionizing radiation 
and DSB inducing agents (Shiloh et al., 1983, Barlow et al., 1996, Chun and Gatti, 2004).  
These findings are also supported by a study on primary (GBM) tumours where high ATM 
expression correlates to increased radioresistance (Tribius et al., 2001).  Since then, 
development of ATM inhibitors and their use as cancer chemotherapeutic agents has been 
investigated and indeed shown some promising results, but only in certain cell types 
(Golding et al., 2012, Korwek et al., 2012). 
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Controversially, in several studies on chronic lymphocytic leukemia (CLL) patients, the loss 
of ATM is associated with poor response to irradiation, resistance to chlorambucil and 
cyclophosphamide plus reduced patient survival (Haidar et al., 2000, Ripolles et al., 2006, 
Austen et al., 2007).  In another study using human T cells, ATM inhibitors actually render 
the cells more resistant to etoposide (Korwek et al., 2012).  It is not surprising to see these 
contrasting results as ATM kinase have many targets which are involved in different cellular 
pathways.  It is largely unknown the exact mechanisms which dictate the action of ATM 
downstream response and the final outcome of cell cycle arrest, repair or apoptotic 
response remain elusive.  
Recent studies have demonstrated that ATM alone is not sufficient to predict the outcome 
of treatment response but it is dependent on both the upstream and downstream of this 
pathway.  In particular, the p53 functional status plays a role in the success of ATM 
inhibition in chemosensitisation (Jiang et al., 2009, Knappskog et al., 2012, Biddlestone-
Thorpe et al., 2013).  Jiang et al. is one of the first reports to have speculated this 
dependency.  They found that p53 WT cells became more resistant to treatment when ATM 
activity was inhibited and that p53 dependent apoptotic response was prevented by ATM 
inhibition (Jiang et al., 2009).  Additionally, Jiang et al. have also demonstrated that p53 
deficient cell lines show the reverse results upon ATM inhibition (Jiang et al., 2009). 
More recent studies in breast cancer models have further demonstrated the importance of 
ATM expression in treatment response and clinical outcome prediction (Knappskog et al., 
2012).  Generally, in this setting, breast cancer containing TP53 and or CHK2 mutations are 
more resistant to treatment and patients have poorer outcome.  However, Knappskog et al. 
have observed that a group of patients, without any TP53 and or CHK2 mutations, also 
displayed poor treatment response and progressive disease (Knappskog et al., 2012, 
Chrisanthar et al., 2008, Geisler et al., 2001).  On further examination, they have revealed 
that 12/18 patient in this group expressed a lower than median level of ATM at a 
transcription level (Knappskog et al., 2012).  Thus, even if cells carry a p53 WT genotype, a 
low expression of ATM effectively renders the chemotherapeutic response similar to that of 
TP53 and or CHK2 mutated cells.  As with our own findings, reduction of ATM activity 
(measured by γH2AX) is associated with resistance in a p53 WT cell line under chronic 
hypoxia.  Altogether, this demonstrates a role of the whole ATM-Chk2-p53 signalling 
cascade in chemoresistance.  It is therefore advisable to consider ATM expression as well as 
p53 status as a prognostic indicator in treatment response. 
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 4.3.4 The effect of hypoxia on cancer cell biology 
Due to the genetic heterogeneous nature of tumours, hypoxia can affect cells within a 
population differently.  Some cells will undergo apoptosis due to the severe conditions, 
while others will promote survival though activation of genes needed for adaptation or cells 
can be naturally more resilient (Attolini and Michor, 2009, Diaz et al., 2012, Wenger, 2002).  
Cells which are unable to adapt will die, as we have witnessed with our model that hypoxia 
itself triggers some cell death.  However, the cells which are either well adapted or with a 
malfunctioned cell death pathway will be favoured.   Thus this selection can be both a 
spontaneous event, i.e. naturally selecting cells which carried mutations with a ‘growth 
advantage’, or by adaptation response which will have a long lasting effect (Pisco et al., 
2013).  Additionally, the tumour oxygenation is also heterogeneous.  Cells across a tumour 
may be differently oxygenated, creating differing severities of hypoxia. This may promote 
heterogeneity within the population of cells, which in turn promotes enough variance to 
increase the tumour survival rate against chemotherapy.  Hence, hypoxia can ultimately 
select for the more resistant, transformed population.  Under chronic hypoxia, the cellular 
biology of the tumour cells is undoubtedly altered and other targets/ pathways are likely to 
contribute to the chemoresistance.  We therefore need to monitor global changes in the 
overall gene expression in hypoxia to further investigate the mechanisms of chronic 
hypoxia-induced resistance. 
 
  
 
 
 
 
 
 
 
 
Chapter 5: Gene Expression in Hypoxia 
Associated with Drug Resistance 
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 5.1 Introduction 
We have demonstrated in the previous chapter that a chronic hypoxic environment is 
associated with poor response to etoposide treatment, whereas, acute hypoxia does not 
alter etoposide effects.  However, it is possible that other mechanisms other than reduction 
of p53 activation could contribute to chemoresistance in chronic hypoxia.  There is for 
example, evidence of hypoxia-induced chemoresistance by expression of multidrug 
resistance genes (Comerford et al., 2002, Liu, L. L. et al., 2008). 
Expression of multidrug resistance genes has been observed in many cancer types, 
correlating to chemotherapy resistance and poor prognosis.  Three of the ATP binding 
cassette (ABC) transporter families, ABCB/C/G (i.e. MDR1/ MRP1/ ABCG1), have been 
associated with drug resistance.  In particular, MDR1 association with drug resistance has 
been shown in gastric, breast and liver cancers (Liu, L. L. et al., 2008, Li et al., 2006, Zhu et 
al., 2005, Sasabe et al., 2007, Volk et al., 2002).  Expression of MDR1 and MRP1 have also 
been observed in neuronal tumours including neuroblastoma, high grade glioma and GBM 
cell lines (Loscher and Potschka, 2005, Hermann and Bassetti, 2007, Hussein et al., 2006, 
Chen, L. et al., 2009, Feun et al., 1994, Matsumoto et al., 1990, Abe et al., 1994, 
Nardinocchi et al., 2009, Cordon-Cardo et al., 1989, Schinkel, 1999, Sun et al., 2003), but 
there are currently few reports on ABC transporters expression in MB (Chou et al., 1995).  
The Chou et al. study is the only report in MB, where they found that the expression of 
MDR1 was correlated to poor patient outcome (Chou et al., 1995).  However, in another 
report, a gene expression study on chemoresistant MB cell lines showed no significant 
expression of MDR1 (Bacolod et al., 2008).  Moreover, the expression of these genes in 
chronic hypoxia remains controversial. 
To better evaluate the implications of hypoxia on drug resistance genes and other genes 
that could be responsible for the lack of sensitivity to etoposide, we have carried out a 
global gene expression study by microarray analysis to allow an efficient search for a range 
of genes.  We first focused on multidrug resistance gene family, as well as other potential 
genes, which might also be associated with drug resistance.  Additionally, the two classical 
DSBs pathway, Homologous End Joining Recombination (NHEJ) and Homologous 
recombination (HR), were investigated to deduce whether the DNA damage sensing 
machinery is altered by chronic hypoxia as hypothesised in chapter 4.  An unbiased analysis 
of the micro-array data is presented chapter 6. 
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Objectives: 
1.  To investigate the regulation of HIF in long term hypoxia 
2.  To examine the expression of multidrug resistance genes in chronic hypoxia  
3.  To investigate, in the micro-array data, potential gene expression related to drug 
resistance 
4.  To specifically analyse the changes in the expression of genes involved in DNA repair and 
p53 signalling during chronic hypoxia 
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 5.2 Results 
 5.2.1 HIF signalling in chronic hypoxia  
HIF-1α is the major transcription factor playing a crucial role under low oxygen tensions.  It 
is well known that HIF-1α expression increases rapidly under hypoxia and accumulates to a 
peak level within 4 to 7 hours in most cell lines (Wang et al., 1995, Stiehl et al., 2006).  In 
some cell lines such as Hep3B (hepatocellular carcinoma), HEK293 and HeLa cells, after 
accumulation, HIF-1α expression returns close to basal levels by 16-24 hours (Wang et al., 
1995, Stiehl et al., 2006, Bagnall, 2013).  It has been reported that HIF-1α can directly 
transcribe many downstream targets, including ones involving drug resistance such as 
MDR1 (Comerford et al., 2002).  However, there are inconsistencies in the literature as to 
whether hypoxia-induced chemoresistance is directly dependent on HIF (Chen, J. et al., 
2009, Nardinocchi et al., 2009, Song et al., 2006, Hussein et al., 2006).  Moreover, most 
published studies only look at a relatively short hypoxic time course.  HIF expression and its 
target gene expression are less well studied over chronic hypoxia.  Here, we will first 
investigate the expression of HIF-1α and the expression of well known HIF target genes in a 
long hypoxic time course.  Secondly, we will investigate whether chronic hypoxia-induced 
resistance is contributed by the induction of multidrug resistance genes and other genes 
potentially involved in the drug resistance mechanism. 
 5.2.1.1 HIF-1α expression in chronic hypoxia 
We measured HIF-1α protein expression over a long hypoxic time course of 96 hours 
(Figure 5.1).  We observed an accumulation of HIF-1α protein within the first 2 to 7 hours of 
hypoxic incubation, with maximum band intensity at 7 hours.  This level returned to basal 
normoxic levels by 24 hours.  The HIF-1α expression observed during the first 24 hours was 
similar to that previously observed in our laboratory in HeLa cells (Bagnall, 2013), by Wang 
& Jiang et al. and by Stiehl & Wirthner et al. (Wang et al., 1995, Stiehl et al., 2006, Bagnall, 
2013).  Interestingly, we also measured secondary peaks of HIF-1α accumulation at later 
time points, with peaks at 40, 64 and 78 hours (Figure 5.1).  These latter HIF-1α peaks were 
not previously observed as most experiments are performed under 48 hours and they were 
not measured at a high resolution time points, thus missing the subsequent HIF-1α peaks. 
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Figure 5.1 Chronic hypoxia induced HIF-1α protein accumulation at different time points.  
D283 medulloblastoma cells were incubated in normoxia (21% O2) as a control or at 
indicated time points in hypoxia (1% O2).  HIF-1α protein levels were assessed by western 
blotting.  Quantification of the band intensity was measured by AQM software.  This blot is 
a representative of two independent experiments. 
 
 5.2.1.2 HIF-1α target genes expression in chronic hypoxia 
We examined whether the continued HIF-1α expression in chronic hypoxia translates to 
long term transcriptional activity and its possible involvement in activating genes involved 
in drug resistance. Three classical well described HIF-1α targets: PHD2, EPO and VEGF and a 
specific target of interest: MDR1 (Elvidge et al., 2006) were measured by qPCR.  As 
expected, the classical target PHD2 was increased ~16 fold after 7 hours of hypoxic 
incubation and returned to basal level by 24 hours (Figure 5.2A).  A secondary and a third 
peak of PHD was also observed at 32 hours and 64 hours.  Interestingly for EPO, mRNA was 
only increased by ~3 fold after 4 hours of hypoxic exposure, yet a 50 fold induction was 
observed after 24 hours and this remained relatively high at later time points (Figure 5.2B).  
Similarly, VEGF was upregulated by 4 hours but a stronger induction was observed after 24 
hours of hypoxic exposure (Figure 5.2C).  These results suggest that HIF-1α remains 
transcriptionally active over a long hypoxic time course, however we cannot exclude 
additional HIF-independent mechanisms. 
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The multidrug resistance gene MDR1 was found to be upregulated in some studies (section 
5.1), suggesting that MDR1 could be responsible for the observed chemoresistance in 
hypoxia.  However, in our model, we did not detect any alterations of MDR1 mRNA levels at 
either early or late time points (Figure 5.2D).  This suggests that other mechanisms or genes 
are involved in hypoxia-induced etoposide resistance.  The expression and involvement of 
other multidrug resistance genes are shown in section 5.2.3 and 5.2.4. 
 
 
 
Figure 5.2 HIF-1α downstream target activation in hypoxia.  HIF-1α target genes, (A) PHD2 
(B) EPO and (C) VEGF (D) MDR1 were assessed using qPCR after exposure in hypoxia (1% O2) 
at indicated time point.  The levels of mRNA were normalised with the house-keeping gene 
cyclophilin A and the untreated control. This is from one single experiment, error bars here 
are technical SD of 1 experiment. 
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 5.2.2 Microarray Gene Expression study  
There are approximately 20000 to 25000 genes within the human genome (Stein, 2004), 
making it a notorious and potentially a biased task to manually select for and perform 
individual qPCR on genes which might be involved in chemoresistance.  Hence, we used 
microarray analysis to allow an efficient view of chemoresistance gene expression under 
chronic hypoxia.  We performed a hypoxic time course (up to 96 hours), and microarray 
data were analysed manually (chapter 2.6.3). 
We observed that, at all time points taken together, over 6124 transcripts were significantly 
up- or down-regulated under hypoxia and ~39,000 transcripts were not regulated by 
hypoxia ( 
Figure 5.3).  As one gene can have more than one transcript, this corresponds to 4303 
significantly regulated and 23, 611 non-regulated genes. 
 
Significantly 
expressed/repressed 
Transcripts 
6124 
Non-significantly 
expressed/repressed 
Transcripts 
38,910 
 
Figure 5.3 Number of significantly and non-significantly expressed/ repressed transcripts.  
Transcripts are said to be ‘significant’ if they meet the criteria of: the ANOVA p value for all 
3 probes is ≤0.01 or the ANOVA p value for 2 out of 3 probes is ≤0.000 and that minimum 
fold change is greater than 2 at any given time points (Methods section Table 2.16). 
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 5.2.3 Expression of multidrug drug resistance genes 
Although ABC transporter have been observed in hypoxic brain tumour, for example, Chen 
et al. have reported that hypoxia-induced resistance to both doxorubicin and etoposide 
treatment in human glioma cells is via HIF-1 is dependent upregulation of MDR1 (Chen, L. 
et al., 2009), in the context of MB, the role of ABC transporters in hypoxia is unclear.  Also, 
considered that MRP1 and ABCG1 transporters are also associated with resistant in other 
tumours (section 5.1), there are few studies of their expression in MB and their roles in MB 
remain elusive.  We will therefore investigate the expression patterns of these ABC 
transporters in our hypoxic model.   
We searched for each of the drug resistance genes mentioned above in our microarray 
‘significant expressed transcript list’ (Figure 5.3) to investigate whether they were 
expressed in hypoxia at any time points (Table 5.1 and Figure 5.4).  From our data, there is 
no significant induction or reduction of any of these efflux transporters, suggesting that 
hypoxia-induced chemoresistance is not due to the expression of these transporters. 
 
Gene Protein Expressed/ Repressed (Y/N) 
MDR1/ABCB1 Multidrug resistance gene/ 
P-glycoprotein 1  
N 
MRP1/ ABCC1 Multidrug resistance-
associated protein 1 
N 
ABCG1/ BCRP breast cancer resistance 
protein 
N 
Table 5.1 ABC transporter genes.  A table of ABC transporters, showing whether they are 
expressed or repressed in the hypoxia microarray data. 
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Figure 5.4 Expression plots of MDR1, MRP1 and ABCG1.  The expression plots of (A) MDR1 
(B) MRP1 (C) ABCG1 in hypoxia.  The filled circle and dark blue line shows the average 
expression plot of the transcript.  The open circle shows the data point for each individual 
probe.  The shaded blue area shows the range of data variation and the number above the 
point indicate the fold change normalised to basal ratio (chapter 2.6.3). 
 
 5.2.4 Expression of hypoxia-induced drug resistance genes 
Currently, besides the ABC transporters, little is known about other mechanisms of 
hypoxia-induced drug resistance.  However, there has been some evidence that hypoxia is 
involved in the expression of other genes, which interfere with drug sensitivity.  Attention 
has been turned to the following gene lists in Table 5.2, as they are candidates, which have 
been demonstrated to be expressed in hypoxic levels similar to our study and found to be 
associated with chemoresistance (Tong et al., 2013, Chen, J. et al., 2009, Zou et al., 2013, 
Flamant et al., 2012).  These genes includes Notch-1, WD repeat and SOCS box (WSB-1), 
Transmembrane protein 45A (TMEM45A), Carbonic Anhydrase IX (CAIX/ CA9), and Pim-1 
kinase (PIM-1). 
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Gene Description 
Expressed/ 
Repressed (Y/N) 
Reference 
Notch-1 Notch homolog 1 Y, Repressed (Zou et al., 2013) 
WSB-1 WD repeat and SOCS box N (Tong et al., 2013) 
TMEM45A Transmembrane protein 45A Y, Expressed (Flamant et al., 
2012) 
CAIX/ CA9 Carbonic Anhydrase IX Y, Expressed (Tan et al., 2009) 
PIM-1 Pim-1 kinase N (Chen, J. et al., 
2009) 
Table 5.2 Known hypoxia-induced chemoresistance related genes.  Table showing Gene 
names, their description and whether they are expressed or repressed in our microarray 
data. 
 
Notch-1 
Notch-1 expression has been shown to play a role in malignancy in different cancer types by 
promoting invasion, metastasis and correlated with chemoresistance (Roy et al., 2007, 
Sahlgren et al., 2008, Nefedova et al., 2004, Nefedova et al., 2008).  Several lines of 
evidence show that hypoxia can mediate Notch-1 activity (Chen et al., 2010, Sahlgren et al., 
2008, Zou et al., 2013). 
WSB-1 
WSB-1 encodes for an ubiquitin ligase, which complexes with other proteins to mediate 
target gene degradation (Choi et al., 2008).  It has been demonstrated that WSB-1 
accumulates in hypoxia (1%) in a hypoxic dependent manner in HepG2 cells. 
TMEM45A 
TMEM45A is a transmembrane protein without clear defined function, however, its 
expression is found to be upregulated by hypoxia (1%) in a HIF dependent manner in breast 
cancer cells.  Furthermore, the silencing of this gene renders the cells resistant to paclitaxel 
and etoposide in HepG2 cell (Flamant et al., 2012). 
CAIX 
In a highly metabolic active tumour, CO2 and lactic acid builds up due to the increase rate of 
glycolysis (Raghunand et al., 2003, Gatenby and Gillies, 2004).  It is often observed that in 
hypoxic tumours of many cancer types, CAIX is overexpressed.  CAIX is a transmembrane 
protein located on the extracellular membrane, it is an enzyme which catalyses the 
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hydration of carbon dioxide to bicarbonate and hydrogen ions.  This process increases 
extracellular acidification (Swietach et al., 2008) and it is associated with resistance to 
slightly basic drug (McCarty and Whitaker, 2010, Staab et al., 2007, Supuran and 
Scozzafava, 2000, Said et al., 2013).  CAIX expression is HIF dependent and its expression is 
correlated to tumour progression and poor drug response in several cancer models 
including GBM and breast cancer (Hui et al., 2002, Chia et al., 2001, Tan et al., 2009, Lou et 
al., 2011, Wykoff et al., 2000a, Said et al., 2007). 
PIM-1 
PIM-1 is a serine/threonine kinase phosphorylating genes such as p21 and BAD, thus 
asserting regulatory roles in cell cycle and apoptosis (Selten et al., 1986, Wang et al., 2002, 
Aho et al., 2004).  In a study performed by Chen et al. (Chen, J. et al., 2009), they found that 
PIM-1 is upregulated in hypoxia in a HIF independent manner, and that PIM-1 expression is 
associated with cisplatin resistance in pancreatic cell lines under 1 % hypoxic incubation 
(48h) (Chen, J. et al., 2009). 
 
The set of genes described above were searched individually in our microarray expressed 
transcript list.  We saw no significant expression of WSB-1 or PIM-1 which was reported to 
be upregulated in Hepatoma cell line and pancreatic cell line respectively (Figure 5.5) (Tong 
et al., 2013, Chen, J. et al., 2009).  For Notch-1, we saw a slight decrease at 64 hours and 
only a mild increase of ~1.5 fold at 96 hours hypoxia (Figure 5.5C). 
In agreement with other findings, we did observe an induction of both TMEM45A and CAIX 
in hypoxia (Figure 5.5D & E) (Flamant et al., 2012, Isa et al., 2006, Tan et al., 2009).  
TMEM45A expression increased continuously for the duration of hypoxic incubation up to 
4.5 fold by 64 hours (Figure 5.5C). While CAIX expression was highest in acute hypoxia (~6 
fold) yet its levels remained above ~2.5 fold in chronic hypoxia (Figure 5.5D).  To conclude, 
although these results might contribute to the observed resistance in hypoxia, further 
validation is required. 
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Figure 5.5 Expression plots of WSB-1, PIM-1, Notch1, TMEM45A, CAIX / CA9 transcripts.  
(A) WSB-1 (B) PIM-1 (C) Notch1 (D) TMEM45A (E) CAIX/ CA9 expression plot in chronic 
hypoxia from our microarray data.  The filled circle and dark blue line shows the average 
expression plot of the transcript.  The open circle shows the data point for each individual 
probe.  The shaded blue area shows the range of data variation and the number above the 
point indicate the fold change normalised to basal ratio (chapter 2.6.3). 
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 5.2.5 Significantly expressed genes 
The gene expression of hypoxic response from the microarray data were further analysed 
for a global overview.  In the next section, only significantly expressed transcripts obtained 
from Figure 5.3 were used. 
 5.2.5.1 Producing heat map clustergrams 
Clustergrams are one of the standard ways for visualising microarray results; it is a heat 
map with dendrograms showing the hierarchical clustering of data.  The default MATLAB 
setting normalise the data over the mean transcript data set, a red colour represents a 
value above mean, black equals the mean and green represents values below mean.  Using 
MATLAB default clustergram function, a clustergram of the list of significantly regulated 
genes was produced (Figure 5.6). 
 
Figure 5.6 A default MATLAB clustergram.  A heatmap of the clustered data result (without 
dendrogram) showing all significantly upregulated (red) and down regulated (green) 
transcripts normalised to mean of each data set. 
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 5.2.5.2 Optimising heatmap clustergrams 
From a biological point of view, clustergrams resulted above can be difficult to interpret for 
two reasons.  Firstly, the data are normalised over the mean of the data set, therefore it 
does not provide a clear visual indication of the relationship of gene expression in hypoxia 
compared to normoxia, which is what we were aiming to measure.  This was resolved by 
manually dividing the data to normoxic control (T0) as well as suppressing the automatic 
normalisation function in MATLAB clutergram code (see Appendix 1.2).  This enabled us to 
generate a clustergram where the values (and in terms of colour representation on the 
clustergram) relative to T0 control (Figure 5.8). 
Secondly, the default MATLAB method of normalising generates data with a weak 
separation of fold changes.  For example, a two-fold decrease and a three-fold decrease 
would result in a value of 0.5 and 0.3 respectively.  On a linear scale, the number of ‘0.3’ 
and ‘0.5’ lies relatively close together even though we are examining a two and three fold 
change.  These data will therefore give a low resolution of separation, yielding a non 
symmetrical scale and making it visually less satisfactory (Figure 5.7A). Therefore, the data 
were log 2 transformed to produce a more symmetrical scale (Figure 5.7B & C). 
 
 
 
Figure 5.7 A schematic diagram demonstrating the relationship of a linear scale versus a 
Log2 scale.  (A) Results as visualised on a Linear scale. (B) Results as visualised on a Log2 
scale.  Upregulated (black line), Downregulated (dotted line) and control (red line) (C) 
Conversion of linear to log2 scale. 
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Clustergram were reproduced after normalisation to control T0 and transforming the data 
on a Log2 scale (Figure 5.8).  We observed very little changes in expression at 6 hours 
hypoxia (indicated by black colour and lack of red and green).  However at 64 and 96 hours, 
many transcripts were upregulated or downregulated (indicated by red or green colour) 
(Figure 5.8).  These results demonstrated that at acute hypoxic time points, there is little 
differential gene expression compared to longer hypoxic incubation. 
 
 
 
Figure 5.8. Gene expression profile of D283 cells in hypoxia.  D283 cells were incubated in 
1% O2 for 0, 6, 64 or 96 hours.  A microarray heatmap of the clustered data result showing 
all significantly upregulated (green) and down regulated (red) genes normalised to control. 
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 5.2.6 Expression of p53 and DNA damage genes in chronic hypoxia 
We previously described the dampening of p53 activation by etoposide in chronic hypoxia 
(chapter 4).  Using the microarray data, we further examined whether hypoxia affects the 
expression pattern of p53 signalling pathway components, which could explain the altered 
p53 activation. 
Here, we have used the microarray raw data to generate heat map clustergrams of specific 
pathways of interest.  The raw expression data containing all transcripts from the 
microarray array were used, therefore the results presented bear no statistical significance 
(otherwise indicated).  The purpose of this analysis was to allow an easier visualisation of 
the expression of a whole group of genes, rather than separately studying individual 
expression plots. 
 
 5.2.6.1 p53 pathway analysis 
The p53 pathway gene list was obtained from KEGG online database (Kanehisa and Goto, 
2000, Kanehisa et al., 2012), and their corresponding transcripts IDs were extracted using 
MATLAB (see Appendix 1.3 for MATLAB codes).  This list was matched with the significantly 
‘expressed transcript lists’ (Figure 5.3) manually and only the significantly expressed data 
were selected to produce a readable heatmap clustergram (Figure 5.9). 
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Figure 5.9 Gene expression profile of significantly expressed p53 pathway transcripts in 
hypoxia.  A heatmap of selected p53 pathway gene lists showing upregulated transcripts 
(red) and downregulated genes (green) normalised to control (black), *significantly 
expressed or repressed.  
 
All 4 transcripts belonging to the MDM4 gene were expressed up to 2.5 fold (Figure 5.9).  
MDM4 protein is structurally similar to MDM2, it also contains a p53 binding domain and 
interacts with p53 (Shvarts et al., 1996).  However, unlike MDM2, MDM4 does not target 
p53 for protein degradation but instead regulates p53 transcriptional activity (Toledo et al., 
2006).  Upon MDM4 binding to p53 N terminal domain, MDM4 inhibits p53 transactivation, 
thus suppressing p53 mediated apoptotic functions (Francoz et al., 2006, Toledo et al., 
2006).  Additionally, both transcripts of the PPM1D (protein phosphatase, 1D) were also 
increased by 2 fold (Figure 5.9).  PPM1D is p53-inducible and it belongs to the 
serine/threonine phosphatase family (Fiscella et al., 1997, Takekawa et al., 2000).  PPM1D 
is a negative regulator of p38 MAP kinase (MAPK), inhibiting its function by 
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dephosphorylating p38 at Thr180, and in turn reduces p53 phosphorylation, thus 
decreasing p53-activated apoptosis (Bulavin et al., 1999, Takekawa et al., 2000).  Moreover, 
PPMID also dephosphorylates both Chk 1 and p53 directly, upon dephosphorylation of both 
Chk1 and p53, p53 activity is inhibited.  Altogether, with the upregulation of both MDM4 
and PPM1D mRNA level, this suggests that p53 transactivation might be dampened in 
chronic hypoxia as observed in chapter 4. 
Moreover, there were 21 genes which were significantly downregulated, these included 
several apoptotic genes: APAF1 (apoptotic peptidase activating factor 1), CASP3 (apoptosis-
related cysteine peptidase) and BAX (Figure 5.9).  We observed from our clustergram that 
APAF1 was reduced by ~3 fold at chronic hypoxia (Figure 5.9).  CASP3 transcript was also 
reduced by ~3 fold in chronic hypoxic incubation.  CASP3 is a member of the caspase 
cascade family, activating caspases 6 and 7 and playing a role in executing apoptosis (Porter 
and Janicke, 1999, Wang and Lenardo, 2000).  Taken together, the induction of negative 
p53 regulators and a decrease of pro-apoptotic genes in chronic hypoxia might have an 
implication on resistance to cell death. 
 5.2.6.2  DSB repair pathways 
In chapter 4, we have also observed a reduction in ATM activity and hypothesised that this 
might contribute to the reduce p53 activation.  Here, we investigated further upstream of 
p53  and probed whether DNA damage sensing is altered in chronic hypoxia. 
The list of genes involved in both NHEJ and HR were exported from KEGG online database 
(Kanehisa and Goto, 2000, Kanehisa et al., 2012).  Firstly the gene lists were converted to 
their corresponding transcripts IDs using MATLAB (see Appendix 1.3 for MATLAB codes).  
Secondly, the transcripts IDs and their corresponding expression data were used to produce 
a heatmap clustergram for both the NHEJ (Figure 5.10) and HR pathway (Figure 5.11). 
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Figure 5.10 Gene expression profile of NHEJ gene transcripts in hypoxia.  A heatmap of 
NHEJ pathway gene lists showing upregulated transcripts (red) and downregulated genes 
(green) normalised to control (black),*significantly expressed 
 
The initial recognition of DSBs in the NHEJ pathway is by Ku70/Ku80 (XRCC6/XRCC5) 
(chapter 1.6.1.1).  The transcripts belonging to these genes were not regulated (Figure 
5.10), suggesting that DNA sensing by this pathway might not be affected by hypoxia.  This 
supports our finding in chapter 4 where we demonstrated that initial detection of physical 
DNA damage was not affected by hypoxia.  However, there is a reduction of transcripts 
belonging to other NHEJ key components.  One transcript of each of the following genes 
was down regulated: DCLRE1C (Artemis), FEN1 (flap structure-specific endonuclease 1) and 
LIG4 (DNA ligase IV) (Figure 5.10) (chapter 1.6.1.1).   Artemis and Fen1 transcripts are both 
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reduced by ~2 fold at 64 and 96 hours hypoxic time point.  LIG4 is reduced by 2 fold at 64 
hours but it was only reduced by 1.2 fold at 96 hours.  Both FEN1 and Artemis function as 
an endonuclease, involved in the end processing and trimming of damaged DNA (chapter 
1.6.1.1), while LIG4 is involved in the ligation step of NHEJ repair (Koch et al., 2004) 
(chapter 1.6.1.1).  Although we have observed reduction of some NHEJ repair gene 
transcripts, not all transcripts of the same gene showed the same expression trend (e.g. 
GADD45A, SENS1).  This could be due to both biological and or technical reasons.  Firstly, 
the probes may target different transcript splice variants of the same gene, thus if the 
mRNA expression levels of the splice variants differ, this will be reflected in our data.  
Secondly, the probe set definitions used in the microarray might be inaccurate, or lack 
specificity and require an update.  As our knowledge of accurately mapping genes and 
transcript improve, an updated probe set will minimise technical errors.  Therefore, due to 
the different expression pattern observed for some of these transcripts, it is not possible to 
make a firm conclusion of whether chronic hypoxia affects the actual protein expression 
levels or the functionality of these NHEJ pathway components. 
 
On investigation of the HR pathway, the clustergram showed that only one candidate was 
significantly upregulated (Figure 5.11), the RAD51L1 (RAD51 homolog 2) transcripts, a gene 
coding for a protein belonging to the RAD51 family (Rice et al., 1997).  For downregulated 
transcripts, we observed that several of the HR repair genes were reduced in chronic 
hypoxia (Figure 5.11), including BRCA2.  BRCA2 is known to play an important role in 
maintaining genomic integrity and its mutation leads to susceptibility to breast cancer 
development (King et al., 2003, Venkitaraman, 2002, Meyn, 1997, Tutt et al., 1999).  
Molecularly, the role of BRCA2 is to directly interact with RAD51, controlling and meditating 
RAD51 catalytic activity in aiding strand exchange during HR response (Wong et al., 1997, 
Marmorstein et al., 1998, Shinohara et al., 1992) (chapter 1.6.1.2). 
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Figure 5.11  Gene expression profile of HR pathway gene transcripts in hypoxia.  A 
heatmap of HR pathway gene lists showing upregulated transcripts (red) and 
downregulated genes (green) normalised to control (black), *significantly expressed. 
 
We further focused on the down regulation on one of the MRN complex components, NBN.  
As described in chapter 1.6.1.2, NBN plays a key role in ATM activation and signal 
amplification of the DNA damage response (Cerosaletti and Concannon, 2004, Cerosaletti et 
al., 2006), reduction of this can explain the dampened p53 response observed in chapter 
4.2.4.1 and 4.2.4.2.  We therefore hypothesised that this reduction in NBN mRNA levels 
might be responsible for reduced p53 activation and have further investigated the role of 
NBN expression in our model. 
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 5.2.7 Microarray target validation 
 5.2.7.1 Target gene validation by qRT-PCR 
The microarray data showed that the NBN mRNA level decreased by 50% after 64 hours of 
hypoxia and this was further reduced to 30% by 96 hours (Figure 5.12A).  To validate this 
result, NBN mRNA levels upon hypoxic exposure were measured by qRT-PCR (Figure 5.12B).  
We have found that the qRT-PCR results were similar to the ones of the microarray.  NBN 
mRNA levels were reduced to 50% at 48 and 64 hours hypoxic incubation.  This was further 
reduced to ~20% by 96 hours hypoxia (Figure 5.12B).  These results confirmed the decrease 
of NBN mRNA levels in chronic hypoxia.  
 
Figure 5.12  Nibrin mRNA levels in chronic hypoxia.  D283 cells were incubated in 1% O2 in 
hypoxia as indicated. The transcription of NBN was assessed by (A) microarray. The filled 
circle and dark blue line shows the average expression plot of the transcript.  The open circle 
shows the data point for each individual probe.  The shaded blue area shows the range of 
data variation and the number above the point indicate the fold change normalised to basal 
ratio (chapter 2.6.3) (B) qPCR.  Nibrin levels measured by qPCR were normalised to T0 and 
cycA housekeeping gene.  Data shown are ± S.E.M of two independent experiments. 
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 5.2.7.2 Nibrin protein levels in hypoxia 
To confirm whether the reduced NBN mRNA translates to a reduction in protein levels, we 
measured NBN protein expression by western blot. We observed that NBN protein levels 
were reduced by ~50 % by 64 and 96 hours hypoxia (Figure 5.13).  These results were 
comparable to the NBN mRNA levels measured by qPCR (Figure 5.12B), supporting the idea 
that nibrin expression is decreased in chronic hypoxia. 
 
 
 
Figure 5.13 Nibrin expression in hypoxia.  D283 cells were pre-incubated in 1% O2 in 
hypoxia as indicated.  NBN protein levels were assessed by western blot.  Western bands 
shown are representative of three independent experiments.  Quantifications of data are ± 
S.E.M of three independent experiments normalised to control. 
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 5.2.8 Role of nibrin in other cell lines 
We have demonstrated that NBN expression is reduced in chronic hypoxia at both the 
transcript and protein level in MB.  We wanted to further investigate if this is a common 
event in other brain tumours and how these changes could be correlated with drug 
resistance.  We examined NBN protein levels in the U87 GB cell line (in which we observed 
a reduction in p53 transactivation by etoposide in hypoxia as well as increased resistance) 
and a neuroblastoma cell line, SK-N-AS.  In the following section the work on SK-N-AS cell 
line was performed by another lab member Dr Catherine Heyward. 
The cell lines were incubated for duration of up to 5 days of hypoxia.  Similar to D283 cells, 
the NBN protein levels in U87 cells were reduced by 50% and 30% at 3 and 5 days of 
hypoxia respectively (Figure 4.16) and this was correlated with an increase in resistance to 
etoposide (Figure 4.18) (Figure 5.15A).  However, for the neuroblastoma cell line, no 
significant difference in nibrin levels were measured up to 5 days of hypoxic incubation 
(Figure 5.14B).  Interestingly, we have observed no changes in chemosensitivity for this cell 
line up to 48 hours of etoposide *20μM] treatment (Figure 5.15B).  These data suggest that 
the presence of changes in NBN mRNA expression in hypoxia might be correlated to the 
acquired drug resistance. 
  
 
 
Figure 5.14 Nibrin mRNA levels in other brain tumour cell lines in hypoxia.  (A) U87 (GB) 
(B) SK-N-AS (neuroblastoma) cell lines were incubated in normoxia or 1% O2 in hypoxia, 
treatment as indicated. The transcription of NBN was assessed by qPCR.  Nibrin levels were 
normalised to T0 and cyclophilin housekeeping gene.  Data shown are ± S.E.M of four 
independent experiments for U87.  Data for SK-N-AS is from one experiment. 
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Figure 5.15 Cell viability assay of U87 and SK-N-AS cells chronic in hypoxia.  (A) U87 (GB) 
(B) SK-N-AS (neuroblastoma) cell lines were incubated in normoxia or 1% O2 (hypoxia), 
treatment as indicated. The percentage of cell viability was measured by MTS assay (for 
U87)/ MTT assay (for SK-N-AS) over the untreated control.  Data shown for U87 are the 
mean ± S.E.M of three independent experiments.  One-way ANOVA followed by Bonferroni 
test was performed (* indicates p<0.05).  Data for SK-N-AS is from one experiment. 
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 5.3 Chapter 5 Discussion 
 5.3.1 HIF kinetics 
We have observed a transient HIF expression peak at an early hypoxic time point agreeing 
with other studies (section 5.1.2).  The resolution of HIF-1α is due to its negative feedback 
system with PHDs enzymes being up-regulated by HIF (Berra et al., 2003, Henze et al., 2010, 
Minamishima et al., 2009, Stiehl et al., 2006).  Other regulatory mechanisms involving 
miRNA expression have also been suggested (Bruning et al., 2011), Bruning et al. have 
shown that HIF-1α expression is also under a negative feedback regulation by a miRNA 
(miR-155), controlling HIF-1α expression at the mRNA level (Bruning et al., 2011). 
Interestingly, we observed a secondary and third peak at later hypoxic time points, which, 
to our knowledge have never been previously reported.  We have also demonstrated that 
this late HIF-1α accumulation is associated with long lasting transcription of specific HIF 
target genes such as VEGF and EPO.  Kamat et al. studied HIF-1α expression and functions 
under long term but using very mild hypoxia (15%) in human epithelial cells (Kamat et al., 
2007).  They showed that HIF-1α protein is still detectable after 14 days of hypoxic 
incubation, but they did not have any other time point over the 14 days (Kamat et al., 
2007).  They showed that this induction was not due to an increase in HIF-1α transcription.  
Additionally, HIF targets such as VEGF, GLUT-1 were also measured on both the protein and 
mRNA levels, suggesting that HIF-1α might still be functionally active after a very long 
period (Kamat et al., 2007).  In another study with neuroblastoma cells, the authors 
investigated HIF-1α expression in a gradual decrease of oxygen concentration from 5% to 
1% during a 72 hours time course and compared it to an acute (24 hours) 1% hypoxia (Lin et 
al., 2011).  They have found that acute hypoxia induced a strong HIF protein expression but 
only barely detectable HIF-1α levels were measured for the gradual decrease oxygen levels.  
Upregulation of VEGF transcription was measured under these conditions (Lin et al., 2011).  
Although the settings of both of these studies are different to ours, these results provide 
evidence that HIF signalling is capable of remaining ‘active’ in chronic hypoxia and 
potentially playing long lasting roles in cellular signalling during prolonged low oxygen 
conditions. 
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 5.3.2 Hypoxia-induced chemoresistance genes 
Hypoxia acquired chemoresistance in tumours has been shown to be correlated with 
HIF-1 induced multidrug resistance genes in a wide range of cancer, including breast, 
gastric, liver, lung and brain (Doublier et al., 2012, Liu, L. L. et al., 2008, Zhu et al., 2005, Xia 
et al., 2004, Brown et al., 2006, Hao et al., 2008, Chen, L. et al., 2009).  Several reports have 
addressed the direct evidence of HIF-1α and MDR1 expression.  One of the earliest studies 
performed by Comerford et al. showed that epithelial cells incubated in hypoxia (2.5%) 
induced a 2 fold induction of MDR1 at 6 hours and a 7 fold increase by 18 hours.  They also 
showed that MDR1 induction is via HIF-1α binding to MDR1 gene and subsequent MDR1 
expression was correlated to the drug resistance observed (Comerford et al., 2002).  This 
direct relationship of HIF-1α inducing a multidrug resistance gene was also reported by 
Doublier et al. (Doublier et al., 2012).  They demonstrated an induction of HIF-1α 
expression in MCF-7 breast cancer cells cultured in 3% hypoxia for 24 hours, associated 
with HIF-1α binding to the MDR1 promoter.  This was again linked to doxorubicin resistance 
(Doublier et al., 2012).  In another study, resistance to doxorubicin-induced apoptosis was 
observed in GBM cells and this was associated with HIF-1α induced MDR1 expression 
(Nardinocchi et al., 2009). 
In other studies where oxygen concentrations used were closer to our own study, Liu et al. 
have also demonstrated that HIF-1α induces both MDR1 and MRP expression under 1% O2 
for as short as 8 hours, in gastric cancer cell line (Liu, L. L. et al., 2008).  This 
hypoxia-induced MDR1 can be prevented by siRNA HIF-1α knockdown.  Furthermore, 
overexpression of HIF-1α increased viscritine resistance, while knockdown increased cells 
sensitivity to drug treatment (Liu, L. L. et al., 2008).  Similarly, Li et al. have shown that 
breast cancer cell lines incubated in 1% hypoxia for 12 hours displayed resistance to 
methotrexate (Li et al., 2006).  Moreover, cell lines with a HIF-1α knockdown by shRNA had 
shown a reduction of MDR1 expression in a time dependent manner, once again 
demonstrating MDR1 dependency on HIF-1α.  This was further correlated to increased 
sensitivity to drug treatment (Li et al., 2006).  However, in our hands with MB where we 
have incubated the cells at 1% hypoxia for duration of 96 hours, we did not observe 
regulated expression of MDR1, MRP1 or ABCG1 in acute or chronic hypoxic time points. Our 
findings are supported by other reports where the authors have observed hypoxia-induced 
resistance, but no expression of multidrug resistance genes (Jogi et al., 2004, Liang, 1996).  
In one case, Jogi et al. has measured a decrease in MDR1 expression in their microarray 
study, where a neuroblastoma cell line was incubated in hypoxia 1% for 72 hours (Jogi et 
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al., 2004).  Interestingly, another study by Liang et al. demonstrated that glioma cell lines in 
hypoxia (0.001% O2) for 24 hours followed by 12 hours reoxygenation, became more 
resistant to BCNU and cisplain, without increased expression of MDR1 or MRP1 (Liang, 
1996).  Taken together, although some reports have demonstrated the association and 
correlation of HIF-1α, MDR1 and chemoresistance, this is clearly not a general mechanism. 
Several studies suggest that there are alternative mechanisms for increased drug resistance 
in hypoxia.  One proposed explanation is that HIF-1α can mediate resistance via apoptosis 
inhibition by altering expression of proapoptotic and anti-apoptotic genes.  Erler et al. has 
demonstrated hypoxia down regulates Bid, Bax in a HIF-1α dependent manner and this is 
associated with hypoxia-induced drug resistance in colon carcinoma (Erler et al., 2004).  
Similarly, Sermeus et al. have shown that hypoxia inhibits the upregulation of Bax and Bak 
(Sermeus et al., 2008, Sermeus et al., 2012).  Additionally, HIF-1α dependent Notch 
expression increases pro-survival gene expression (Bcl-2 & Bcl-xL) (Zou et al., 2013).  
Moreover, in some cases, inactivation of HIF-1α did not sensitise cancer cells to drug 
treatments, thus challenging the direct role of HIF-1α in chemoresistance (Hussein et al., 
2006). 
 
 5.3.3 DNA repair in hypoxia 
DSBs are repaired by NHEJ and HR pathways, defects and inhibition of these mechanisms 
have been linked to genomic instability and tumourgenesis (Thompson and Schild, 2001, 
Stark et al., 2004, Bertrand et al., 2003).  The effect of hypoxia on these responses is not 
well studied.  We have observed from our data that some genes belonging to the HR 
pathway are regulated in chronic hypoxia.  The regulation of NHEJ related genes in hypoxia 
is less conclusive in both our own observations and studies perform by others.  There is 
only one study, which suggests that NHEJ is upregulated in hypoxia.  Um et al. has shown 
that acute (4 hours) hypoxia of 1% O2 increases Ku70 and Ku80 expression in hepatoma 
cells (Um et al., 2004).  Yet, in another study, incubation in 0.2% O2 up to 72 hours has 
shown no change in protein expression of essential NHEJ genes (Meng et al., 2005). 
On the other hand, the expressions of HR genes in hypoxia has been better documented.  It 
is generally agreed that HR gene expression is reduced in chronic hypoxia.  Meng et al. have 
shown that in prostate cancer cells treated in 0.02% O2 for 72 hours, both the mRNA 
synthesis and protein levels of several HR genes including RAD51, BRCA1 and BRCA2 were 
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downregulated (Meng et al., 2005).  The regulation of HR gene transcription in hypoxia is 
suggested to be through the alteration of transcription regulators and/or repressors 
(Iwanaga et al., 2004, Bindra et al., 2005).  For example, it has been demonstrated that the 
reduction of Rad51 is due to a switch of E2F transcriptional activation to repression 
(Iwanaga et al., 2004). The idea of translational repression as the base of decreased HR 
protein expression is also supported by other models (Chan et al., 2008, Wouters et al., 
2004). 
How these changes affect the actual repair and downstream pathway is not well 
characterised and it is important to consider the protein expression as well as to perform 
functionality studies beyond gene expression levels to make any further conclusion. 
 
 5.3.4 Role of nibrin and p53 
Currently, the majority of studies on DNA repair and chemotherapeutic response are 
performed under normoxic or anoxic conditions.  It is generally agreed that cancer cells 
with a functional repair response are less sensitive to treatment in particular to ionization 
radiation (Abbott et al., 1998, Takata et al., 1998, Mahaney et al., 2009).  The consensus is 
that DSBs induced by DNA damaging agents are repaired more effectively, allowing the cells 
to continue to proliferate post repair.  For example, mutations in both or either two of the 
HR component, BRCA1 and BRCA2 (Powell and Kachnic, 2003) accounts not only for breast 
cancer susceptibility (Peto et al., 1999) but also increased sensitivity to cancer treatment 
such as mitomycin (Moynahan et al., 2001, Bhattacharyya et al., 2000, Bartz et al., 2006, 
Treszezamsky et al., 2007).  There is one study, which demonstrated that chronic hypoxia-
induced HR defective cells were more sensitive to ionization radiation, to drugs such as 
cisplatin and mitomycin C (Chan et al., 2008).  These studies are in contrast to our results 
where we have observed a reduction in expression of some of the HR components, namely 
NBN and MRE11, but an increase in resistance.  
NBN is an important protein which plays an essential part of the HR pathway (Tauchi et al., 
2002).  NBN’s role is to activate ATM and recruit ATM to break sites.  Moreover, NBN and 
ATM phosphorylate each other, together amplifying downstream signals including p53 
(Gatei et al., 2000).  Hence we proposed the idea that a reduction of NBN and ATM 
expression might reduce p53 activation (chapter 4).  Although NBN is not generally directly 
listed as part of the p53 pathway, it is clear that NBN is upstream of p53 and that there are 
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links between these two components.  There is evidence which also suggest that NBN 
mutations are directly associated with TP53 gene inactivation (Huang et al., 2008).  It is 
considered that TP53 gene mutation is a secondary effect of NBN mutations.  The evidence 
came from a MB tumour sample from a patient, which was assessed for genetic mutation, 
only a NBN mutation was found.  When a second biopsy sample was taken from the same 
patient 2 years later, the screening showed additional new mutations which included TP53 
(Huang et al., 2008), suggesting that NBN mutations might drive genomic instability.  
However, the definite role of NBN on p53 will have to be ascertained in the future by 
knockdown and expression experiments. 
 
 5.3.5 Prognostic value of nibrin 
In MB, therapy responses due to NBN mutation is not understood but there are two case 
studies, which showed that MB patients with Nijmegen Breakage Syndrome (NBS) are more 
sensitive to radiotherapy (Bakhshi et al., 2003, Kraakman-van der Zwet et al., 1999).  In 
other cancers, Eich et al. have demonstrated that human lymphoblastoid cells and human 
fibroblasts derived from NBS patients were more sensitive to methylating cancer drugs 
(Eich et al., 2010).  These results are in contrast to our hypothesis, but we have to be 
cautious with direct comparison to NBS cancer patients.  As in the case of NBS, NBN is 
mutated and non-functional, while in our case, NBN is reduced in level of expression only. 
Currently, the exact correlations of NBN expression and treatment outcome have shown 
contradictory results.  In some cancer models, overexpression of NBN is associated with 
more aggressive cancer types and poor prognosis (Yang, M. H. et al., 2006, Ehlers and 
Harbour, 2005, Le Scodan et al., 2010).  These observations concluded that cancer cells are 
more proficient in recognising DNA damage, increase DNA repair and thus become resistant 
to treatment.  Conversely, other clinical studies revealed that expression of NBN or an 
intact MRE11 complex is essential for good treatment outcome (Kuo et al., 2012, Soderlund 
et al., 2007, Gao et al., 2008, Choudhury et al., 2010).  These later studies support our own 
and can be explained by the downregulation of NBN or MRE11 components, which reduces 
the cells ability to recognise DNA damage thus failing to induce cell cycle arrest and 
apoptosis.  The discrepency of these studies can be due to different cell types, where basal 
levels of these components are not the same; cancer cell samples obtained at different 
stage of the disease; the definition of overexpression; and importantly how these 
measurements are obtained.  For example, Yang et al. took the staining measurement of 
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NBN abundance in both the cytoplasm and nucleus (Yang, M. H. et al., 2006), whilst others 
only took nuclear intensity into account (Soderlund et al., 2007).  Here, we have 
demonstrated that higher nibrin expression were correlated with better chemosensitivity 
response in the different brain tumour types.  We therefore propose that it might be 
possible to use NBN expression as a prognostic marker for brain tumour response to drug. 
 
  
 
 
 
 
 
 
 
 
Chapter 6: Global Gene Expression in Acute 
and Chronic Hypoxia 
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 6.1 Introduction 
Following the biased examination of drug resistance genes in attempt to explain the 
observed etoposide resistance of MB cells in chronic hypoxia, we took a more general 
approach to analyse the microarray data for a global gene expression overview. 
Although there are other studies of gene expression profiles in hypoxia, these are either 
comparing the severity of hypoxia or only performed after relatively short hypoxic 
exposure, i.e. generally 18-24h (Ragel et al., 2007, Wykoff et al., 2000b, Koong et al., 2000).  
Gene expression profiling of chronic hypoxia is under explored and currently there are no 
reports on MB.  To better evaluate, the broad implications of hypoxia on cells in hypoxia, 
we have decided to analyse the global changes in gene expression by biological functional 
analysis. 
The aim of this chapter is to investigate the global cellular response to hypoxic exposure 
and to especially focus on genes and pathways potentially contributing to tumourgenesis in 
MB. 
 
Aims: 
1.  To carry out genome-wide investigation of acute and chronic hypoxia induced genes in 
D283 cells 
2.  To perform biological pathway analysis and achieve a global perspective of the effect of 
acute and chronic hypoxia on MB cells 
3.  To perform upstream analysis of chronic hypoxia on MB cells 
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 6.2 Results 
 6.2.1 Microarray further analysis 
In an earlier chapter (4.2.2.1), we observed that hypoxia-induced resistance required 
chronic hypoxia.  Here, we further explore gene expression under acute and chronic 
hypoxic conditions to elucidate the implication of chronic hypoxia on MB cells. 
 6.2.1.1 Profile Clustering by hypoxic time points 
A ‘Profile search’ function was added to the MATLAB code to allow us to obtain an output 
list of expressed transcripts at a particular time point, which can be used for further 
functional analysis.  Profile clustering was achieved by adding a simple ‘binary code’ within 
our microarray analysis coding.  The output search profile was then grouped by each or a 
combination of time points to allow better visualisation of genes up- or down- regulated 
during a given time frame. 
The ordering (left to right) of the binary codes corresponds to the hypoxic time points 0, 6, 
64 and 96 hours.  In the binary code, it is set to be ‘1’, ‘0’ or ‘-1’, where ‘1’ means the data 
have met the criteria of ≥two fold upregulation; ‘0’ means criteria not met; and ‘-1’ means 
data met criteria of   ≥two fold downregulation.  Some possible binary code combinations 
are illustrated in Figure 6.1.  As we are interested to differentiate between the gene 
expressions in acute and chronic hypoxia, we have manually altered the MATLAB binary 
codes between each run to generate transcript lists up- and down-regulated at early and 
late hypoxic time points. 
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Figure 6.1 Binary combination for Profile searches.  Hypoxic time points are across the top 
row of the table.  Rows underneath are some possible binary combinations for a given 
profile search.  (A)  Upregulated transcripts.  For example, first line are transcripts, which 
are not expressed in hypoxia (Figure 5.3);  second line for transcripts upregulated at 6 hours 
only; third line for transcripts upregulated at 64 hours only. (B) Downregulated transcripts.  
For example, second line for transcripts downregulated at 6 hours only; third line for 
transcripts down regulated at 64 hours only and fifth line for transcripts downregulated at 
both 64 and 96 hours hypoxia. 
 
Taking into account that a gene can have more than one transcript, we have here 
condensed the output transcript lists by grouping them into their corresponding gene 
names.  The gene lists resulting from of all the profiles analysed were used to produce Venn 
diagrams for both up/down regulated genes (Figure 6.2).  We first examined genes, which 
were expressed at a single time point and at that time point only.  We observed an 
upregulation of 28 genes at 6 hours hypoxia only, the expression of these genes returned to 
a non-significant expression level for the remaining duration of the hypoxic time course.  At 
64 hours, 401 genes were upregulated, these genes were not regulated before or after this 
time point.  Lastly, there were 625 genes which were upregulated at the 96 hours hypoxic 
time point but they are not expressed at 6 or 64 hours (Figure 6.2A).  For the hypoxia 
repressed genes at each individual time point, there were 4 genes which were 
downregulated at 6 hours, 590 genes at 64 hours only and 551 genes at 96 hours (Figure 
6.2B). 
When we analysed genes expressed at 2 different time points, interestingly, the highest 
number of genes regulated was seen at the joint time points of 64 and 96 hours, where 
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~900 genes were upregulated and over ~1000 genes were downregulated at both of these 
times (Figure 6.2).  Of note, the total number of genes which were upregulated at 96 hours 
will therefore be the combination value of 625 genes (upregulated at T96) plus 927 genes 
(upregulated at T64& 96).  These results demonstrate that chronic hypoxia has a larger 
influence in genetic expression than acute hypoxia and this is likely to affect the cellular 
response of cells cultured under these conditions. 
 
 
 
 
Figure 6.2 Venn diagram showing up/down regulated genes at each hypoxic time point.  
D283 cells were incubated in 1% O2 for 0, 6, 64 or 96 hours.  Data were analysed using 
MATLAB binary code profile search functions. (A) Upregulated genes.  For examples, 28 
genes are upregulated at 6 hours only; 401 genes are upregulated at 64 hours only; and 927 
genes are upregulated at combined time point of 64 and 96 hours (B) Downregulated 
transcripts.  For examples, 4 genes are downregulated at 6 hours only; 590 genes are 
downregulated at 64 hours only; and 1012 genes are downregulated at combined time 
point of 64 and 96 hours. 
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 6.2.1.2 Grouping by expression pattern using k-means clustering 
We have demonstrated that the clustering by hypoxic time points results in a large list of 
genes which are expressed or repressed in chronic hypoxia.  In order to resolve this further 
into smaller clusters, we took the pattern of expression profile into account and performed 
clustering using another method.  This allowed us to better deduce whether there is a 
correlation between a groups of genes with similar expression dynamics in relation to their 
biological functions.  The significantly expressed transcripts were clustered by their 
expression pattern using a method called k-means clustering.  k-means is a partition 
method based on actual observations, treating data as an object belonging to a location in 
space.  The data (observations) are separated into k number of cluster using an iterative 
algorithm.  Initially, k means are computationally generated within the data domain, ideally 
placing the means as far away from each other as possible.  Then each observation 
(objects) in the data are associated with the nearest k mean thus partitioning into the 
defined number of k clusters.  After the initial k clusters partitioning, a new mean is 
calculated for each of the cluster, this will be the centroid of all the objects within that 
cluster.  The process of associating each object with the nearest k means and recalculating 
new k cluster centroid is repeated till the sum of distances of every object within one 
cluster to the centroid is minimised.  The final k clusters would then be produced when the 
algorithm has converged, producing the most possible well-separated compacted clusters. 
We have utilised MATLB built in K-means function, “kmeans” algorithm to run a 16 partition 
clustering using the default settings with the exceptions of parameters listed in Table 6.1. 
 
Parameter Value Description 
‘replicates’ 15 Number of times to repeat the clustering, 
each with a new set of cluster centroid 
position 
‘display’ final Level of display output 
Table 6.1 Alterations to k-means clustering parameters.  The number of replicates is set to 
‘15’, this increase in repeated clustering ensures a good separation of all the transcripts 
with similar expression patterns.  The display is set as final, meaning that only the final 
output of the clustering analysis is exported. 
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The 16 k-means clusters generated are shown in (Figure 6.3).  Each cluster display the 
expression plot of each of the transcripts grouped to that cluster due to mean 
normalisation.  Although some of the expression trends look similar between clusters, the 
data actually fall on different scales.  For example, to look at upregulated transcripts in 
hypoxia, candidates from both cluster 8 and 14 should be considered. 
 
 
 
Figure 6.3 MATLAB k-mean clustering output.  Significantly expressed transcripts are 
clustered into one of sixteen clusters.  Transcripts with similar expression pattern and level 
of expression in hypoxia are grouped together in the same cluster. 
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 6.2.2 Biological analysis of acute and chronic hypoxia gene expression 
The genes clustered by time points or by kmeans described resulted in large lists of 
transcripts, which necessitated further classification to deduce meaningful biological 
significance.  Using the expression data clustered by time points, functional analysis were 
carried out with Ingenuity Pathway analysis (IPA) software.  The basis of IPA analysis 
software relies on the utilisation of a database (IPA Knowledge Base) generated from 
published literature to predict biological functions.  Due to limited access of IPA software 
and time constraints, the clustered results from kmeans were not used for further analysis.  
Here, we compared the effect of acute (T6) and chronic (combined T64 and T96) hypoxia on 
biological functions. 
 6.2.2.1 Network and canonical pathway analysis in acute hypoxia  
The IPA Network analysis uses an algorithm to connect the interaction between genes 
within our data set, however this interaction is linked without functional directions.  
Nevertheless, highly-interconnected networks are accepted to represent a more trusted 
genuine biological interaction.  We have first used this analysis function to deduce the 
connection between the molecular networks of regulated genes in acute hypoxia.  
Noticeably, the network diagram indicated several connections involving HIF-1α and related 
genes (Figure 6.4).  HIF-1α is connected to EGLN3 and PFKFB3 (6-phosphofructo-2-
kinase/fructose-2, 6-biphosphatase 3).  This is as expected as both of these are HIF-1α 
downstream targets (Obach et al., 2004).  Additionally, we can see a connection between 
PLOD2 (procollagen-lysine) and PPP1R3B (protein phosphatase 1, regulatory subunit 3B) to 
HIF-1α through links with NEDD9 (neural precursor cell expressed).  NEDD9 is a HIF-1α 
regulated gene which mediates cell migration (Kim, S. H. et al., 2010).  Moreover, we saw 
that 7 other genes in our data are interlinked in this network, meaning altogether, ~30% of 
our upregulated genes in acute hypoxia are able to show an interconnection with HIF-1, 
providing confidence that the cells displayed a clear hypoxic response. 
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Figure 6.4 Network connection of upregulated genes in acute hypoxia.  IPA network 
analysis linking the genes interaction in our acute hypoxia expression data.  The connections 
with HIF-1α are highlighted in light blue demonstrating a direct connection with two of its 
target genes, EGLN3 and PFKFB3.  Genes highlighted in red are upregulated in our data at 6 
hours hypoxia. 
 
We next examined the canonical pathways which are affected in acute hypoxia.  IPA 
Canonical pathways are pre-generated based on literature before our results were input.  
Upregulated gene list in acute hypoxia was uploaded and compared to these known 
pathways in IPA.  Statistical analyses are performed by IPA using Fisher’s Exact p-value 
methods (chapter 2.6.3.4).  The number of genes expressed in our data is calculated over 
the total number of genes involved in that pathway and expressed as a ‘Ratio’.  For acute 
hypoxia, the predicted involvement of canonical pathways includes HIF-1α signalling, DNA 
methylation & transcription repression signalling, AMPK (AMP-activated protein kinase) 
and ILK (integrin-linked kinase) signalling (Figure 6.5).  The only result which was above 
statistical threshold was DNA methylation and transcription repression.  However, the 
higher p-value and low ratio can be due to smaller number of genes involved in DNA 
methylation and transcription repression signalling.  Vice versa, larger numbers of genes 
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are involved with the other pathways will thus give a higher p-value and or low ratio.  We 
must also be aware that a low p-value or value above the threshold does not mean that the 
pathway is the most affected, it is only an indication that it is less likely to happen by 
chance.  In terms of HIF-1α signalling and current knowledge, we do expect this pathway to 
be affected positively by hypoxia even though the p-value fell below 0.05.  However, based 
on these results and analysis, we cannot accurately comment on whether the other 
pathways are regulated in acute hypoxia without further investigation. 
 
 
 
Figure 6.5 IPA Canonical Pathway analysis of acute hypoxia.  Canonical pathway hits 
associated with our expression data set at 6 hours hypoxia.  The p-value is calculated using 
Fisher’s extract methods, the threshold is preset at p<0.05. NOTE: IPA automatically uses 
the minus log p-value instead of the p-value on the y-axis for a better represented scale bar 
purposes.  The Ratio represents the number of genes in our expression data over the total 
number of genes found to be involved in that pathway. 
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 6.2.2.2 Upstream transcription factor analysis in acute hypoxia 
We further searched for upstream transcription factors which might be activated or 
inhibited in acute hypoxia using IPA Regulators prediction function.  IPA listed HIF-1α, 
EPAS1 (HIF-2α) and NURP1 (nuclear protein, transcriptional regulator, 1) and their 
downstream targets (Table 6.2).  Although they did not receive a prediction activation state 
by the software, it still provides clear indication that in acute hypoxia, the main 
transcription factors involved are the HIF family. 
 
Transcription 
regulators 
p-value  Target genes in data 
Predicted 
activation state 
EPAS1 (HIF-2A) 2.03E-03 EGLN3,PFKFB3 N/A 
NUPR1 2.08E-02 C8orf58,FUT11,PFKFB3 N/A 
HIF-1A 1.20E-02 EGLN3,PFKFB3 N/A 
Table 6.2  IPA transcription regulators analysis in acute hypoxia.   A table showing 
transcription factor involved in acute hypoxia and their target gene. p-value is obtained 
using Fisher’s Extact method. 
 
 6.2.2.3 Canonical pathway analysis for chronic hypoxia  
Using the expressed/ repressed data at 64 and 96 hours of hypoxia, IPA Canonical Pathway 
analysis resulted in an extensive list of pathways associated with the gene expression at this 
combined time point.  A selected section of the results with the highest p-values are 
displayed in Figure 6.6.  The pathway which is the most significantly above threshold is the 
human embryonic stem cells (hESCs) pluripotency, other highly predicted pathways include 
PI3K/AKT kinase signalling, p70S6K signalling, Wnt/β-catenin signalling and MIF regulation 
of innate immunity pathway.  Each all these pathway, a gene ratio of 0.10 to 0.15 was 
observed.  
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Figure 6.6  IPA Canonical Pathway analysis of selected signalling pathway hits in chronic 
hypoxia.  Canonical pathway hits associated with our expression data in chronic hypoxia.  
The p-value is calculated using Fisher’s extract methods, the threshold is preset at p<0.05. 
NOTE: IPA automatically uses the minus log p-value instead of the p-value on the y-axis for a 
better represented scale bar purposes.  The Ratio represents the number of genes in our 
expression data over the total number of genes found to be involved in that pathway. 
 
We focused in more detail on the hESCs signalling pathway as this pathway plays a key role 
in cells dedifferentiating into a more stem cells like phenotype.  It has been previously 
shown that hypoxia is associated with hESCs pluripotency in other models and often linked 
to tumourgenesis (Keith and Simon, 2007, Covello et al., 2006, Hill et al., 2009, Forristal et 
al., 2010).  We saw that several components implicated in hESCs pluripotency are regulated 
in chronic hypoxia, including the downregulation of SMAD family components, upregulation 
of BMP (bone morphogenetic proteins) and EDG (endothelial differentiation gene) (Figure 
6.7).  However, we do not have  strong evidence of how these molecules will contribute to 
the activation of pluripotency pathway as inhibitory signals are also observed upstream in 
the signalling.  However, a major transcription regulator relating to stem cells pluripotency, 
Oct-4 (Loh et al., 2006, Chambers, 2004, Niwa et al., 2000), is upregulated by 2.4 fold 
(Figure 6.7, lower). As Oct-4 overexpression regulates ESC pluripotency, this provides an 
indication that the cells have may an increased potential to be more stem-like in chronic 
hypoxia. 
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Figure 6.7 Human embryonic stem cells pluripotency (hESC) pathway obtained from IPA.  
(Upper) A component pathway of the hESC highlighting genes which are regulated 
(highlighted in purple) in chronic hypoxia.  Expressed genes are shaded in red, repressed 
genes are shaded in green.  (Lower) A zoom-in of the OCT-4 gene, showing a 2.4 fold 
upregulation. 
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We next focused on the Wnt signalling pathway, due to its implication with MB 
development (chapter 1.5.1.4).  Wnt signalling is involved in normal embryonic 
development, activation is via Wnt-protein ligand binding to the frizzled family of receptors.  
The binding of these proteins allow a cascade of signal transduction which ultimately 
prevent the degradation of β-catenin and aid its transport into the cell nucleus.  In the 
nucleus, β-catenin activates transcription factors which induce cellular responses such as 
cell growth and cell migration.  Here, we observed that a majority of the Wnt signalling 
components are regulated in chronic hypoxia, but yet again the global direction of pathway 
inhibition or activation is not clear (Figure 6.8).  However, we did observe that a couple of 
downstream effectors components are upregulated, such that of Oct-4, as mentioned 
earlier and the C-Jun proto-oncogene.  C-Jun has a key biological role in cell proliferation 
and embryonic morphogenesis (Johnson et al., 1993, Hilberg et al., 1993, Schreiber et al., 
1999, Johnson et al., 1996).  The activation of C-Jun has also been implicated with 
tumourgenesis (Black et al., 1994, Black et al., 1991, Bos et al., 1990, Dunn et al., 2002).  
Altogether, it appears that chronic hypoxia directs the cells to a more stem cell like 
phenotypes, potentially contributing to tumourgenesis. 
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Figure 6.8  Wnt signalling pathway obtained from IPA.  A component pathway of the Wnt 
signalling pathway, highlighting the genes which are regulated (highlighted in purple) in 
chronic hypoxia.  Expressed genes are shaded in red, repressed genes are shaded in green. 
 
Lastly, we will discuss on the P13K/Akt pathway (see Appendix 1.4 for pathway).  Changes 
in cellular metabolism are one of the major characteristics detected in cells when exposed 
to hypoxic insults (chapter 1.2.2).  This is also reflected in the canonical analysis where we 
saw that P13K/Akt was regulated in chronic hypoxia.  The PI3K (phosphatidylinositol 3 
kinase)/AKT signalling is a complex pathway which plays a central role in transduction of 
cytokines and growth factors signals and is important for insulin signalling and glucose 
metabolism.  Akt is a key mediator involved in cell survival through inhibition of apoptotic 
regulators (Osaki et al., 2004).  Here, we observed that some of the P13K/Akt signalling 
components are affected in chronic hypoxia but again, the global direction of pathway 
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inhibition or activation is not clear.  However, it is reasonable to consider that, during 
chronic hypoxia, cellular energy consumption is regulated through this pathway. 
 
 6.2.2.4 Upstream transcription factor analysis in chronic hypoxia 
In chronic hypoxia (combined 64 and 96 hours time point), several transcription factors are 
predicted to be regulated (Table 6.3).  Using comparison analysis, where both the 
expressed and repressed gene lists were uploaded into IPA, the top hits were NURP1, 
SPDEF (SAM pointed domain containing Ets transcription factor) being activated and ERG 
(ETS belated gene) being inhibited.  The upregulation of NURP1 found in our data can be 
due to stress, as NURP1 is primarily a stress sensor found to be upregulated by high 
temperature or change in culturing medium (Garcia-Montero et al., 2001, Jiang et al., 
1999).  The function of NURP1 appears to be both pro- and antiapoptotic (Su et al., 2001, 
Vasseur et al., 2002, Carracedo et al., 2006, Ree et al., 1999), thus it is difficult to determine 
what impact of this transcription factor has on cells in chronic hypoxia.  Both SPDEG and 
ERG belongs to the ETS transcription factor family of proteins, with a diverse role in 
biological processes including cellular differentiation, cell cycle, apoptosis and angiogenesis 
(Sharrocks, 2001).  SPDEF is positively associated with tumours and was found to be 
upregulated in breast, prostate and lung cancers (Feldman et al., 2003, Sood et al., 2007), 
contributing to cells migration and invasion (Feldman et al., 2003, Osisami and Keller, 2013, 
Turner et al., 2008).  The predicted activation of SPDEF in chronic hypoxia suggests that MB 
might similarly undergo a more tumourgenesis state.  ERG is found to be overexpressed in 
several cancer types, indicating an oncogenic function but the molecular mechanisms of 
this ERG transcription factor are unclear (Baldus et al., 2006, Metzeler et al., 2009, Li et al., 
2012).  Moreover, we have found that ERG is down-regulated in our data, thus its 
contribution to increased tumourgenesis in our model is unlikely. 
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Transcription 
regulators 
p-value 
Number of 
Genes 
Predicted activation state 
NUPR1 5.42E-10 79 Activated 
SPDEF 1.58E-03 12 Activated 
ZNF217** 2.06E-02 8 Activated 
EZH2* 2.10E-02 7 Activated 
ERG 1.83E-02 17 Inhibited 
Table 6.3  IPA transcription regulators analysis in chronic hypoxia.   A table showing 
transcription factor involved in combined expressed and repressed gene list in chronic  
hypoxia of (predicted from *expressed gene list, ** repressed gene list only) and number of 
target genes involved. The p-value is obtained using Fisher’s Extact method. 
 
When the expressed and repressed data were analysed separately, two other transcription 
factors were found to be regulated.  IPA predicted that both ZNF217 (zinc finger protein 
217) and EZH2 (enhancer of zeste homologue 2) are activated.  However, these 
transcription factors were not predicted to be regulated when the expressed and repressed 
gene list were analysed together.  This is due to contradictory results or the up- and 
downregulated gene lists, thus giving a low prediction score (Figure 6.9).  Nevertheless, we 
looked more closely at these findings as both of these transcription factors are potential 
interesting targets.  Both EZH2 and ZNF217 are transcription repressors.  EZH2 catalyzes 
trimethylation of histone 3, while ZNF217 binds to promoters of target genes and primarily 
acts as a transcription repressor (Cao et al., 2002, Tsang and Cheng, 2011, Cowger et al., 
2007, Banck et al., 2009).  The upregulation of these genes may suggest that transcription 
might be repressed in chronic hypoxia. 
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Figure 6.9 Network display of transcription factors interactions obtained from IPA.  
Prediction of activated transcription factor (A) ZNF217 (B) EZH2 and their relationship with 
downstream targets found in chronic hypoxia  
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 6.3 Chapter 6 Discussion 
 6.3.1 A global view of microarray analysis 
In this chapter we have carried out a global gene expression profiling of MB cells in hypoxia, 
primarily focused on the differential gene expression between early and late hypoxic time 
points.  We found that there was little change in genetic expression in acute compared to 
chronic hypoxia.   
There are currently no other global gene expression studies of MB in any length of hypoxic 
duration, only one microarray of another brain tumour, GBM in 1% hypoxia for 24 hours 
(Ragel et al., 2007).  However, there was minimal overlap in our data, likely due to the 
different experimental conditions.  Ragel et al. has primarily only examined HIF targets and 
stress response genes.  Similar to our finding, upregulatioin of VEGF, IGFBP3 (insulin-like 
growth factor binding protein 3) and CAIX were detected.  However, the upregulation of 
stress response genes found by Ragel et al. was not observed in our data at any time point.  
It is possible that the expression of these genes might have been missed in the 6 hour time 
point and that, at later time points, cells under stress were already dead.  Moreover, it 
must be noted that under hypoxic incubation, we would expect genes involved in the 
glycolytic pathway to be altered.  Perhaps surprisingly, the regulation of this pathway was 
not highlighted in our analysis in either acute (T6) or chronic hypoxia (T64 and T96).  
However, on manual searches for several key enzymes which promote a transition of 
oxidative to glycolytic metabolism (Semenza, 2012b, Kim et al., 2006, Papandreou et al., 
2006, Zhang et al., 2008), we found that enzymes such as PDK1 (pyruvate dehydrogenase 
kinase 1) and BNIP3 expression are in fact up-regulated throughout the hypoxic incubation.  
Thus when we compared acute versus chronic hypoxia, this result and potentially other 
results could be missed as they do not fall in the acute or chronic group but in a 
‘continuously expressed in hypoxia’ group. 
It will therefore be useful in the near future, to compare some of the gene clusters 
obtained from (Figure 6.3), examining the genes with differential expression dynamics.  For 
example, to compare group of genes only expressed at the later time point and the ones 
which were increased gradually over hypoxia.  This will provide an insight to the cellular 
response in relation to the time frame of hypoxic exposure, giving us the finer details of 
how cells as a population behave in hypoxia. To further implement our current microarray 
results, network integration approaches could be useful.  This method first uses metabolic 
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interactions from published databases to construct an integrated network.  Then using 
differential values of gene expressions data between different microarrays (e.g 
chemoresistance versus chemo sensitive), pathway are scored.  For example, Chao et al. 
used this method and identified chemoresistance-associated pathways using ovarian and 
lung models (Chao et al., 2011).  They identified a high score of several pathways including 
Wnt and P13K/Akt signalling and suggested that these pathways play a role in 
tumourgenesis in their cancer model as with our own finding (Chao et al., 2011, Gatcliffe et 
al., 2008).  In the future, similar studies should be performed using different brain tumour 
cell lines, to help further predict key pathways and genes which are involved in resistance. 
 6.3.1.1 Signalling pathways affected by chronic hypoxia 
This study confirms that hypoxia has a major effect in cellular gene expression as found by 
others (Rocha, 2007, Kenneth and Rocha, 2008).  These changes are likely the cause of 
helping the cells to adapt to the reduced oxygen level.  Besides the acute HIF regulation, 
hypoxia can affect many other cellular pathways as described in the result of section 
6.2.2.3.  IPA analysis has predicted that the most regulated pathways in chronic hypoxia are 
those involved in cellular energy metabolism, stem cells pluripotency and the 
developmental Wnt signalling pathway. 
 
 P13K/Akt pathways are of major importance in regulating many cellular processes 
including glucose signalling and insulin metabolism (Fruman et al., 1998, Osaki et 
al., 2004, Lawlor and Alessi, 2001).  Amplification of Akt is frequent in cancers 
(including GBM) (Staal, 1987, Knobbe and Reifenberger, 2003) and its activation is 
known to promote cell growth and treatment resistance (Testa and Bellacosa, 
2001, Vivanco and Sawyers, 2002, Vara et al., 2004, Franke et al., 1997).  The 
activation of this pathway is correlated with the loss of tumour suppressor PTEN, 
which generally inhibits Akt (Hartmann et al., 2006, Carnero et al., 2008). 
 
 One interesting pathway regulated in hypoxic MB is the Wnt signalling, as 
mis-regulation of this pathway is associated with MB (chapter 1.4.1.2).  Mutations 
in the Wnt pathway accounts for 25% of all MB (Northcott et al., 2011, Clifford et 
al., 2006, Ellison et al., 2005, Fattet et al., 2009).  In normal embryonic growth, 
Wnt/β-catenin plays an important role in neuronal stem cell proliferation and 
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contributes to cerebellum development (Thomas and Capecchi, 1990).  However, 
the continuous activation of Wnt signalling can thus lead to dysregulated cell 
proliferation and MB development.  As found by independent studies, MB is 
associated with activation mutation of β-catenin gene (CTNBN1) (Thompson et al., 
2006, Kool et al., 2008, Parsons et al., 2011, Northcott et al., 2011) or inactivation 
of β-catenin inhibitory molecules such as APC and Axin (Eberhart, 2003, Huang et 
al., 2000, Baeza et al., 2003).  Although we did not observe a direct upregulation of 
Wnt or its downstream targets, changes of several Wnt components and reduction 
of APC was measured, thus chronic hypoxia might potentially alter this pathway 
and contribute to MB development. 
 
 Oct-4/ Sox and NANOG where induced in hypoxia and these are the major 
transcription factors involved in the process of cancer cells dedifferentiating into a 
more stem-like phenotype (Nichols et al., 1998, Boiani and Scholer, 2005, Ponti et 
al., 2005, Wen et al., 2010, Ji and Zheng, 2010).  The implication of stem cells and 
tumourgenesis is witnessed in brain tumours including MB (Hemmati et al., 2003, 
Bao et al., 2006, Beier et al., 2007, Hambardzumyan et al., 2008).  For example, 
detection of neural stem cells markers CD15 and CD133 have been found in both 
MB models and MB tumours (Hemmati et al., 2003, Read et al., 2009, Annabi et al., 
2008, Gowda et al., 2012).  Gowda et al. had found that 42 of 60 MB tumour 
samples were CD133+ and that 37/60 were CD15+ and that the expression of both 
these markers are associated with worst outcome (Gowda et al., 2012).  Other 
examples of stem cell marker expression in MB such as SOX2 and SOX9, has also 
been found to be associated with poorer clinical outcome (Sutter et al., 2010).  
Furthermore, Shutter et al. demonstrated that Nanog activation in human 
cerebellar stem cells resulted in MB development in a mouse model (Sutter et al., 
2010).  These studies and findings of our own suggest that chronic hypoxia might 
have an involvement of activating pathways involved in MB dedifferentiation, thus 
driving the cells into a more stem-like and progressive tumour phenotype. 
 
Altogether, the alteration of these signalling pathways all point towards MB development, 
hence indicating a potential role of hypoxia in MB, not only in drug resistance but also in 
driving tumour progression. 
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 6.3.1.2 Transcription factor regulation in chronic hypoxic conditions: and the role of 
ZNF217 and EZH2 transcription repressor  
IPA analysis has revealed and predicted the activation and inhibition of several transcription 
factors in chronic hypoxia.  Of interest, we focused on the two transcriptional regulators, 
ZNF217 and EZH2.  ZNF217 is a Krüppel-like zinc-finger protein found to be amplified in 
several tumour types and relates to poor survival (Kallioniemi et al., 1994, Nonet et al., 
2001, Li et al., 2007, Mao et al., 2011).  ZNF217 primarily acts as a transcription repressor 
by interacting with co-repressors and histone modifying proteins within the nucleus. 
High expression of ZNF217 is associated with poor prognosis in breast cancer (Sun, G. et al., 
2008, Krig et al., 2010, Quinlan et al., 2007, Vendrell et al., 2012).  Vendrell et al. have 
demonstrated that overexpression of ZNF217 in breast cancer cell lines stimulated cells 
migration, invasion and that it promoted EMT in human mammary epithelial cells (Vendrell 
et al., 2012).  In breast cancer, ZNF217 expression have also been found to be associated 
with chemoresistance (Huang et al., 2005, Thollet et al., 2010).  For example, Thollet et al. 
have demonstrated that overexpression of ZNF217 in a breast cancer cell line conferred 
resistance to paclitaxel and that siRNA inhibition of ZNF217 re-sensitised the cells to 
treatment (Thollet et al., 2010). 
In a GBM study, ZNF217 is associated with aggressive tumour behaviour and poor 
prognosis, it is amplified in 32% of GBM and it is overexpressed in 71.2% of GBM’s patients. 
(Mao et al., 2011).  Expression of ZNF217 is higher in Glioma stem cells than non-GSC and 
siRNA knockdown of ZNF217 in GSC inhibited cell growth and promote differentiation.  Mao 
et al. have also reported that ZNF217 expression is dependent on both HIF-1α and HIF-2α, 
as both GSCs and GBM cell lines incubated in hypoxia show upregulation of ZNF217 and 
hypoxia-induced ZNF217 is inhibited upon HIF knockdown by siRNA (Mao et al., 2011).  
These studies support our prediction that ZNF217 could potentially be upregulated in 
chronic hypoxia and that ZNF217 might contribute to chemoresistance and also to the 
dedifferentiation phenotype observed.  However, there are currently no reports of ZNF217 
and its implication in MB, thus the role of ZNF217 in MB remains an interesting target to be 
studied in the near future. 
EZH2 is the active catalytic subunit part of the Polycomb repressive complex 2 (PRC2) which 
function to methylate lysine 27 on histone 3.  It is responsible for chromatin compaction 
and thus acts as a transcriptional repressor (Cao et al., 2002, Tsang and Cheng, 2011, 
Margueron and Reinberg, 2011).  EZH2 is also associated with tumourgenesis, poor clinical 
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prognosis and drug resistance in prostate, breast and ovarian cancer (Bachmann et al., 
2006, Rizzo et al., 2011).  Moreover, EZH2 have been demonstrated to be involved in 
tumour stem cell maintenance in GBM (Suva et al., 2009, Crea et al., 2012).  Interestingly, 
EZH2 was predicted to be activated in our data and that EZH2 has been reported to be 
associated with group 3 and group 4 MB.  Recently, a study performed by Alimova et al. has 
shown that inhibition of EZH2 by RNAi suppresses MB cell growth and reduces tumour 
sphere formation (Crea et al., 2012).  Similar to ZNF217, we once again speculate the 
potential role of EZH2 in MB and that both these transcription factors might drive a more 
aggressive, chemoresistance, and stem cell phenotype in chronic hypoxia. 
 6.3.1.3 Limitations of microarray  
The genomic studies we have performed have yielded vast amounts of genetic expression 
data.  Besides from correctly filtering out genuine changes of gene expression that have 
occurred in hypoxia, interpretation of the results remained challenging.  Although the 
sophisticated software IPA has provided us with a good platform for an overview of 
biological functions affected in chronic hypoxia, these are after all bioinformatic predictions 
which rely on known published literature.  Thus, the upmost limitation of this software is 
the availability of known information.  Thus say, if knowledge on a certain pathway has not 
been established yet, this information will be missed out in the analysis.  So although IPA 
can calculate statistical p-value and ratio of predicted results, output results should be 
interpreted carefully dependent on how well known a pathway is.  Moreover, IPA cannot 
provide a clear indication of which pathway is the most regulated as low p-value does not 
equate to ‘most affected’. Also, because there are many genes involved in any given 
pathway, it is likely that for a pathway some genes will drive both up and down regulation, 
as found with some of our results. It is therefore difficult to get a clear picture of the final 
outcome of the pathway.  To deduce a clear meaning of a predicted affected pathway, a 
more focused investigation is required.  Moreover, the apparent contradicting regulation of 
a given signalling pathways, might be caused by cell heterogeneity, hence a single cell 
analysis approach could help to provide a clearer mechanism. 
 
  
 
 
 
 
 
 
 
 
Chapter 7: General Discussion 
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 7.1 Project overview 
The purpose of this study was to investigate how brain tumour cells respond to 
chemotherapeutic treatment and how this was affected by their genomic status (p53) and 
their hypoxic microenvironment.  The aim of this work was to gain a better understanding 
of the molecular mechanisms contributing to chemoresistance in order to improve current 
therapeutic strategies for MB treatment.  
We have confirmed that (1) MB and GBM cell lines exhibit altered sensitivities to 
chemotherapeutic drugs and that drug resistance observed was associated with the cells’ 
ability to transactivate p53; (2) MB p53 WT cells became more resistant to etoposide 
treatment in chronic but not acute hypoxic incubation; (3) Hypoxia-induced resistance is 
not caused by the expression of multidrug resistance transporters in our model but, at least 
in part, is due to a reduction in DNA damage sensing mechanisms; (4) Chronic hypoxia 
triggered a substantial effect on global genetic expression, affecting many biological 
functions of tumour cells. 
 
 7.1.1 The significance of p53 in MB 
In general, most cancer types with p53 mutations are found to be more prone to 
tumourgenesis, this is due to the lack of cell cycle arrest control and apoptotic response in 
the presence of DNA damage which may have been inflicted upon the cells.  In terms of 
association of TP53 mutations and worst survival, it is clear in some cancers such as breast, 
liver and head & neck (Olivier et al., 2006, Robles and Harris, 2010, Erber et al., 1998). 
For MB, accumulating studies have revealed the association of TP53 mutation and bad 
prognosis in patients (Tabori et al., 2010, Zhukova et al., 2013).  In particular, it is found 
that the TP53 status in Shh group MB is of high predictive outcome (Northcott et al., 2012) .  
TP53 mutations in this group have extremely poor survival and a worse outcome compared 
to Shh/ WT tumours (Zhukova et al., 2013).  A whole-genome-sequencing-based analysis 
has further revealed that Shh group patients with TP53 germline mutations are linked to 
chromosome rearrangement (chromothripsis).  Raush et al. found that in 10 out of 10 
tumour samples tested, where the cells carried a loss of TP53 or heterozygosity mutation, 
there were occurrences of chromothripsis.  Whilst, in the twenty two p53 WT samples 
examined, none displayed unusual chromosomal arrangement (Rausch et al., 2012). 
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When investigating TP53 mutations, caution must be taken due to the nature of p53 
mutations.  Unlike other gene mutations, TP53 mutations tend not to result in a loss of 
protein expression but rather a mutated protein.  Mutated p53 protein can be functionally 
active, asserting a dominant negative effect on WT protein or gain of function (GOF) 
(chapter 1.7.3).  For example, in breast and colon cancer, p53 GOF down-regulated miR-223 
can lead to treatment resistance (Masciarelli et al., 2013).  The method of p53 detection 
must be able to differentiate between WT and mutated protein, otherwise a 
malfunctioning p53 protein can be wrongly labelled as a p53 WT tumour.  Evaluation of p53 
status by sequencing is the best detection method for somatic mutations.  Moreover, WT 
protein can still be functionally prohibited, for example TopBP1 (Topoisomerase IIβ binding 
protein) can interact with the p53 DNA binding domain and inhibit its promoter binding 
activity leading to repression of p53 transactivation (Liu et al., 2009).  Thus when 
determining MB p53 status, it is also important to access the protein activity, yet this can 
be more complicated at a large scale for diagnosis or stratification purposes. 
 
 7.1.2 The global cellular effect of hypoxia  
There are surprisingly few reports of MB experiments performed in hypoxia compared to 
other solid brain tumours.  Although there is no direct study that measures hypoxia 
markers in MB, it has been shown that MB arises from stem cells (Fan and Eberhart, 2008) 
and that hypoxia is a classic feature of the stem cell niche (Mohyeldin et al., 2010).  Stem 
cell arisen MB is further associated with HIF dependent Notch activation which maintains 
MB in an undifferentiated state (Pistollato et al., 2010, Manoranjan et al., 2012, Fan et al., 
2006).  These studies demonstrate that the characteristics of MB are similar to other 
hypoxic brain tumours such as GBM (Collingridge et al., 1999, Rampling et al., 1994, Evans 
et al., 2004).  Therefore, our work reflects the necessity and importance of taking hypoxia 
into account when studying these tumours. 
The mechanism behind the control of gene transcription under prolonged hypoxia could be 
due to changes in the DNA chromatin structure.  Beside DNA organisation, histones are 
involved in transcriptional activity and epigenetic control of transcription factors via post 
translation modifications (Berger, 2002, Felsenfeld and Groudine, 2003).  It has been shown 
that in hypoxia, certain gene promoters (e.g. VEGF) display an increase in trimethylation of 
histone3 at lysine4, which corresponds to an active transcription state (Shilatifard, 2006, 
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Johnson et al., 2008).  Moreover, it is speculated that other mechanisms, such as miRNA 
can have a role in the regulation of gene expression in hypoxia.   
It will also be essential to see how the transcriptomic data would translate to the proteome 
as protein translation could be slowed down or inhibited in hypoxia (Bi et al., 2005, 
Koritzinsky et al., 2005, Liu et al., 2006, Uniacke et al., 2012).  Thus transcriptomic data 
does not always reflect the protein levels and does not provide any information on their 
activity.  Therefore a future proteomic approach would help further elucidate the role of 
hypoxia in MB. 
 
 7.1.3 Future perspective for MB treatment  
Despite the fact that treatments for MB have improved in the recent years, cancer 
reoccurrence seen in children is as high as 40% (Faria, 2013).  Importantly, due to the 
nature of tumour location and the high incidence of MB in young children, treatment 
choices are frequently limited to drugs.  Yet, treatment causes significant long term side 
effects leaving survivors with lifelong disabilities.  Therefore, there is a need for a better, 
more specific treatment for MB patients to improve their outcome. 
Recently, classification of MB, tumour subgroup and their genetic status has provided a 
step-change in the understanding of MB behaviour clinically.   With the advances in genetic 
screening, the large genetic variations of these tumours have been revealed, with different 
mutations linked to key biological pathways.  This demonstrates that MB is a 
heterogeneous tumour and explains why histopathologically identical tumours have a 
different response to treatments and different clinical outcomes.  
 7.1.3.1 Targeted therapy  
The idea of cancer targeted therapy is based on using compounds and inhibitors, which 
interfere and block a specific signalling pathway.  In the past few years, development of 
specifically targeted anticancer drugs for MB has generated lots of hope and excitement.  
However, due to acquired resistance, the only targetable group with good results so far is 
the Shh subgroup.  Using SHH inhibitors such as GDC-0449 and NVP-LDE225, promising 
results were obtained in reducing tumour growth (LoRusso et al., 2011, Buonamici et al., 
2010).  GDC-0449 inhibitors have been tested in phase II clinical trials (LoRusso et al., 2011).  
For the other subgroups, a deeper understanding and development of target therapy is still 
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required, especially for Group 3 patients, which only have 20-30% survival rate (Cho et al., 
2011).  Group 3 tumours are the most aggressive with high reoccurrence and metastasis 
rate.  Hence, they tend to be treated with a higher treatment dose, resulting in an 
increased toxicity and morbidity.  
 
There are other more general cancer targeted therapies developed to target pathways such 
as growth signal transduction, gene expression and angiogenesis.  For example, cancer cell 
proliferation can be blocked by using compounds such as pertuzumab, docetaxel, gefitinib 
and erlotinib which target EGFR and HER-2 growth factors (Baselga et al., 2012, Geoerger et 
al., 2011, Pollack et al., 2011).  These compounds are being used to treat metastatic breast 
cancer and small-cell lung cancer (Tan et al., 2004, Fukuoka et al., 2003, Shepherd et al., 
2005).  Inhibitors such as sorafenib and bevacizumab (Ichihara et al., 2011) have been 
developed to block angiogenesis.  Some promising results with compounds such as gefitinib 
and sorafenib in MB cell lines have been shown and this could be useful for future MB 
treatment (Meco et al., 2009, Yang et al., 2008, Blechacz et al., 2009). 
 
 7.1.4 Moving towards in vivo study 
The work in this project is based on using cultured cell lines as a model for MB.   Although 
the results provided a good bases on how chemoresistance arises, results obtained with cell 
lines and their actual responses in patient might differ (Baguley and Marshall, 2004).  
Testing on cultured tissue gives concerns of its true representation of original tumour and 
unfortunately, primary MB tumour cells are difficult to grow (Romer and Curran, 2005).  
Moreover, culture cells might hinder the true characteristic of the disease in vivo, as in vitro 
work neglects many physiological factors that a complex biological system might 
experience.  The use of mouse models can provide information on how MB is initiated, 
progresses and metastasises (Read et al., 2009).  Furthermore, using an in vivo model to 
study chemotherapeutic response would provide a more accurate tumour response closer 
to human cancer.  The testing of these new targets in vivo is therefore necessary and more 
experiments are now being performed with mouse models (Romer and Curran, 2005, Lee et 
al., 2012). 
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 7.1.5 Final Remarks 
The increase in our understanding of cancer cell biology has allowed discovery of novel 
targets, drugs and biomarkers, hence therapeutic approaches have better efficiency.   
The major concern clinicians still face are the insensitivity to drug treatment and the 
relapse associated with acquired resistance to particular molecular targets.  In theory, 
knowing the MB subgroup and genetics could provide a clearer direction for surgeons and 
oncologists to treat the patients in a more specific, personalised regime.  However, the 
practicalities of sequencing methods for individual patients are not available due to cost 
issues.  Moreover, knowing the cancer genetics would still not take into account the large 
tumour heterogeneity (some subpopulations of cells bearing different mutations), nor the 
important role of tumour microenvironment such as hypoxia as we have shown, and also 
the interaction with stromal cells.  Efforts in the development of drugs which target 
different pathways or by using combination therapy would therefore be advantageous to 
tackle the tumour heterogeneity, the role of the microenvironment and avoid relapse.  
Finally, based on our observations we propose that the activity and levels of DNA damage 
sensing and repair machinery proteins (such as nibrin) should be taken into consideration 
for defining the therapeutic strategy and might also be useful indicators to predict 
treatment outcome. 
Our work provided a general principle of the relationship between hypoxia and 
chemosensitivity in MB and this can be translated for other closely related tumours such as 
GBM for future investigations. 
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Appendix 
1.1 Significant transcripts analysis on MatLAB 
The following coding is for selecting significantly expressed transcripts. 
Additional functions including: profile searches, kmeans clustering and hierarchy clustering. 
 
MATLAB CODES: 
function cfrunwithprofileID 
(fulldata,allgenenames,alltranscriptsIDs) 
 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%% 
 
% This bit sets up the microarray analysis, reading in data 
and setting up 
% any empty vectors or matrices that need to be defined. 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%% 
 
 
includeborderlinetranscripts = 1;  % =1 if you want to allow 
borderline transcripts 
 
clusteranalysis = 1;         % =1 to carry out a cluster 
analysis 
 
profilesearch = 1;   % =1 to search for a specific profile 
 
profile = [0,1,0,0];  % the specific profile to search for 
 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%% 
 
probes = 3;     % there are three probes for every transcripts 
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p = fulldata;   % This reads in the input matrix to the p data 
matrix 
datalength = length(p(:,1));  % this works out how many data 
points there are  
 
a = 2;  %this will start the analysis at row 2 (row 1 in title 
is the time points header) 
 
number_of_sig_transcripts = (datalength-1)/probes; % works out 
how many transcripts to be tested 
 
time_points = 4; % tells us for how many time points the 
experiment covered 
time = [0 6 64 96]; % lets us know the time points of the 
experiment 
 
count = 0;  % starts the count of expressed transcript at zero 
bordercount = 0; % starts the count for borderline transcript 
at zero 
 
results = [];  % sets up the results matrix for any transcript 
which are found 
               % to be significantly different in stats test             
borderresults = []; % sets up the same for borderline 
transcript 
 
 
probevec1 = zeros(3,1); % empty vector for all 12 transcript 
measurements of T0 
probevec2 = zeros(3,1); % empty vector for all 12 transcript 
measurements of T6 
probevec3 = zeros(3,1); % empty vector for all 12 transcript 
measurements of T64 
probevec4 = zeros(3,1); % empty vector for all 12 transcript 
measurements of T96 
anovamatrix = zeros(3,4);  % empty matrix to store above 
vectors 
 
vec1 = zeros(9,1); % empty vector for all 12 gene measurements 
of T0 
vec2 = zeros(9,1); % empty vector for all 12 gene measurements 
of T6 
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vec3 = zeros(9,1); % empty vector for all 12 gene measurements 
of T64 
vec4 = zeros(9,1); % empty vector for all 12 gene measurements 
of T96 
 
 
sigtranscriptresults = [];  % used to store profiles for 
expressing transcript 
borderlinetranscripresults = []; 
 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%% 
% this section does the actual analysis to see if a transcript 
expression 
% profile shows significant change over time 
% 
 
for i = 1:number_of_sig_transcripts 
     
% This bit reads in the data for each time point into a vector 
% this is then placed in the matrix anova matrix read for 
stats test 
 
 
%%% 
%%% PROBE 1 %%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%% 
    probevec1(1:3) = p(a,1:3);  
    probevec2(1:3) = p(a,4:6); 
    probevec3(1:3) = p(a,7:9); 
    probevec4(1:3) = p(a,10:12); 
     
    anovamatrix(:,1) = probevec1; 
    anovamatrix(:,2) = probevec2; 
    anovamatrix(:,3) = probevec3; 
    anovamatrix(:,4) = probevec4; 
     
     
% gets the p value of above profiles for probe 1 
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    pvalue1 = anova1(log2(anovamatrix),[],'off');  
    
     
     
%%% 
%%% PROBE 2 %%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%% 
    probevec1(1:3) = p(a+1,1:3);  
    probevec2(1:3) = p(a+1,4:6); 
    probevec3(1:3) = p(a+1,7:9); 
    probevec4(1:3) = p(a+1,10:12); 
     
    anovamatrix(:,1) = probevec1; 
    anovamatrix(:,2) = probevec2; 
    anovamatrix(:,3) = probevec3; 
    anovamatrix(:,4) = probevec4; 
     
     
% gets the p value of above profiles for probe 1 
 
    pvalue2 = anova1(log2(anovamatrix),[],'off');  
     
     
 
%%% 
%%% PROBE 3 %%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%  
    probevec1(1:3) = p(a+2,1:3);  
    probevec2(1:3) = p(a+2,4:6); 
    probevec3(1:3) = p(a+2,7:9); 
    probevec4(1:3) = p(a+2,10:12); 
     
    anovamatrix(:,1) = probevec1; 
    anovamatrix(:,2) = probevec2; 
    anovamatrix(:,3) = probevec3; 
    anovamatrix(:,4) = probevec4; 
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% gets the p value of above profiles for probe 1 
 
    pvalue3 = anova1(log2(anovamatrix),[],'off');  
  
 
    
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%% 
%  
% This next bit records those genes which have a low p value 
in the matrix  
% results.  It also counts how many transcripts are 
significant and records 
% their names.  Change the p value below for a different level 
of significance 
 
     
    if pvalue1 < 0.01 && pvalue2 < 0.01 && pvalue3 < 0.01 
                 
        vec1(1:9) = [p(a,1:3),p(a+1,1:3),p(a+2,1:3)]; 
        vec2(1:9) = [p(a,4:6),p(a+1,4:6),p(a+2,4:6)]; 
        vec3(1:9) = [p(a,7:9),p(a+1,7:9),p(a+2,7:9)]; 
        vec4(1:9) = [p(a,10:12),p(a+1,10:12),p(a+2,10:12)]; 
                 
       count = count+1;  
       sigtranscript(count) = allgenenames(a-1); 
       sigtranscript2(count) = alltranscriptsIDs(a-1);        
      
     
%%% Delete as appropriate below to use either mean or median 
for 
%%% expression values of a transcript at a particular time 
point 
 
      results(count,:) = 
log2([mean(vec1),mean(vec2),mean(vec3),mean(vec4)]); 
      rawresults(count,:) = 
[mean(vec1),mean(vec2),mean(vec3),mean(vec4)]; 
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    end 
     
     
%%%     
%%% This next section tests for transcripts which may express 
but have one faulty 
%%% probe.  The expression criteria is change from 0.01 to 
0.001 but this 
%%% time only 2 of the 3 probes have to pass the condition 
%%%  
%%% 
 
if includeborderlinetranscripts == 1; 
 
    pvaluevec = [pvalue1 pvalue2 pvalue3]; 
     
    if min(pvaluevec) < 0.01 && median(pvaluevec) < 0.01 && 
max(pvaluevec) > 0.01 
         
        bordercount = bordercount +1 ; 
                 
        vec1(1:9) = [p(a,1:3),p(a+1,1:3),p(a+2,1:3)]; 
        vec2(1:9) = [p(a,4:6),p(a+1,4:6),p(a+2,4:6)]; 
        vec3(1:9) = [p(a,7:9),p(a+1,7:9),p(a+2,7:9)]; 
        vec4(1:9) = [p(a,10:12),p(a+1,10:12),p(a+2,10:12)]; 
                 
       count = count+1;  
       sigtranscript(count) = allgenenames(a-1); 
       sigtranscript2(count) = alltranscriptsIDs(a-1); 
       bordertranscript(bordercount) = allgenenames(a-1); 
      
        
 
%%% Delete as appropriate below to use either mean or median 
for 
%%% expression values of a transcript at a particular time 
point 
 
      results(count,:) = 
log2([mean(vec1),mean(vec2),mean(vec3),mean(vec4)]); 
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      borderresults(bordercount,:) = 
log2([mean(vec1),mean(vec2),mean(vec3),mean(vec4)]); 
      rawresults(count,:) = 
[mean(vec1),mean(vec2),mean(vec3),mean(vec4)]; 
 
    end 
     
end 
     
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%% 
 
     
     
   
    a=a+3;  % the analysis for this gene is done, we move a 
along 3 for next gene 
 
     
end 
 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%% 
% 
% We now have all expressing transcripts.  The next section 
filters out only 
% those transcripts which show a satisfactory level of 
expression 
% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%% 
% 
 
expressingcount = 0; % initially no transcripts are said to be 
expressing 
 
minfoldchange = 1; % This is the minimum required fold change 
for a 
                   % significant transcript to be called an 
expressing transcript 
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                   % (1 relates to a 2fold change on log2 
scale) 
 
 
% Below we go through each significant transcript profile from 
results matrix 
% and get the min and max.  the ratio between these has to be 
greater than 
% the minimum fold change to be included in the 
expressingresults matrix 
% which holds the profiles for all expressing transcript. 
 
for j = 1:length(results(:,1)) 
    
    minimum = min(results(j,:));  % gets max expression of 
transcript 
    maximum = max(results(j,:));  % gets min expression of 
transcript 
     
    change = maximum - minimum;   % works out the ratio 
     
 
% this bit stores those gene names that meet the condition in 
% expressinggenes and the corresponding profile in expressing 
results.  The 
% count also moves up by 1. 
     
    if change > minfoldchange 
         
       expressingcount = expressingcount +1; 
         
       sigtranscriptresults(expressingcount,:) = results(j,:); 
       rawexpressingresults(expressingcount,:) = 
rawresults(j,:); 
        
        
       expressinggenes(expressingcount) = sigtranscript(j); 
       expressinggenes2(expressingcount) = sigtranscript2(j); 
         
    end 
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end 
 
 
 
 
 
if includeborderlinetranscripts == 1 
 
borderexpressingcount = 0; 
 
for q = 1:length(borderresults(:,1)) 
    
    minimum = min(borderresults(q,:));  % gets max expression 
of transcript 
    maximum = max(borderresults(q,:));  % gets min expression 
of transcript 
     
    change = maximum -minimum;   % works out the ratio 
     
 
% this bit stores those gene names that meet the condition in 
% expressinggenes and the corresponding profile in expressing 
results.  The 
% count also moves up by 1. 
     
    if change > minfoldchange 
         
       borderexpressingcount = borderexpressingcount +1; 
         
       borderlinetranscripresults(borderexpressingcount,:) = 
borderresults(q,:); 
        
       borderexpressinggenes(borderexpressingcount) = 
bordertranscript(q); 
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    end 
     
 
     
     
end 
 
 
end 
 
 
 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%% 
% 
% We now have all that we need to say that a transcript is 
expressed by a given 
% fold change, and that it has already been found to change 
over time to a 
% satisfactory p value.   
% 
% This section is optional and can be commented out.  It takes 
a specific 
% profile and looks at each expressed gene for any which match 
the criteria. 
% 
% for example the profile [0,0,0,1] looks for any transcript 
which only 
% express at the last time point when compared to T0. 
% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%% 
% %  
% %  
% %  
 
if profilesearch == 1 
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profilecount = 0;       % intially zero as before 
 
for k = 1:length(sigtranscriptresults(:,1)) 
    
% we set each time pont to zero first and then work out the 
normalised values     
     
    binary_results = [0,0,0,0];    
     
    normalised_profile(1:4) = sigtranscriptresults(k,:) - 
sigtranscriptresults(k,1); 
     
     
    % following this we go through each time point and if a 
particular time 
    % point meets the condition then we change it to a 1 
     
    for l = 1:time_points 
        
        if (normalised_profile(l))>minfoldchange 
             
            binary_results(l) = 1; 
             
        end 
         
         if (normalised_profile(l))< -1*(minfoldchange) 
             
            binary_results(l) = -1; 
             
        end 
         
         
    end 
     
     
    % We now compare a genes binary profile to the desired 
profile 
    % if they match we save the transcript name in 
profileexpressinggenes and we 
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    % move the count up by 1 
     
        if binary_results(1:4) == profile(1:4) 
         
        profilecount = profilecount+1; 
         
        profileexpressinggenes(profilecount) = 
expressinggenes(k); 
        profileexpressingIDs(profilecount) = 
expressinggenes2(k); 
        end 
     
end 
 
 
if profilecount >0 
 
profilecount 
dlmwrite('Matching_Profile_Expressed_Genes_Names.txt',char(pro
fileexpressinggenes),'') 
dlmwrite('Matching_Profile_Expressed_transcript_IDs.txt',char(
profileexpressingIDs),'') 
 
end 
 
end 
 
% %  
% %  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%% 
% 
% 
% Now all the analysis is done and we just need to return the 
desired 
% aspects of the analysis. 
% 
% Below we print out to screen the number of sig transcript 
(count) and the 
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% number of expressing transcript (expressinggenes).  We also 
write to file a 
% text file of all expressing genes as well as the profiles 
associated with 
% each. 
% 
% Note that for particular profiles, if the above section is 
uncommented 
% then these gene names too are written to file and the count 
is printed to 
% the screen 
% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%% 
% 
% 
% 
% 
% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%% 
 
if clusteranalysis == 1  
     
    normalisedexpressingresults = []; 
     
% % %     for d = 1:length(rawexpressingresults(:,1)) 
% % %         mean_expression = 
mean(rawexpressingresults(d,:)); 
% % %         normalisedexpressingresults(d,:) = 
[(rawexpressingresults(d,1)/mean_expression) 
(rawexpressingresults(d,2)/mean_expression) 
(rawexpressingresults(d,3)/mean_expression) 
(rawexpressingresults(d,4)/mean_expression) 
(rawexpressingresults(d,5)/mean_expression)]; 
% % %     end 
     
    for d = 1:length(sigtranscriptresults(:,1)) 
    mean_expression = mean(sigtranscriptresults(d,:)); 
    normalisedexpressingresults(d,:) = 
[(sigtranscriptresults(d,1)/mean_expression) 
(sigtranscriptresults(d,2)/mean_expression) 
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(sigtranscriptresults(d,3)/mean_expression) 
(sigtranscriptresults(d,4)/mean_expression)]; 
    end 
     
     
     
     
% % %     %%% 
% % %     %%% heirarchal clustering 
% % %     %%% 
% % %      
% % %     corrdist = 
pdist(normalisedexpressingresults,'euclidean'); 
% % %     clustertree = linkage(corrdist,'average'); 
% % %     clusters = cluster(clustertree,'maxclust',16); 
% % %      
% % %     f = figure('visible','off'); 
% % %     for c = 1:16 
% % %        subplot(4,4,c) 
% % %        
plot(time,normalisedexpressingresults((clusters==c),:)'); 
% % %        axis tight 
% % %     end 
% % %     saveas(f,'heirarchal_clusters.pdf'); 
% % %     close(f) 
% % %      
% % % 
fprintf(fopen('heirarchalclusters.txt','w'),'%d\n',clusters); 
% % %  
% % %   
 
 
    %%% 
    %%% k means clustering 
    %%% 
 
    [cidx,ctrs] = 
kmeans(normalisedexpressingresults,16,'dist','sqEuclidean','re
p',15,'disp','final'); 
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    newf = figure('visible','off'); 
    for c = 1:16 
       subplot(4,4,c) 
       plot(time,normalisedexpressingresults((cidx==c),:)'); 
       axis tight 
    end 
    saveas(newf,'kmeans_clusters.pdf'); 
    close(newf) 
     
fprintf(fopen('kmeansclusters.txt','w'),'%d\n',cidx); 
 
   
    newerf = figure('visible','off'); 
    for c = 1:16 
       subplot(4,4,c) 
       plot(time,ctrs(c,:)'); 
       axis tight 
       axis off 
    end 
    saveas(newerf,'kmeans_clusters_profiles.pdf'); 
    close(newerf) 
     
end 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%% 
 
count 
expressingcount 
 
dlmwrite('Sig_Expressed_Gene_Names.txt',char(expressinggenes),
'') 
dlmwrite('Sig_Expressed_Gene_IDs.txt',char(expressinggenes2),'
') 
csvwrite('Sig_Expression_Profiles.csv',sigtranscriptresults) 
csvwrite('Raw_Expression_Profiles.csv',rawexpressingresults) 
 
 
if bordercount > 0 
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dlmwrite('Borderline_Expressed_Gene_Names.txt',char(borderexpr
essinggenes),'') 
csvwrite('Borderline_Expression_Profiles.csv',borderlinetransc
ripresults) 
end 
 
 
end 
 
1.2 Coding for producing heatmaps  
 
The following coding are for generating heat maps on data which are not normalised by the 
average means (this is the general case when using MATLAB clustergram built in functions).  
In another word, this part of the coding is for producing a heatmap where the time points 
are normalised to T0 control. 
CODES: 
function output = clustergramscalebar (data,names,scalebar) 
 
 
output = clustergram(data,'ColumnLabels',[0 6 64 
96],'DisplayRatio',[1/10,1/3],'RowLabels',names,'Cluster',1,'C
olormap',scalebar); 
 
set(output,'Standardize',3) 
 
 
 
end 
 
%  when running this function, create a temp folder name then 
save the file 
% eg DNArepair = clustergram (list of data,list of 
names,upmatrix) 
% 'DNArepair' folder will be created in the temporary 
workspce, save this 
% file 
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1.3 Extracting transcripts ID and gene names  
In order to extract data from the microarray, we  
The microarray data are listed by transcripts IDs and gene names, in order extract data, we 
need these information first.  However, when we look at pathway of interest, only the Gene 
ID’s are provided.  Therefore, the following section describes how to extract gene names 
and transcript ID number from a gene ID list exported from KEGG pathway, the matlab 
coding is also provided. 
1.  From KEGG, export and save the gene ID of a particular pathway as a text file 
2. Open up Matlab and load the following files:- Gene_Names_full, AllIDs, Data_full, 
Transcript_full and“Gene ID of interest.text” 
3. Run ‘search by Gene_IDs.m’  
 
MATLAB CODES:- 
 
function Search_by_Gene_IDs 
(data_full,AllGeneIDnumbers,GeneNames,TranscriptsIDs,GeneIDsof
Interest) 
 
probes = 3;         % there are three probes for every 
transcript 
p = data_full;   % This reads in the input matrix to the p 
data matrix 
datalength = length(p(:,1));  % this works out how many data 
points there are  
 
a = 2;  %this will start the analysis at row 2 (row 1 is time 
points) 
 
number_of_transcripts = (datalength-1)/probes; % works out how 
many genes to be tested 
number_of_interestinggenes = length(GeneIDsofInterest); 
 
count = 0;  % starts the count of expressed genes at zero 
 
vec1 = zeros(9,1); % empty vector for all 12 gene measurements 
of T0 
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vec2 = zeros(9,1); % empty vector for all 12 gene measurements 
of T6 
vec3 = zeros(9,1); % empty vector for all 12 gene measurements 
of T64 
vec4 = zeros(9,1); % empty vector for all 12 gene measurements 
of T96 
 
for i = 1:number_of_transcripts 
 
    for j = 1:number_of_interestinggenes 
                 
         
         
         if AllGeneIDnumbers(a) == GeneIDsofInterest(j) 
                          
            vec1(1:9) = 
sort([p(a,1:3),p(a+1,1:3),p(a+2,1:3)]); 
            vec2(1:9) = 
sort([p(a,4:6),p(a+1,4:6),p(a+2,4:6)]); 
            vec3(1:9) = 
sort([p(a,7:9),p(a+1,7:9),p(a+2,7:9)]); 
            vec4(1:9) = 
sort([p(a,10:12),p(a+1,10:12),p(a+2,10:12)]); 
                 
            count = count+1;  
            genename(count) = GeneNames(a); 
            transcriptname(count) = TranscriptsIDs(a);   
            geneID(count)=AllGeneIDnumbers(a); 
 
            rawresults(count,:) = 
[mean(vec1(2:8)),mean(vec2(2:8)),mean(vec3(2:8)),mean(vec4(2:8
))]; 
         
              
         end 
 
    end 
     
    a=a+3;  % the analysis for this gene is done, we move a 
along 3 for next gene 
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end     
 
geneID=geneID'; 
 
count 
 
dlmwrite('Gene_Names_Interest.txt',char(genename),'') 
dlmwrite('Transcript_IDs_Interest.txt',char(transcriptname),''
) 
csvwrite('Gene_IDs_Interest.csv',geneID) 
csvwrite('Raw_Expression_Profiles_Interest.csv',rawresults) 
 
end 
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1.4 MICROARRAY CANONICAL PATHWAY ANALYSIS 
 
 
 
 
PI3K/Akt pathway obtained from IPA.  A component pathway of the PI3K/Akt pathway, 
highlighting the genes which are regulated (highlighted in purple) in chronic hypoxia.  
Expressed genes are shaded in red, repressed genes are shaded in green 
 
